Skip to main navigation Skip to main content

CMH : Clinical and Molecular Hepatology

OPEN ACCESS
Search
Advanced Search
ABOUT
BROWSE ARTICLES
FOR CONTRIBUTORS

Page Path

34
results for

"Liver diseases"

Article category

More +

Keywords

More +

Publication year

More +

"Liver diseases"

Reviews

Pediatric metabolic dysfunction–associated steatotic liver disease and the gut microbiome: from research landscape to targeted modulation
Lu Jiang, Lan-Duoduo Du, Jing Zeng, Hui-Kuan Chu, Zhong Peng, Jian-Gao Fan
Clin Mol Hepatol 2026;32(1):53-68.
Published online August 19, 2025
DOI: https://doi.org/10.3350/cmh.2025.0718
Metabolic dysfunction–associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, has become the most common form of chronic liver disease in children. The spectrum of pediatric MASLD ranges from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and in rare cases, hepatocellular carcinoma. Its pathogenesis involves a complex interplay among genetic, epigenetic, and environmental factors, along with alterations in the gut microbiota and its associated metabolites. Given the staggering prevalence and the distinct etiopathogenesis of pediatric MASLD, characterization of the gut microbiota and microbial products could facilitate the development of diagnostic tools and inform targeted therapeutic strategies. Current research on the gut microbiome in the context of pediatric MASLD is limited by small sample size, inadequate use of liver biopsy, methodological inconsistencies in sequencing, and confounding effects from metabolic comorbidities. In this review, we summarize clinical studies on alterations in the gut microbiota and microbial products (short-chain fatty acids, bile acids, and ethanol) that impact the pathogenesis of pediatric MASLD. We discuss the therapeutic potential of dietary modification, pharmacological treatments, and probiotics in improving disease progression by summarizing current clinical studies. Enhancing our understanding of the gut-liver axis may aid in the development of effective therapeutic strategies for pediatric MASLD.
  • 4,779 View
  • 213 Download
Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance
Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke
Clin Mol Hepatol 2025;31(4):1115-1138.
Published online June 9, 2025
DOI: https://doi.org/10.3350/cmh.2025.0541
Mendelian randomization (MR), a powerful statistical tool for causal inference, has been widely applied in various fields of medical research, even extending to economics and psychology. In hepatology, MR has been utilized to identify risk factors and potential therapeutic targets for liver diseases, including metabolic dysfunction-associated steatotic liver disease, cholestatic and autoimmune liver diseases, and hepatobiliary cancer. MR can provide evidence of causation via associations between genetic variants, modifiable exposures and liver disease occurrence or outcomes, using large existing datasets. However, results from MR studies are sometimes scattered, biologically not plausible or even controversial between analyses, potentially reflecting a trend of inappropriate application of this method (e.g., inappropriate selection of genetic instruments, insufficient assessment of horizontal pleiotropy, compromised statistical power, and neglected genetic diversity among different populations), and thus hinder the translation of MR findings from bench to bedside. Assessing these critical issues and pinpointing bona fide evidence are essential but quite challenging for clinicians. In this review, we aim to introduce the MR method to hepatologists and provide a comprehensive overview of the current MR findings that are relevant for hepatologists. Furthermore, we will discuss how to evaluate the quality of MR publications, interpret MR findings, and illustrate good practice of using MR studies in hepatology.

Citations

Citations to this article as recorded by  Crossref logo
  • Childhood Obesity and Age‐Related Diseases: A Systematic Review and Meta‐Analysis of Mendelian Randomization Evidence
    Haoxue Zhu, Xinghao Yi, Mengyu He, Siyi Wu, Ming Li, Shan Gao
    Pediatric Obesity.2026;[Epub]     CrossRef
  • Helicobacter pylori, peptic ulcer disease, and colorectal cancer: a prospective study with genome-wide interaction analysis and Mendelian randomization
    Ziqi Wan, Jiarui Mi, Xiaoyin Bai, Dong Wu, Sunny Hei Wong
    Infectious Agents and Cancer.2025;[Epub]     CrossRef
  • Evaluating causal protective effect of dual GLP-1R/GIPR agonists on MASLD: A Mendelian randomization and colocalization study
    Yangke Cai, Siyuan Xie, Liyi Xu, Jiamin Chen, Jianting Cai
    European Journal of Pharmacology.2025; 1005: 178088.     CrossRef
  • Integrative genome-wide analysis unveils the genetic landscape of gallstone disease and highlights novel loci with therapeutic potential
    Haotian Chen, Zhengye Liu, Hanze Du, Mixue Zheng, Ziqi Wan, Nan Zhao, Guanqiao Li, Xiaoyin Bai, Dong Wu, Jiarui Mi
    BMJ Open Gastroenterology.2025; 12(1): e001976.     CrossRef
  • 4,562 View
  • 240 Download
  • 2 Web of Science
  • Crossref

Research Letters

Lipidomic analysis of alcohol use disorder patients revealed the biomarkers for alcohol-related liver disease susceptibility
Dongyao Wang, Hongwei Zhang, Yuxiao Tang
Clin Mol Hepatol 2025;31(3):e259-e262.
Published online April 2, 2025
DOI: https://doi.org/10.3350/cmh.2025.0227

Citations

Citations to this article as recorded by  Crossref logo
  • Targeting Annexin A2 to reactivate tumor-associated antigens presentation and relieve immune tolerance in liver cancer
    Yuxiao Tang, Jianxin Yang, Qicong Shen, Zelong Gao, Mengpu Wu, Chenghua Wu, Jicong Du, Min Li, Changquan Ling, Feng Lu, Yifeng Chai, Xin Dong, Jianxin Qian, Chenqi Li, Feng Xie, Zhenhong Guo, Hui Shen, Dongyao Wang
    Journal for ImmunoTherapy of Cancer.2025; 13(6): e011716.     CrossRef
  • 8,118 View
  • 94 Download
  • 1 Web of Science
  • Crossref
Mendelian randomization does not support the effects of G CSF on decompensated liver disease
Liling Li, Hui Wang, Hong Wang, Jinchang Huang
Clin Mol Hepatol 2025;31(3):e254-e258.
Published online March 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0172
  • 8,066 View
  • 66 Download

Special Review

Liver disease trends in the Asia-Pacific region for the next 50 years
Shuichiro Shiina, Javkhlan Maikhuu, Qing Deng, Terguunbileg Batsaikhan, Lariza Marie Canseco, Maki Tobari, Hitoshi Maruyama, Hiroaki Nagamatsu, Diana Alcantara-Payawal, Rino Gani, Yi-Hsiang Huang, Tawesak Tanwandee, Giovanni Galati, Yoon Jun Kim
Clin Mol Hepatol 2025;31(3):671-684.
Published online March 4, 2025
DOI: https://doi.org/10.3350/cmh.2025.0043
Liver disease has emerged as a critical and escalating public health concern worldwide, with the Asia-Pacific region at the forefront of this challenge due to its vast population and diverse socioeconomic landscape. Over the coming five decades, this region will experience profound changes in liver disease patterns, shaped by rapid urbanization, lifestyle modifications, advancements in medical technologies, and evolving public health strategies. This article offers an in-depth analysis of six transformative areas defining the trajectory of liver disease in the region. First, it highlights the alarming rise of metabolic dysfunction-associated fatty liver disease and metabolic dysfunction-associated steatohepatitis, diseases driven by modern lifestyle factors and inherent metabolic susceptibilities. Concurrently, it celebrates the declining burden of viral hepatitis, underscoring the success of sustained public health interventions. However, new challenges are emerging, such as the growing impact of environmental and occupational exposures on liver health. Breakthroughs in genomic and epigenetic research promise to advance precision medicine, offering targeted therapeutic solutions. Additionally, the integration of artificial intelligence, big data, and telemedicine is poised to revolutionize liver disease management, improving accessibility and personalized care. Finally, the article emphasizes the critical role of robust health policies, preventive strategies, and cross-border collaboration in shaping a healthier future. By synthesizing these insights, the study aims to guide innovative and effective responses to the evolving liver disease landscape in the Asia-Pacific region.

Citations

Citations to this article as recorded by  Crossref logo
  • Trends and future projections of liver cancer attributable to metabolic dysfunction-associated steatohepatitis in China from 1990 to 2050
    Jincheng Tang, Renyi Yang, Kexiong Li, Wei Peng, Zuomei He, Wenhui Gao, Puhua Zeng
    Scientific Reports.2025;[Epub]     CrossRef
  • Bridging the Gap in Elimination of Hepatitis C Virus among People Who Use Drugs in South Korea
    Beom Kyung Kim
    Gut and Liver.2025; 19(5): 635.     CrossRef
  • Precision prevention of liver cancer based on risk factors
    Jian-Guo Chen
    Exploration of Digestive Diseases.2025;[Epub]     CrossRef
  • MAFLD in Vietnam: a neglected public health challenge requiring urgent policy action
    Thong Duy Vo, Huong Tu Lam
    Frontiers in Clinical Diabetes and Healthcare.2025;[Epub]     CrossRef
  • 9,940 View
  • 207 Download
  • 3 Web of Science
  • Crossref

Review

Liver fibrosis, cirrhosis, and portal hypertension

Prediction and prevention of post-procedural bleedings in patients with cirrhosis
Alix Riescher-Tuczkiewicz, Pierre-Emmanuel Rautou
Clin Mol Hepatol 2025;31(Suppl):S205-S227.
Published online February 18, 2025
DOI: https://doi.org/10.3350/cmh.2024.0928
Although post-procedural bleedings are infrequent in patients with cirrhosis, they are associated with significant morbidity and mortality. Therefore, predicting and preventing such bleedings is important. Established predictors of post-procedural bleeding include high-bleeding risk procedure, severe cirrhosis and high body mass index; prognostic value of anemia, acute kidney injury and bacterial infection is more uncertain. While prothrombin time and international normalized ratio do not predict post-procedural bleeding, some evidence suggests that platelet count, whole blood thrombin generation assay and viscoelastic tests may be helpful in this context. Prevention of postprocedural bleeding involves careful management of antithrombotic drugs during the periprocedural period. Patients with cirrhosis present unique challenges due to altered pharmacokinetics and pharmacodynamics of antithrombotic drugs, but there is a lack of dedicated studies specifically focused on this patient population. Guidelines for periprocedural management of antithrombotic drugs developed for patients without liver disease are thus applied to those with cirrhosis. Some technical aspects may decrease the risk of post-procedural bleeding, namely ultrasoundguidance, opting for transjugular route rather than percutaneous route, and the level of expertise of the operator. The effectiveness of platelet transfusions or thrombopoietin-receptor agonists remains uncertain. Transfusion of fresh-frozen plasma, of fibrinogen, and administration of tranexamic acid are not recommended for reducing post-procedural bleeding in patients with cirrhosis. In conclusion, prediction of post-procedural requires a global approach taking into account the patients characteristics, the risk of the procedure, and the platelet count. There is little data to support prophylactic correction of hemostasis, and dedicated studies are needed.

Citations

Citations to this article as recorded by  Crossref logo
  • Liver biopsy quality criteria to exclude cirrhosis in case of suspicion of porto-sinusoidal vascular disorder
    Chloé de Broucker, Valérie Paradis, Maria Luisa Botero, Miguel Albuquerque, Audrey Payancé, Aurélie Plessier, Laure Elkrief, François Durand, Sophie Hillaire, Paul-Emile Zafar, Juan Carlos Garcia Pagan, Pierre-Emmanuel Rautou
    JHEP Reports.2026; 8(1): 101670.     CrossRef
  • 7,520 View
  • 186 Download
  • 1 Web of Science
  • Crossref

Original Article

Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal transition and mesenchymal-to-epithelial transition subsequent to hepatic fibrosis
Jae Yeon Kim, Hyeri Park, Soo Young Park, Se Ho Kim, Ja Yun Lim, Ki Seog Lee, Si Hyun Bae, Gi Jin Kim
Clin Mol Hepatol 2025;31(3):823-840.
Published online January 22, 2025
DOI: https://doi.org/10.3350/cmh.2024.0741
Background/Aims
Epithelial-to-mesenchymal transition (EMT) plays a crucial role in hepatic fibrogenesis and liver repair in chronic liver disease. Our research highlights the antifibrotic potential of placenta-derived mesenchymal stem cells (PD-MSCs) and the role of phosphatase of regenerating liver-1 (PRL-1) in promoting liver regeneration.
Methods
We evaluated the efficacy of PD-MSCs overexpressing PRL-1 (PD-MSCsPRL-1) in a bile duct ligationinduced rat injury model, focusing on their ability to regulate EMT.
Results
PD-MSCsPRL-1 significantly reduced mesenchymal markers by downregulating TGFB1/SMAD2, outperforming naïve PD-MSCs. The transplantation of PD-MSCsPRL-1 enhanced BMP7/SMAD1/5 expression, promoting epithelial marker expression and stimulating BMP7 within hepatocytes, modulating downstream SMAD signaling. Importantly, further validation confirmed that PRL-1 directly interacts with BMP7 in hepatocytes.
Conclusions
PRL-1 expression in PD-MSCsPRL-1 restores TGFB1/BMP7 balance, promoting hepatic regeneration through mesenchymal-to-epithelial transition. These findings highlight the therapeutic potential of engineered MSCs for liver disease and suggest innovative strategies for future stem cell therapies.

Citations

Citations to this article as recorded by  Crossref logo
  • Modulation of PRL-1 in placental MSCs: A novel therapeutic strategy for hepatic fibrosis: Editorial on “Modulation of phosphatase of regenerating liver-1 within placental mesenchymal stem cells instigates the transition between epithelial-to-mesenchymal t
    Lihai Jiang, Wenjie Zheng
    Clinical and Molecular Hepatology.2026; 32(1): 377.     CrossRef
  • Advances in Biliary Disease Organoid Research: From Model Construction to Clinical Applications
    Boming Peng, Min Huang, Jianquan Zhang, Yang Xiang
    Advanced Healthcare Materials.2025;[Epub]     CrossRef
  • Mechanisms, efficacy, and future perspectives of cellular-based therapies for liver fibrosis/cirrhosis: focusing on mesenchymal stromal cells
    Xuan Pan, Tianyun Gao, Bin Wang
    Cell & Bioscience.2025;[Epub]     CrossRef
  • 13,092 View
  • 908 Download
  • 2 Web of Science
  • Crossref

Correspondence

Steatotic liver disease

Correspondence to letter to the editor 2 on “Evolutionary changes in metabolic dysfunction-associated steatotic liver disease and risk of hepatocellular carcinoma: A nationwide cohort study”
Seogsong Jeong, Won Kim, Sang Min Park
Clin Mol Hepatol 2025;31(2):e210-e211.
Published online January 6, 2025
DOI: https://doi.org/10.3350/cmh.2024.1175
  • 6,423 View
  • 35 Download

Reviews

Hepatic neoplasm

Hepatocellular carcinoma: updates on epidemiology, surveillance, diagnosis and treatment
Soo Young Hwang, Pojsakorn Danpanichkul, Vatche Agopian, Neil Mehta, Neehar D. Parikh, Ghassan K. Abou-Alfa, Amit G. Singal, Ju Dong Yang
Clin Mol Hepatol 2025;31(Suppl):S228-S254.
Published online December 26, 2024
DOI: https://doi.org/10.3350/cmh.2024.0824
Hepatocellular carcinoma (HCC) is a major global burden, ranking as the third leading cause of cancer-related mortality. HCC due to chronic hepatitis B virus (HBV) or C virus (HCV) infection has decreased due to universal vaccination for HBV and effective antiviral therapy for both HBV and HCV, but HCC related to metabolic dysfunction-associated steatotic liver disease and alcohol-associated liver disease is increasing. Biannual liver ultrasonography and serum α-fetoprotein are the primary surveillance tools for early HCC detection among high-risk patients (e.g., cirrhosis, chronic HBV). Alternative surveillance tools such as blood-based biomarker panels and abbreviated magnetic resonance imaging (MRI) are being investigated. Multiphasic computed tomography or MRI is the standard for HCC diagnosis, but histological confirmation should be considered, especially when inconclusive findings are seen on cross-sectional imaging. Staging and treatment decisions are complex and should be made in multidisciplinary settings, incorporating multiple factors including tumor burden, degree of liver dysfunction, patient performance status, available expertise, and patient preferences. Early-stage HCC is best treated with curative options such as resection, ablation, or transplantation. For intermediate-stage disease, locoregional therapies are primarily recommended although systemic therapies may be preferred for patients with large intrahepatic tumor burden. In advanced-stage disease, immune checkpoint inhibitor-based therapy is the preferred treatment regimen. In this review article, we discuss the recent global epidemiology, risk factors, and HCC care continuum encompassing surveillance, diagnosis, staging, and treatments.

Citations

Citations to this article as recorded by  Crossref logo
  • Emerging evidence supports direct-acting antiviral therapy for HCC patients beyond the early stage: Correspondence to editorial on “Direct-acting antiviral therapy for patients with HCV-related hepatocellular carcinoma: A nationwide cohort study”
    Teng-Yu Lee, Pei-Chien Tsai, Shou-Wu Lee, Ming-Lung Yu
    Clinical and Molecular Hepatology.2026; 32(1): e68.     CrossRef
  • Advancing policy and practice in alcohol-associated liver disease and alcohol-attributable cancer: Correspondence to the editorial on “Sex disparities in alcohol-associated liver disease and subtype differences in alcohol-attributable cancers in the Unite
    Pojsakorn Danpanichkul, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
    Clinical and Molecular Hepatology.2026; 32(1): e96.     CrossRef
  • Transarterial radioembolization versus atezolizumab-bevacizumab for the treatment of hepatocellular carcinoma with portal vein tumor thrombosis
    Youngsu Park, Yuri Cho, Seung Up Kim, Aryoung Kim, Hyunjae Shin, Hyo-Cheol Kim, In Joon Lee, Gyoung Min Kim, Dongho Hyun, Yunmi Ko, Jeayeon Park, Jae Woong Yoon, Gyung Sun Lim, Moon Haeng Hur, Yun Bin Lee, Eun Ju Cho, Jeong-Hoon Lee, Su Jong Yu, Jung-Hwan
    Diagnostic and Interventional Imaging.2026; 107(1): 25.     CrossRef
  • Gender, Age, Alpha-fetoprotein, and Des-gamma-carboxyprothrombin Score as a Novel Approach to Early Detection of Hepatocellular Carcinoma: A Narrative Review
    Ludovico Abenavoli, Giuseppe G.M. Scarlata, Maria L. Gambardella, Ivo Lopez, Giuseppe Sena, Domenico Laganà, Francesco Luzza, Giuseppe Currò
    Journal of Clinical and Experimental Hepatology.2026; 16(1): 103203.     CrossRef
  • MRI-based Habitat Imaging Enhances the Preoperative Prediction of Microvascular Invasion in Hepatocellular Carcinoma
    Xiaogang Li, Anbin Hu
    Academic Radiology.2026; 33(1): 59.     CrossRef
  • Split biosensor based on nano-enzymatic ferrocene-tyramine deposition reaction for detection of SMP30 antibody
    Yanping Xing, Xixiang Xie, Jiangtao Liu, Tao Zhao, Xiyu Liu, Pan Wu, Faquan Lin, Yong Huang
    Analytica Chimica Acta.2026; 1382: 344834.     CrossRef
  • Ferroptosis modulation by METTL14 in cancers: From molecular insights to therapeutic strategies
    Boran Huang, Chenglin Zhu, Xinyu Zhang, Qi Zhang, Honggang Wang
    Cellular Signalling.2026; 138: 112212.     CrossRef
  • Integrated multi-Omics and network toxicology elucidate the multi-target mechanisms of environmental hormones in driving hepatocellular carcinoma
    Rong Huang, Jinyue Ma, Jiaxin Yao, Jiyu Pang, Min Zhang, Lu Wen, Liang Wang, Yanan Deng, Xiu He, Chunyan Zhao, Bo Mu
    Ecotoxicology and Environmental Safety.2026; 309: 119519.     CrossRef
  • The regulatory role of circGDI2 in hepatocellular carcinoma proliferation and glycolysis with the involvement of m6A modification
    Shiyi Chen, Hongxiang Xia, Shuwei Chen
    Non-coding RNA Research.2026; 17: 21.     CrossRef
  • CTTN overexpression on circulating tumor cells promotes hepatocellular carcinoma recurrence via enhancing the proliferation and clonality of circulating tumor cells
    Yongzhi Liu, Zhidong Fu, Lihui Jiang, Yang Chen, Feng Jiang, Chuanling Zhang, Tieming Zhu
    Cytotechnology.2026;[Epub]     CrossRef
  • Phenylalanine-Coated PLGA Nanoparticles for Targeted Delivery of Silibinin in Hepatocellular Carcinoma
    Claudia Mari, Federica Aliperta, Amadeo Sanz-Pérez, Mario Alonso, Elena González-Burgos, Juan Francisco González, Irene Lozza, Ana Fernández-Carballido, Ana Isabel Fraguas-Sánchez
    Molecular Pharmaceutics.2026; 23(1): 487.     CrossRef
  • Outcomes of Nivolumab Plus Ipilimumab After Atezolizumab Plus Bevacizumab in Advanced HCC: An International Multicentre Study
    Jung Sun Kim, Jeffrey Wong, San‐Chi Chen, David Tai, Hannah Yang, Youngun Kim, Beodeul Kang, Ilhwan Kim, Hyeyeong Kim, Chansik An, Su Jin Jang, Masatoshi Kudo, Ho Yeong Lim, Chan Kim, Thomas Yau, Hong Jae Chon
    Liver International.2026;[Epub]     CrossRef
  • Integrative analyses of network pharmacology and bioinformatics reveal the synergistic antitumor effects of cantharidin and ginsenosides Rg3 on hepatocellular carcinoma
    Xianggang Gou, Zhongzheng Zhou, Yuehua Wang, Henye Yuan, Ziyao Wang, Jie Chen, Wei Yan, Haisheng Wang, Jia Yan
    Biochemical Pharmacology.2026; 246: 117700.     CrossRef
  • Risk stratification for hepatocellular carcinoma in metabolic dysfunction-associated steatotic liver disease: Editorial on “High Steatosis-Associated Fibrosis Estimator scores predict hepatocellular carcinoma in viral and non-viral hepatitis and metabolic
    Ho Soo Chun, Minjong Lee
    Clinical and Molecular Hepatology.2026; 32(1): 368.     CrossRef
  • An Inflammation-Associated Prognostic Model for Hepatocellular Carcinoma Following Radical Resection
    Yanyun Zhai, Biling Gan, Renguo Guan, Ye Lin, Yanxia Lu
    Journal of Hepatocellular Carcinoma.2026; Volume 13: 1.     CrossRef
  • Distinct tumor immune microenvironment modulation by anti-PD-1/PD-L1, VEGF, and CTLA-4 blockade provides a rationale for triplet therapy in hepatocellular carcinoma
    Hideki Iwamoto, Hironori Koga, Takumi Kawaguchi
    Clinical and Molecular Hepatology.2026; 32(1): e38.     CrossRef
  • Landscape of Somatic and Age‐Related Pathogenic Structural Variations in Hepatocellular Carcinoma Revealed by Long‐Read Sequencing
    Zhewen Wei, Yinghao Cao, Hongchao Liu, Mei Liu, Bolun Zhang, Jianming Ying, Jianqiang Cai, Xinyu Bi, Jianjun Zhao, Jianguo Zhou, Zhiyu Li, Zhen Huang, Jianmei Liu, Xueyan Lv, Zhiwen Luo, Zhicheng Wei, Xiaoshi Zhang, Yi Yang, Yiqiao Deng, Yanjiang Yin, Jin
    MedComm.2026;[Epub]     CrossRef
  • Gastrointestinal cancer statistics in 2022 and projection to 2050: GLOBOCAN estimates across 185 countries
    Pojsakorn Danpanichkul, Yanfang Pang, Primrose Tothanarungroj, Disatorn Dejvajara, Donghee Kim, Preenapun Saokhieo, Kanokphong Suparan, Mark D. Muthiah, Kwanjit Duangsonk, Diego Olavarria Bernal, Rashid N. Lui, Karn Wijarnpreecha, Ghassan K. Abou‐Alfa, Mi
    Cancer.2026;[Epub]     CrossRef
  • Integrating CyTOF with scRNA-seq reveals that Cyclovirobuxine D inhibits HCC progression through hepatic immune microenvironment remodeling
    Fuqiang Ma, Lele Zhang, Yitao Fan, Ziyi Xu, Yuhua He, Jiachun Sun, Juan Lu, Xinyu Gu
    Phytomedicine.2026; 150: 157751.     CrossRef
  • A Biomimetic Manganese Complex Synergistically Disables Antioxidant Defenses and Amplifies Oxidative Stress to Potentiate Ferroptosis in Hepatocellular Carcinoma
    Pengchen Ren, Yan Huang, Linhong Zhong, Ranran Luo, Chenxi Zhang, Zening Zhang, Rui Tang, Zhongsheng Xu, Yun Liu
    Advanced Healthcare Materials.2026;[Epub]     CrossRef
  • Effectiveness of Machine Learning in Detecting Vessels Encapsulating Tumor Clusters in Hepatocellular Carcinoma: Systematic Review and Meta-Analysis
    Huili Shui, Wenyu Wu, Zhenming Xie, Bing Yang, Jia Deng, Dongxin Tang
    Journal of Medical Internet Research.2026; 28: e82839.     CrossRef
  • Emerging DNA- and RNA-based therapeutic strategies in hepatocellular carcinoma: A molecular approach to precision medicine
    Zulfa Nooreen, Ankita Wal, Anjali Shukla, A. Venkata Badarinath, Nishant Kumar, Tanmay Sarma, Abida Khan, Amin Gasmi
    Letters in Drug Design & Discovery.2026; : 100268.     CrossRef
  • Stemness CD24 activation promotes hepatocellular carcinoma progression via an immune escape mechanism
    Yin Cai, Lu-Yin Liu, Xiao-Xiao Xia, Hao Tang, Min Xu, Wen-Li Sai, Deng-Fu Yao, Min Yao
    World Journal of Gastroenterology.2026;[Epub]     CrossRef
  • Identification of novel circulating protein biomarkers for hepatocellular carcinoma superior to alpha-fetoprotein through a stemness index and secretome analysis
    Cai Gao, Xuebing Li, Xinwei Liu, Sha Yan, Xiaodan Ran, Jingxian Han
    World Journal of Surgical Oncology.2026;[Epub]     CrossRef
  • NOP56 interacts with Fibrarin to regulate the PI3K/AKT signaling pathway and inhibit apoptosis of hepatocellular carcinoma
    Hongwei Chen, Xinggang Fan, Di Cui
    Frontiers in Oncology.2026;[Epub]     CrossRef
  • Unmet needs in hepatology: The guidance of the Italian association for the study of the liver (AISF)
    Stefano Gitto, Filippo Gabrielli, Giovanni Addolorato, Claudia Tarli, Giacomo Zaccherini, Rosaria Calia, Giacomo Germani, Patrizia Burra, Alberto Zanetto, Francesca Ferri, Roberta D’Ambrosio, Pierluigi Toniutto, Nicola Pugliese, Fiammetta Cosci, Giuseppe
    Digestive and Liver Disease.2026;[Epub]     CrossRef
  • Endoplasmic reticulum stress-related CLIP4 plays a procarcinogenic role in hepatocellular carcinoma: an integrated analysis
    Anqi Wang, Sitong Yan, Weijia Jiang, Xiang Chen, Yuhan Huang, Xiangyu Zu, Xiao Du, Lulu Fan, Jiatao Liu, Guoping Sun
    BMC Cancer.2025;[Epub]     CrossRef
  • Progress in the Application of Novel Nanomaterials in Targeted Therapy for Liver Cancer
    Xin Wei, Weihua Cao, Shiyu Wang, Yaqin Zhang, Zixuan Gao, Shuojie Wang, Linmei Yao, Ziyu Zhang, Xinxin Li, Wen Deng, Yao Xie, Minghui Li
    International Journal of Nanomedicine.2025; Volume 20: 2623.     CrossRef
  • Rising Incidence of Early-Onset Liver Cancer and Intrahepatic Bile Duct Cancer: Analysis of the National Childhood Cancer Registry Database
    Pojsakorn Danpanichkul, Yanfang Pang, Thanida Auttapracha, Omar Al Ta’ani, Thanathip Suenghataiphorn, Apichat Kaewdech, Mark D. Muthiah, Donghee Kim, Karn Wijarnpreecha, Amit G. Singal, Ju Dong Yang
    Cancers.2025; 17(7): 1133.     CrossRef
  • Role of SMYD2 in gastrointestinal cancer progression (Review)
    Kun Xia, Yaoxiang Zhou, Youping Xie, Yinzhong Cai
    Oncology Letters.2025; 29(6): 1.     CrossRef
  • Longitudinal study of factors associated with the anti-cancer efficacy and liver function in HCC patients treated with TACE in combination with percutaneous ablation
    Huhu Ren, Jian Chen, Zhiqun Wu, Chen Li
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • A Review of Risk Prediction Model for Hepatocellular Carcinoma in Chronic Hepatitis B
    Jiwon Yang, Mark D. Muthiah, Won-Mook Choi
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • LPAR6 Inhibits the Progression of Hepatocellular Carcinoma (HCC) by Suppressing the Nuclear Translocation of YAP/TAZ
    Gegentuya Bao, Manjue Zhai, Yali Yan, Yuewu Wang, Alatangaole Damirin
    International Journal of Molecular Sciences.2025; 26(9): 4205.     CrossRef
  • PP1A Modulates the Efficacy of Lenvatinib Plus ICIs Therapy by Inhibiting Ferroptosis in Hepatocellular Carcinoma
    Jitong Zhou, Meng Gao, Shikun Zhang, Wing‐Wa Guo, Wenzhi He, Minghe Zhang, Xi Chen, Cairang Dongzhi, Xiaomian Li, Yufeng Yuan, Weijie Ma
    Advanced Science.2025;[Epub]     CrossRef
  • Pathogenesis and Treatment of Hepatocellular Carcinoma Associated with Nonalcoholic Steatohepatitis
    舒惟 梁
    Advances in Clinical Medicine.2025; 15(05): 2063.     CrossRef
  • Engineered E. coli OMVs Carrying the Membrane-Binding hGC33 Fragment Precisely Target Liver Cancer and Effectively Treat Tumor
    Yufei Deng, Bangya Yang, Zelan Yang, Hanyu Xiao, Yan Zou, Cheng Zou, Song Yang, Xi Sun, Yiting Wang, Jin Bai, Liaoqiong Fang, Zhibiao Wang
    International Journal of Nanomedicine.2025; Volume 20: 6573.     CrossRef
  • Peripheral blood inflammatory score using a cytokine multiplex assay predicts clinical outcomes in patients treated with atezolizumab-bevacizumab for unresectable HCC
    Hee Sun Cho, Soon Kyu Lee, Ji Won Han, Jung Hyun Kwon, Soon Woo Nam, Jaejun Lee, Keungmo Yang, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Jong Young Choi
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Adding salt to foods and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases
    Shunming Zhang, Zhenyu Huo, Yan Borné, Emily Sonestedt, Lu Qi
    European Journal of Nutrition.2025;[Epub]     CrossRef
  • Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications
    Chang-Lei Li, Zhi-Yuan Yao, Ao Sun, Jing-Yu Cao, Zu-Sen Wang
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Molecular mechanisms underlying Fagopyrum dibotrys-derived nanovesicles induced ferroptosis in hepatocellular carcinoma: a dual-pathway analysis of lipid peroxidation and mitochondrial damage
    Ling Wu, Hongyao Chen, Jingting Zhang, Jincheng Tang, Zhibin Wang, Peisen Xue, Wenhui Gao, Renyi Yang, Puhua Zeng
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • An Artificial Intelligence Pipeline for Hepatocellular Carcinoma: From Data to Treatment Recommendations
    Xuebing Zhang, Liuxin Yang, Chengxiang Liu, Xingxing Yuan, Yali Zhang
    International Journal of General Medicine.2025; Volume 18: 3581.     CrossRef
  • Enhancing ultrasonographic detection of hepatocellular carcinoma with artificial intelligence: current applications, challenges and future directions
    Janthakan Wongsuwan, Teeravut Tubtawee, Sitang Nirattisaikul, Pojsakorn Danpanichkul, Wisit Cheungpasitporn, Sitthichok Chaichulee, Apichat Kaewdech
    BMJ Open Gastroenterology.2025; 12(1): e001832.     CrossRef
  • Exploring the impact of sleep duration and sleep disorders on metabolic dysfunction-associated steatotic liver disease in older adults
    Fan Zhang, Yuan Xue, Wenjian Li
    BMC Geriatrics.2025;[Epub]     CrossRef
  • Integrating machine learning and molecular docking to decipher the molecular network of aflatoxin B1-induced hepatocellular carcinoma
    Junjie Gao, Meijun Zhang, Qun Chen, Kai Ye, Jing Wu, Tao Wang, Puhong Zhang, Gang Feng
    International Journal of Surgery.2025; 111(7): 4539.     CrossRef
  • Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors
    Mohammad Saeid Rezaee-Zavareh, Soo Young Hwang, Naomy Kim, Hasmik Adetyan, Nguyen H. Tran, Ju Dong Yang
    Discover Oncology.2025;[Epub]     CrossRef
  • Addressing Africa's marginalisation in hepatocellular carcinoma clinical trials
    Mohamed El-Kassas, Hend Shousha, Lewis R Roberts
    The Lancet Gastroenterology & Hepatology.2025; 10(11): 966.     CrossRef
  • Response Assessment in Hepatocellular Carcinoma: A Primer for Radiologists
    Nayla Mroueh, Jinjin Cao, Shravya Srinivas Rao, Soumyadeep Ghosh, Ok Kyu Song, Sasiprang Kongboonvijit, Anuradha Shenoy-Bhangle, Avinash Kambadakone
    Journal of Computer Assisted Tomography.2025;[Epub]     CrossRef
  • Targeting tumor-associated macrophages to overcome immune checkpoint inhibitor resistance in hepatocellular carcinoma
    Fen Liu, Xianying Li, Yiming Zhang, Shan Ge, Zhan Shi, Qingbin Liu, Shulong Jiang
    Journal of Experimental & Clinical Cancer Research.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma of non-viral etiology: From theory to real practice
    V. V. Petkau, N. E. Krasilnikova, E. N. Bessonova, A. A. Tarkhanov
    Meditsinskiy sovet = Medical Council.2025; (10): 66.     CrossRef
  • The transcription factor HOXB7 significantly enhances the expression of PIGT through the Wnt/β-catenin signaling pathway, thereby promoting the proliferation and deterioration of HCC
    Jiaxin Huang, Jiaqi Tan, Nanfeng Meng, Junrong Wang, Peng Han, Hang Wang
    Expert Review of Anticancer Therapy.2025; 25(11): 1299.     CrossRef
  • A Clinical-Imaging Nomogram for Predicting Early Recurrence in Patients with Solitary Hepatocellular Carcinoma After Postoperative Adjuvant TACE
    Jiachen Liu, Xiurong Ding, Yanyan Zhang, Hongjun Li
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1835.     CrossRef
  • Augmenting conventional criteria: a CT-based deep learning radiomics nomogram for early recurrence risk stratification in hepatocellular carcinoma after liver transplantation
    Ziqian Wu, Danyang Liu, Siyu Ouyang, Jingyi Hu, Jie Ding, Qiu Guo, Jidong Gao, Jiawen Luo, Ke Ren
    Insights into Imaging.2025;[Epub]     CrossRef
  • Exploration of the Mechanism of Action of Dendrobium officinale in the Treatment of Liver Cancer Based on Network Pharmacology, Molecular Docking and in vitro Validation
    Shuimeng Zhan, Xinyan Lu, Hongyan Guo, Yang Liu, Zhi Li, Wei Xu, Fang Xia, Huanjun Tang, Yi Tian, Jing Chen, Xuan Lin
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 1973.     CrossRef
  • Direct-acting Antivirals Therapy for Hepatocellular Carcinoma in Hepatitis C Patients
    Seul Ki Han, Soon Koo Baik, Moon Young Kim
    Journal of Digestive Cancer Research.2025; 13(2): 150.     CrossRef
  • Glypican-3: Novel Theranostic Agent for Hepatocellular Carcinoma
    Luca Filippi
    Seminars in Nuclear Medicine.2025; 55(6): 928.     CrossRef
  • Dihydroartemisinin inhibits histone lactylation through YAP1 to act as a ‘hot’ switch for ‘cold’ tumor in hepatocellular carcinoma
    Yuting Gao, Yi Gong, Xiaoyong Song, Yajun Xiong, Junlan Lu, Yanguang Yang, Yanli Gong, Zhimin Du, Shanshan Wang, Ruilong Jia, Peng Gong, Xinli Shi
    Phytomedicine.2025; 148: 157307.     CrossRef
  • ANTIFIBROTIC STRATEGY IN THE TREATMENT OF CHRONIC LIVER DISEASES
    Mariana M. Seliuk, Anatolii M. Pechinka
    Ukrainian educational and scientific medical space.2025; (1): 28.     CrossRef
  • The diagnostic value of 18 F-FAPI-04 PET/CT in unresectable hepatocellular carcinoma: a head-to-head comparison with 18 F-FDG PET/CT
    Huanyu Gong, Yong Cheng, Qiang Li, Yingjun He, Qijun Cai, Yongjin Tang, Yulong Liu, Lu Kuang, Yingxin Li, Jingjie Shang, Chengzhi Li, Kangshou Liu, Mingrong Cao, Lu Wang, Xueying Ling, Hao Xu
    European Journal of Nuclear Medicine and Molecular Imaging.2025;[Epub]     CrossRef
  • Selective Angiographic Roadmap Analysis (SARA) of Hepatocellular Carcinoma Feeding Arteries for Transarterial Chemoembolization
    Sultan R. Alharbi
    Diagnostics.2025; 15(19): 2533.     CrossRef
  • Binding and ubiquitination-mediated degradation of ACKR3 by the novel Scutellarein derivative TBS6b potently suppresses hepatocellular carcinoma
    Xing Jiang, Ying Liang, Guotao Tang, Haiyan Quan, Lijun Ruan, Mengli Zhang, Zhijun Song, Min Ou, Zhien Tan, Na Lu, Fangfang Wu, Xiaonan Yang
    Bioorganic Chemistry.2025; 166: 109073.     CrossRef
  • Role of ALBI Grade as a Predictive Factor for Long‐Term Mortality in Patients With Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization
    Kyoung A Ko, Hyunwoo Oh, Myung Sub Kim, Hyun Pyo Hong, Yong Kyun Cho, Byung Ik Kim, Won Sohn
    Journal of Gastroenterology and Hepatology.2025; 40(11): 2758.     CrossRef
  • Innovative Approaches to Hepatocellular Carcinoma: Diagnostic Breakthroughs, Biomarker Integration, and Artificial Intelligence
    Evangelos Koustas, Eleni-Myrto Trifylli, Panagiotis Sarantis, Michalis V. Karamouzis
    Biomedicines.2025; 13(10): 2439.     CrossRef
  • Subset of Child-Pugh Score 7 Shows Comparable Survival Outcomes to Child-Pugh Score 6 in Patients with Hepatocellular Carcinoma Treated with Atezolizumab and Bevacizumab
    Jaejun Lee, Keungmo Yang, Ji Won Han, Pil Soo Sung, Jeong Won Jang, Seung Kew Yoon, Hee Sun Cho, Hyun Yang, Si Hyun Bae, Ji Hoon Kim, Heechul Nam, Chang Wook Kim, Hae Lim Lee, Hee Yeon Kim, Sung Won Lee, Ahlim Lee, Do Seon Song, Myeong Jun Song, Soon Woo
    Clinical Cancer Research.2025; 31(20): 4323.     CrossRef
  • Plasma exosomal lncRNA-related signatures define molecular subtypes and predict survival and treatment response in hepatocellular carcinoma
    Fangmin Zhong, Fangyi Yao, Xin-Lu Wang, Zihao Wang, Bo Huang, Jing Liu, Xiaozhong Wang, Lei Zhang
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Hepatocellular carcinoma: modern aspects of interdisciplinary management. Part 1. Epidemiology, risk factors, diagnosis
    Yu.M. Stepanov, N.Yu. Zavhorodnia, O.M. Vlasova
    GASTROENTEROLOGY.2025; 59(3): 206.     CrossRef
  • Repurposing HIV-Protease Inhibitor Precursors as Anticancer Agents: The Synthetic Molecule RDD-142 Delays Cell Cycle Progression and Induces Autophagy in HepG2 Cells with Enhanced Efficacy via Liposomal Formulation
    Fabiana Crispo, Antonio Vassallo, Immacolata Faraone, Alessandro Santarsiere, Lucia Chiummiento, Mara Martinelli, Nicoletta Cascelli, Xavier Fernàndez-Busquets, Rocchina Miglionico, Ilaria Nigro, Carla Caddeo, Maria Francesca Armentano
    International Journal of Molecular Sciences.2025; 26(21): 10305.     CrossRef
  • The multidimensional role of SLC16A4 in hepatocellular carcinoma in silico analysis: prognostic significance, metabolic pathways, and immune microenvironment regulation
    Lili Jiang, Yi Shen, Zhengyang Feng, Yong Wang, Yaqun Zhu, Yuntian Shen, Qiliang Peng
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • The potential of soluble programmed cell death-ligand 1 and soluble programmed cell death 1 as diagnostic and prognostic biomarkers for hepatocellular carcinoma: a meta-analysis
    Jie Li, Xiangyang He, Tingting Gao, Qingjun Zhang, Xu Han
    Irish Journal of Medical Science (1971 -).2025; 194(6): 2037.     CrossRef
  • Multi-omics analysis reveals the role of tumor-infiltrating CD4+CCR7+ T cells in EGFR antibody resistance and prognosis of hepatocellular carcinoma
    Zizhong Yang, Lupeng Qiu, Guhe Jia, Zhuoya Sun, Yixin Gong, Yin Chen, Yu Wang, Lai Song, Xiao Zhao, Shunchang Jiao
    BMC Cancer.2025;[Epub]     CrossRef
  • Identification and validation of icaritin-associated prognostic genes in hepatocellular carcinoma through network pharmacology, bioinformatics analysis, and cellular experiments
    Yaru Shi, Yanan Bai, Jianglan Wu, Yunfeng Yu, Xinyu Yang, Haobo Yang, Weixiong Jian, Jun Qing
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Enhancing cancer risk awareness and screening management through artificial intelligence: a narrative review
    Jiaxuan Wu, Xiaolong Tang, Qian Zheng, Xinhang Gu, Li Ma, Jinghong Xian, Hui Mao, Jiadi Gan, Guiyi Ji
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • miR-122-5p Regulates Ferroptosis through Targeting the Glutamine Transporter SLC1A5 in Hepatocellular Carcinoma
    Mingxuan Lei, Jiayin Xu, Xiaoying Hu, Lin Feng, Baoping Luo
    BIOCELL.2025; 0: 1.     CrossRef
  • Targeting endoplasmic reticulum stress-induced CLGN resensitizes hepatocellular carcinoma to apoptosis: paeonol synergistically enhances efficacy by dual inhibition of CLGN and NF-κB
    Sitong Yan, Anqi Wang, Xiang Chen, Weijia Jiang, Xiao Du, Yuhan Huang, Xiangyu Zu, Yue Zhu, Jiatao Liu, Lulu Fan, Lingling Zhang, Guoping Sun
    Frontiers in Oncology.2025;[Epub]     CrossRef
  • Lactylation in Cancer: Unlocking the Key to Drug Resistance and Therapeutic Breakthroughs
    Xiangnan Feng, Dayong Li, Pingyu Wang, Xinyu Li, Guangyao Li
    Oncology Research.2025; 33(11): 3327.     CrossRef
  • Organokine-Mediated Crosstalk: A Systems Biology Perspective on the Pathogenesis of MASLD—A Narrative Review
    Sandra Maria Barbalho, Lucas Fornari Laurindo, Vitor Engracia Valenti, Nahum Méndez-Sánchez, Mariana M. Ramírez-Mejía, Ricardo de Alvares Goulart
    International Journal of Molecular Sciences.2025; 26(23): 11547.     CrossRef
  • Systematic analysis of the expression profiles and prognostic values of the FAM72 family in liver cancer
    Weihao Kong, Long Teng, Kangjie Zhang, Yajun Zou, Xingyu Wang, Jianlin Zhang
    Biochemistry and Biophysics Reports.2025; 44: 102358.     CrossRef
  • Bioinformatics Analysis Reveals the Role of DLGAP4 in the Development and Progression of Hepatocellular Carcinoma
    Feng Yang, Shoufeng Chang, Ruxia Li, Jing Wei, Hua Zhang, Qiqi Wang, Zhenjun Li, Yamei Dang
    Journal of Gastrointestinal Cancer.2025;[Epub]     CrossRef
  • Early screening for liver cancer must be performed
    Zi-Han Liu, Wen-Jun Wang, Shuang-Suo Dang
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • –A novel peptide SMIM45-107aa promotes HCC progression via MTDH pathways and its anticancer peptide derivative
    Yan An, Xiangyang Shi, Wentao Huang, Mingyi Shang, Guang-Zhi Jin
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • Liver Transplantation for Hepatocellular Carcinoma: A Comprehensive Review
    Seok-Hwan Kim
    Convergence Hepatology.2025; 1(1): 24.     CrossRef
  • Clinical significance of citrullinated glial fibrillary acidic protein in predicting outcomes in hepatocellular carcinoma
    Yoon Ah Cho, Dong Woo Shin, Mo-Jong Kim, Ji-Won Park, Ji-Young Choe, Jung-Woo Lee, Sung-Hoon Moon, Akihito Ishigami, Eun Kyoung Choi, Sung-Eun Kim
    World Journal of Gastrointestinal Oncology.2025;[Epub]     CrossRef
  • Intra-tumoral microbiota: Key modulators of tumor immunity and therapeutic potential
    Junju He, Hui Tan, Yanru Qiu, Yuchao Dan, Qian Wan, Lan Li, Jie Wu, Qibin Song, Hongbin Chen, Bin Xu
    Genes & Diseases.2025; : 101963.     CrossRef
  • Prognostic nutritional index and the survival of patients with hepatocellular carcinoma on immune checkpoint inhibitors: a meta-analysis
    Jia Fu, Wei Peng, Jinqiong Jiang, Tan Deng, Huaxin Duan, Kanghan Liu
    BMC Cancer.2025;[Epub]     CrossRef
  • Comparative Evaluation of Proprietary and Open-Source Large Language Models for Systematic Multi-source Information Extraction in Interventional Oncology
    Elif Can, Wibke Uller, Elmar Kotter, Katharina Vogt, Michael Doppler, Michael Brönnimann, Raid Alshinibr, Aboelyazid Elkilany, Felix Busch, Avan Kader, Sebastian Gassenmaier, Saif Afat, Marcus R. Makowski, Keno K. Bressem, Lisa C. Adams
    CardioVascular and Interventional Radiology.2025;[Epub]     CrossRef
  • Survival benefits of different immunotherapies for hepatocellular carcinoma: a meta-analysis highlighting age, gender, etiology, and tumor burden
    Ming-Cheng Guan, Na Li, Qian Ding, Di Sun, Hao Li, Mei Yang, Lei Hong, Hong Zhu
    Frontiers in Immunology.2025;[Epub]     CrossRef
  • Visit‑to‑visit variability of inflammation–immunity indices and prognosis in hepatocellular carcinoma
    Qiajun Du, Youli Zhao, Jing Yang, Yongxin Yang
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Biomimetic Nanomedicine for Senescence‐Modulated Immune Activation Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma
    Shiji Fang, Liyun Zheng, Bin Lin, Jiale Chen, Dehai Hou, Yiming Ding, Mengzhu Han, Pan Qin, Mengyuan Wang, Xiaoju Guo, Yeyu Zhang, Gaofeng Shu, Fazong Wu, Jianfei Tu, Minjiang Chen, Zhongwei Zhao, Zhuang Liu, Jiansong Ji
    Advanced Science.2025;[Epub]     CrossRef
  • Protein induced by vitamin K absence or antagonist II as a prognostic marker in hepatocellular carcinoma patients with normal serum alpha-fetoprotein levels
    Kuan-Jung Huang, Chun-Ting Ho, Pei-Chang Lee, San-Chi Chen, Chien-An Liu, Shu-Cheng Chou, I-Cheng Lee, Yi-Hsiang Huang, Jiing-Chyuan Luo, Ming-Chih Hou, Jaw-Ching Wu, Chien-Wei Su
    Journal of the Chinese Medical Association.2025; 88(12): 915.     CrossRef
  • CDCA3 Regulates Tumor-Associated Macrophages Polarize to Promote the Malignant Progression of Hepatocellular Carcinoma
    Shanmei Lyu, Enqin Wang, Juan Lyu, Hongkun Xu, Daochang Zhang, Zhijun Fang, Lihong Zhang
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 3029.     CrossRef
  • Combining Transarterial Chemoembolization with Sorafenib Improves Survival in Selected Patients with Hepatocellular Carcinoma and Extrahepatic Spread: A Multicenter Real-World Study
    Yue Yuan, Yu Qiao, Yejing Zhu, Ping Guo, Jiakun Gou, Kai Liu, Linqian Wang, Shoujie Zhao, Yongchao Zhang, Yunjie Liu, Enxin Wang, Lei Liu
    Journal of Hepatocellular Carcinoma.2025; Volume 12: 3049.     CrossRef
  • Biomarker-Based Precision Prediction of Immunotherapy Response in Hepatocellular Carcinoma
    Hsu-Wen Chao, Yi-Mei Joy Lin, Chen-Shiou Wu
    Diagnostics.2025; 16(1): 85.     CrossRef
  • Effect of statin use on prognostic outcomes in hepatocellular carcinoma following liver surgery: a systematic review and meta-analysis
    Diski Saisa, Syifa Mustika, Mochamad Fachrureza, Stevanus Christian Surya, Derren Rampengan, Juan Alessandro Jeremis Maruli Nura Lele, Ammar Nojaid, Michael Owen Hogipranata
    European Journal of Gastroenterology & Hepatology.2025;[Epub]     CrossRef
  • 28,213 View
  • 1,100 Download
  • 81 Web of Science
  • Crossref

Steatotic liver disease

Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
Clin Mol Hepatol 2024;30(4):620-648.
Published online July 11, 2024
DOI: https://doi.org/10.3350/cmh.2024.0315
Steatotic liver diseases (SLD) are the principal worldwide cause of cirrhosis and end-stage liver cancer, affecting nearly a quarter of the global population. SLD includes metabolic dysfunction-associated alcoholic liver disease (MetALD) and metabolic dysfunction-associated steatotic liver disease (MASLD), resulting in asymptomatic liver steatosis, fibrosis, cirrhosis and associated complications. The immune processes include gut dysbiosis, adiposeliver organ crosstalk, hepatocyte death and immune cell-mediated inflammatory processes. Notably, various immune cells such as B cells, plasma cells, dendritic cells, conventional CD4+ and CD8+ T cells, innate-like T cells, platelets, neutrophils and macrophages play vital roles in the development of MetALD and MASLD. Immunological modulations targeting hepatocyte death, inflammatory reactions and gut microbiome include N-acetylcysteine, selonsertib, F-652, prednisone, pentoxifylline, anakinra, JKB-121, HA35, obeticholic acid, probiotics, prebiotics, antibiotics and fecal microbiota transplantation. Understanding the immunological mechanisms underlying SLD is crucial for advancing clinical therapeutic strategies.

Citations

Citations to this article as recorded by  Crossref logo
  • Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation
    Senping Xu, Zhaoshan Zhang, Zhongquan Zhou, Jiawei Guo
    Biology.2026; 15(2): 148.     CrossRef
  • Unveiling the distinctive gut microbiota and metabolites in liver cirrhosis and its complications: Novel diagnostic biomarkers: Editorial on “Gut microbiome and metabolome signatures in liver cirrhosis-related complications”
    Soon Kyu Lee, Jong Young Choi
    Clinical and Molecular Hepatology.2025; 31(1): 301.     CrossRef
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • Prospective Hepatoprotective Actions of Novel Nano-formulations of Sildenafil and Neem Extract in Counteracting Oral Carbon Tetrachloride-induced Liver Injury in Rats
    Mahmoud S. Sabra, Essmat A. H. Allam, Madeha H. A. Darwish, Al-Hassan Mohammed Mostafa, Abeer S. Hassan, Marwa G. Gamea, Dalia Hassan, Mohamed M. Elbadr
    Journal of Pharmaceutical Innovation.2025;[Epub]     CrossRef
  • Response to the Letter to the Editor: What Is the Optimal Anti‐Diabetic Regimen Among CHB and T2DM Patients?
    Beom Kyung Kim
    Liver International.2025;[Epub]     CrossRef
  • Advances in identifying risk factors of metabolic dysfunction-associated alcohol-related liver disease
    Rui-Qi Ye, Yi-Fan Chen, Chang Ma, Xi Cheng, Wei Guo, Sha Li
    Biomedicine & Pharmacotherapy.2025; 188: 118191.     CrossRef
  • Chronic Inflammation and Immune Dysregulation in Metabolic-Dysfunction-Associated Steatotic Liver Disease Progression: From Steatosis to Hepatocellular Carcinoma
    Young-Min Jee, Jeong-Yoon Lee, Tom Ryu
    Biomedicines.2025; 13(5): 1260.     CrossRef
  • Immunopathogenic mechanisms and immunoregulatory therapies in MASLD
    Yong He, Yingfen Chen, Shengying Qian, Schalk van Der Merwe, Debanjan Dhar, David A. Brenner, Frank Tacke
    Cellular & Molecular Immunology.2025; 22(10): 1159.     CrossRef
  • Gut-Liver Axis: The Role of Intestinal Microbiota and Their Metabolites in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease
    Chao Cui, Shuai Gao, Jingfei Shi, Kai Wang
    Gut and Liver.2025; 19(4): 479.     CrossRef
  • Association of High-Density Lipoprotein Cholesterol-Based Inflammatory Markers With MASLD and Significant Liver Fibrosis in US Adults: Insights From NHANES 2017–2020
    Shuangzhen Jia, Xiaolin Ye, Yan Kong, Zhaoxia Wang, Jie Wu
    Clinical and Translational Gastroenterology.2025; 16(8): e00873.     CrossRef
  • Soybean genistin-driven gut microbiota-derived butyrate synthesis activates the SIRT1 signaling pathway to ameliorate metabolic fatty liver
    Guohui Yi, Wanying Sun, Xueer Zhang, Zhongtao Wang, Xiaodan Yu, Canyang Zhu, Kaiwen Lin
    Free Radical Biology and Medicine.2025; 239: 336.     CrossRef
  • Understanding MASLD — from molecular pathogenesis to cardiovascular risk: A concise review for the clinical cardiologist
    Carlo Ratti, Mattia Malaguti, D'Aniello Emanuele, Antonio Bellasi, Gianluca Sanna
    Atherosclerosis.2025; 409: 120495.     CrossRef
  • Octenyl Succinic Anhydride Starch Alleviates Alcoholic Liver Disease by Modulating Gut Microbiota and Metabolism
    Chang Liu, Tangqian Liu, Rongrong Ma, Xiaohua Pan, Yaoqi Tian
    Nutrients.2025; 17(17): 2779.     CrossRef
  • Resmetirom for MASH: A Comprehensive Review of a Novel Therapeutic Frontier
    Angad Tiwari, Ashish Sharma, Harendra Kumar, Varnika Gupta, Vishal Deshpande, Jaya Sai Mupparaju, Tanisha Mishra, Hareesha Rishab Bharadwaj, Dushyant Singh Dahiya, Varun Jain
    Biomedicines.2025; 13(9): 2079.     CrossRef
  • Astragalus polysaccharides restore neutrophil functions and gut microbiota homeostasis in dairy cows with subclinical ketosis
    Shang Jiang, Li Na, Ke Zhang, Kexin Wang, Zhiyong Li, Yiqi Zhang, Yan Ren, Chao Wang, Xiancheng Feng, Yuchen Yang, Chenxi Xue, Jun Chen, Xiliang Du, Lin Lei, Wenwen Gao, Guowen Liu, Yuxiang Song, Xinwei Li
    Journal of Dairy Science.2025; 108(11): 12632.     CrossRef
  • Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD
    Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu
    Antioxidants.2025; 14(10): 1196.     CrossRef
  • Paired snRNA-seq and scRNA-seq analysis of MASLD patients to identify early-stage markers for disease progression
    Suebin Park, Su-Hyeon Lee, Se-eun Han, Beom Kyung Kim, Byungjin Hwang
    Hepatology Communications.2025;[Epub]     CrossRef
  • Even Lower Alcohol Intake Might Be Harmful for East Asian Males With MASLD Spectrum
    Byungyoon Yun, Juyeon Oh, Heejoo Park, Jian Lee, Beom Kyung Kim, Jin-Ha Yoon
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Metabolic dysfunction and alcohol-associated liver disease (MetALD)
    Bin Gao, Juan Pablo Arab, Suthat Liangpunsakul, Wen-Xing Ding, Gyongyi Szabo, Wajahat Mehal, Hua Wang, Yong He, Peter Stärkel, Cristina Llorente, Bernd Schnabl, Seonghwan Hwang, Schalk Vandermerwe, Yanhang Gao, Ming-Hua Zheng, Won Kim, Jacob George, Ramon
    eGastroenterology.2025; 3(4): e100319.     CrossRef
  • Pathogenesis and management of metabolic dysfunction-associated steatohepatitis-related hepatocellular carcinoma: a narrative review
    Han Ah Lee
    The Ewha Medical Journal.2024;[Epub]     CrossRef
  • The Interplay Between Depression, Probiotics, Diet, Immunometabolic Health, the Gut, and the Liver—A Secondary Analysis of the Pro-Demet Randomized Clinical Trial
    Oliwia Gawlik-Kotelnicka, Jakub Rogalski, Karolina H. Czarnecka-Chrebelska, Jacek Burzyński, Paulina Jakubowska, Anna Skowrońska, Dominik Strzelecki
    Nutrients.2024; 16(23): 4024.     CrossRef
  • Small intestinal bacterial overgrowth and metabolic dysfunction-associated steatotic liver disease
    Ziteng Wang, Wentao Tan, Jiali Huang, Qian Li, Jing Wang, Hui Su, Chunmei Guo, Hong Liu
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Exploring the Role of Peroxisome Proliferator-Activated Receptors and Endothelial Dysfunction in Metabolic Dysfunction-Associated Steatotic Liver Disease
    Ana Paula Madariaga Traconis, Misael Uribe-Esquivel, Varenka Julieta Barbero Becerra
    Cells.2024; 13(24): 2055.     CrossRef
  • 10,526 View
  • 322 Download
  • 20 Web of Science
  • Crossref

Acute liver injury and Acute liver failure

Current status and perspective on molecular targets and therapeutic intervention strategy in hepatic ischemia-reperfusion injury
Jia Liu, Ranyi Luo, Yinhao Zhang, Xiaojiaoyang Li
Clin Mol Hepatol 2024;30(4):585-619.
Published online July 1, 2024
DOI: https://doi.org/10.3350/cmh.2024.0222
Hepatic ischemia‒reperfusion injury (HIRI) is a common and inevitable complication of hepatic trauma, liver resection, or liver transplantation. It contributes to postoperative organ failure or tissue rejection, eventually affecting patient prognosis and overall survival. The pathological mechanism of HIRI is highly complex and has not yet been fully elucidated. The proposed underlying mechanisms include mitochondrial damage, oxidative stress imbalance, abnormal cell death, immune cell hyperactivation, intracellular inflammatory disorders and other complex events. In addition to serious clinical limitations, available antagonistic drugs and specific treatment regimens are still lacking. Therefore, there is an urgent need to not only clarify the exact etiology of HIRI but also reveal the possible reactions and bottlenecks of existing drugs, helping to reduce morbidity and shorten hospitalizations. We analyzed the possible underlying mechanism of HIRI, discussed various outcomes among different animal models and explored neglected potential therapeutic strategies for HIRI treatment. By thoroughly reviewing and analyzing the literature on HIRI, we gained a comprehensive understanding of the current research status in related fields and identified valuable references for future clinical and scientific investigations.

Citations

Citations to this article as recorded by  Crossref logo
  • Emerging nano/micro drug delivery system for hepatic ischemia-reperfusion injury
    Xiao Fu, Wanqi Yang, Dongxue Ge, Haozhen Ren
    Coordination Chemistry Reviews.2026; 549: 217357.     CrossRef
  • TPPU alleviates hepatic ischemia–reperfusion injury by regulating macrophage polarization
    Hao Pan, Jiansen Lu, Tian Han, Hongliang Liang, Weiye Zhang, Wen Hou, Zhongyang Shen
    Biochemical Pharmacology.2026; 245: 117657.     CrossRef
  • Artesunate reduces oxidative stress and inflammation in NAFLD by activating the Nrf2 pathway
    Qinyu Meng, Mengru Zhong, Jiangrong Zhao, Hong Xu, Wentao Jiang, Chenru Lin, Ghaffar Karishma, Feng Wang, Fang Xu, Yana Li
    Biochemical Pharmacology.2026; 245: 117643.     CrossRef
  • A Multifunctional Nanoplatform for Treating Hepatic Ischemia–Reperfusion Injury by Modulating the Nrf2 and NF-κB Pathways
    Ling Shuai, Xiaojun Wang, Xudong Wen, Cong Peng, Tian Dong, Jiejuan Lai, Ling Yao, Shijun Fan, Changchun Zhao, Leida Zhang, Yujun Zhang, Xiang Xiong
    ACS Applied Materials & Interfaces.2026;[Epub]     CrossRef
  • Identification of key genes related to metabolic cell death in hepatic ischemia-reperfusion injury from transcriptome data and mechanism research using single-cell data
    HongLi Yu, YingLi Cao, Jiebo Wang, Xianfeng Weng, Weituan Xu
    Frontiers in Immunology.2026;[Epub]     CrossRef
  • Crosstalk-free two-channel visualization and precise assessment of autophagy-regulated hepatic ischemia-reperfusion injury by a two-photon fluorescent probe
    Qing Chang, Qi Wang, Jingyu Zhang, Yan Fang, Jiale Ou, Huimin Zhou, Xianyun Xu, Qi Chen, Yan Feng, Xiangming Meng
    Sensors and Actuators B: Chemical.2025; 431: 137402.     CrossRef
  • Sinensetin attenuates hepatic ischemia-reperfusion injury through suppressing GRP78/CHOP-mediated endoplasmic reticulum (ER) stress in mice
    Yihong Yang, Guanghua Xiong, Huangqi Shi, Yulin Peng, Jinghong Liu, Yaxuan Jiang, Min Lu, Hongbo Liu, Yong Liu
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Biomedical applications of fluorescent probes for detecting ischemia-reperfusion injury in different organs
    Xinying Jing, Song Han, Yi Yang, Youbo Lai, Weiying Lin
    Coordination Chemistry Reviews.2025; 534: 216607.     CrossRef
  • Study on the Role of Schisandrin B in Ameliorating Hepatic Ischemia-Reperfusion Injury by Modulating Hepatocyte Autophagy
    Zhao Fei, Pan Haihang, Chen Xueyang, Shen Miao
    Iranian Journal of Pharmaceutical Research.2025;[Epub]     CrossRef
  • Mesenchymal stem cell-derived exosomes: an emerging therapeutic strategy for hepatic ischemia-reperfusion injury
    Bo Zhao, Jiping Wei, Zijian Jiang, Yiming Long, Yan Xu, Botao Jiang
    Stem Cell Research & Therapy.2025;[Epub]     CrossRef
  • Emerging roles of cuproptosis in liver diseases
    Qi Yang, Xiaoxuan Liu, Huixin Tang, Yu Chen, Li Bai
    Digestive and Liver Disease.2025; 57(8): 1541.     CrossRef
  • Identification of PANoptosis related biomarkers to predict hepatic ischemia‒reperfusion injury after liver transplantation
    Zhihong Chen, Junwei Zhang, Lei Zhang, Yaoge Liu, Ting Zhang, Xinting Sang, Yiyao Xu, Xin Lu
    Scientific Reports.2025;[Epub]     CrossRef
  • Knowledge graph and emerging trends in oxidative stress research on hepatic ischemia-reperfusion injury: a bibliometric analysis (1995–2024)
    Simeng Lei, Yangkai Fu, Bo Zhang, Hanwen Yang, Zhili Ji
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • Crocetin, a versatile carotenoid: Novel insights into pharmacological effects, molecular mechanisms, and therapeutic potential
    Liping Liu, Fan Qiu, Dawei Wu, Tingyu Ding, Wenying Zhang, Yuelei Mao, Ke Xu, Fengying Diao, Huiying Yang, Yunjia Wu, Yuhang Zhang, Lei Zhang, Qin Wu
    International Immunopharmacology.2025; 162: 115125.     CrossRef
  • Lipid metabolism in liver transplantation: from challenge to chance
    Yuguan Zhang, Wang Rui, Xinhao Liu, Ya Ye, Sicheng Pu, Kezhen Zong, E Yang, Shanshan Li, Zuotian Huang, Zhongjun Wu
    Metabolism and Target Organ Damage.2025;[Epub]     CrossRef
  • Perioperative Risk Factors for Early Acute Kidney Injury After Living Donor Liver Transplantation: A Single Transplant Center in Vietnam
    Ngo Dinh Trung, Do Van Nam, Nguyen Thi Thu, Nguyen Tai Thu, Ho Nam, Hoang Xuan Su
    Transplantation Proceedings.2025; 57(6): 1063.     CrossRef
  • Feedback Loops Shape Oxidative and Immune Interactions in Hepatic Ischemia–Reperfusion Injury
    Kenneth J. Dery, Richard Chiu, Aanchal Kasargod, Jerzy W. Kupiec-Weglinski
    Antioxidants.2025; 14(8): 944.     CrossRef
  • Discovery of a Hepatoprotective Trinor-Sesterterpenoid from the Marine Fungus Talaromyces sp. Against Hepatic Ischemia-Reperfusion Injury
    Wenxun Lan, Jian Cai, Liyan Yan, Xinyi Wu, Lisha Zhang, Chunmei Chen, Zhongqiu Liu, Xuefeng Zhou, Lan Tang
    Marine Drugs.2025; 23(8): 329.     CrossRef
  • Elucidating the integrative role and possible molecular mechanisms of Salvia miltiorrhiza ingredients and gut microbiota-derived metabolites in alleviating pyroptosis-mediated hepatic ischemia–reperfusion injury throug
    Rujia Wang, Danhong Yang, Yi Chen, Jiabing Wang
    Artificial Cells, Nanomedicine, and Biotechnology.2025; 53(1): 420.     CrossRef
  • CKS2 Mediates Hepatocellular Carcinoma Recurrence After Hepatic Ischemia-Reperfusion Injury Related to M2 Macrophages
    Senzhe Xia, Xueqian Qin, Chenggeng Pan, Dingwei Fan, Daqing Yang
    Journal of Inflammation Research.2025; Volume 18: 11801.     CrossRef
  • Electroacupuncture Attenuates Hepatic Ischemia‐Reperfusion Injury by Modulating the Esr1/TAK1–JNK/p38 Signaling Pathway in Rats
    Xiaofang Fan, Wei Guo, Xiaodan Yang, Hao Zhang, Bruno Fink, Lingyu Hu, Xiaoguang Wang, Mirella Giovarelli
    Mediators of Inflammation.2025;[Epub]     CrossRef
  • FTO-m6A demethylation in cerebral I/R injury: Dual regulation of cell death and neuroinflammation towards therapeutic translation: A review
    Chenglin Zhu, Xinyu Zhang, Boran Huang, Xinyu Wang, Honggang Wang
    International Journal of Biological Macromolecules.2025; 328: 147739.     CrossRef
  • Effect of remote ischemic postconditioning on hepatic ischemia–reperfusion injury in patients undergoing laparoscopic hepatectomy: a randomized double-blinded controlled trial
    Chao Yang, Lijun Yang, Mingwang Zeng, Yunyan Zhu, Chuanwu Zhang, Jing Chen, Yi Wang, Jinji Peng, Li-feng Wang, Maolin Zhong, Haiyu Xie, Weidong Liang
    Frontiers in Medicine.2025;[Epub]     CrossRef
  • Plasma Proteomic Profiling of Colorectal Cancer: Insights from Minimally Invasive Surgical Cohorts
    Yang Yan, Yizhao Ma, Pan Xiao, Jingyuan Wang, Sai Xiao, Enqiang Linghu, Pengyue Zhao, Qianqian Chen
    Journal of Proteome Research.2025; 24(12): 6252.     CrossRef
  • Nicotinic acid protects against hepatic ischemia-reperfusion injury via suppressing mitochondrial damage-induced ferroptosis
    Qian Zeng, Yina Sun, Mengzhen Lei, Zihan Liu, Xijing Yan, Rong Li, Jun Zheng, Jiandong Zha, Lijun Zhang, Xiaoling Guan, Jia Yao
    Liver Research.2025; 9(4): 324.     CrossRef
  • Transcriptomic exploration combined with experimental validation: uncovering the potential value of biomarkers related to ammonia-induced cell death in hepatic ischemia–reperfusion injury
    Runyu Zhuang, Junhao Xiao, Benliang Mao, Yong Yan, Wei Yuan, Fan Wu, Bailin Wang
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Discovery of Bergamotanes against Hepatic Ischemia–Reperfusion Injury Based on DeepSAT Technology from Paraconiothyrium sp. H–B
    Xinye Huang, Xiangli Zhao, Xiaosheng Tan, Yeting Zhang, Zhengyi Shi, Gang Chen, Changxing Qi, Yonghui Zhang
    Journal of Agricultural and Food Chemistry.2025; 73(49): 31390.     CrossRef
  • Novel Perspectives in Hepatic Ischemia-Reperfusion Injury: The cGAS-STING Pathway
    Runsheng Chen, Tingfeng Yang, Zhonghao Jiang, Yang Long, Baolin Qian, Wenguang Fu
    Journal of Inflammation Research.2025; Volume 18: 16427.     CrossRef
  • Protective effects of treprostinil and ischemic preconditioning on hepatic ischemia-reperfusion injury and biomarkers in experimental studies in rats
    Christina Mouratidou, Efstathios T Pavlidis, Georgios Katsanos, Serafeim-Chrysovalantis Kotoulas, Maria Papaioannou, Georgios Tsoulfas, Emmanouela Apostolopoulou, Georgia D Brellou, Ioannis N Galanis, Theodoros E Pavlidis
    World Journal of Gastrointestinal Surgery.2025;[Epub]     CrossRef
  • Ubiquitination of Rhomboid 5 Homolog 2 by Constitutive Photomorphogenic 1 Alleviates Hepatic Ischemia-reperfusion Injury by Regulating the Transforming Growth Factor-Β Activating Kinase 1-C-Jun N-terminal Kinase/p38 Signaling Pathway
    Wendong Li, Tongtong Wu, Hao Li, Zhenyu Guan, Mingjie Ding, Wenzhi Guo
    Cellular and Molecular Gastroenterology and Hepatology.2025; : 101695.     CrossRef
  • Artesunate: A potential drug for the prevention and treatment from hepatitis to hepatocellular carcinoma
    Xinyue Liu, Yilin Cai, Yuanhao Zhang, Hetian Zhang, Sisi Tian, Yuxia Gong, Qinmei Song, Xiaotong Chen, Xiao Ma, Yueqiang Wen, Yu Chen, Jinhao Zeng
    Pharmacological Research.2024; 210: 107526.     CrossRef
  • 11,461 View
  • 386 Download
  • 29 Web of Science
  • Crossref

Reply to Correspondence

Artificial intelligence, epidemiology, methodology, or others

Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol 2024;30(4):1037-1038.
Published online May 2, 2024
DOI: https://doi.org/10.3350/cmh.2024.0320
  • 5,346 View
  • 56 Download

Correspondence

Artificial intelligence, epidemiology, methodology, or others

Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol 2024;30(4):987-988.
Published online April 19, 2024
DOI: https://doi.org/10.3350/cmh.2024.0266
  • 5,623 View
  • 53 Download

Editorial

Artificial intelligence, epidemiology, methodology, or others

Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
Clin Mol Hepatol 2024;30(2):150-153.
Published online February 22, 2024
DOI: https://doi.org/10.3350/cmh.2024.0116

Citations

Citations to this article as recorded by  Crossref logo
  • Causal relationship and mediating role between depression and cognitive performance
    Xinyu Hao, Fuyang Cao, Ziyao Xu, Shaohua You, Tianyue Mi, Lei Wang, Yongxin Guo, Zhuoning Zhang, Jiangbei Cao, Jingsheng Lou, Yanhong Liu, Xianyang Chen, Zhikang Zhou, Weidong Mi, Li Tong
    The Journal of Prevention of Alzheimer's Disease.2025; 12(8): 100196.     CrossRef
  • Prospects of Mendelian randomization in hepatology: a comprehensive literature review with practice guidance
    Lanlan Chen, Qi Rao, Menghan Gao, Guoyue Lv, Frank Tacke
    Clinical and Molecular Hepatology.2025; 31(4): 1115.     CrossRef
  • Serum complement C3 as a diagnostic biomarker for metabolic dysfunction -associated steatotic liver disease in middle-aged and elderly adults: a cross-sectional study
    Dan Ye, Haifen Ma, Jingjing Zhou, Jiaofeng Wang, Jiaheng Shi, Jie Chen, Zhijun Bao, Xiaona Hu
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Reassessing the Impact of Coffee Consumption on Liver Disease: Insights from a Large-Scale Cohort Study with IPTW Adjustment
    Keungmo Yang, Young Chang, Soung Won Jeong, Jae Young Jang, Tom Ryu
    Nutrients.2024; 16(13): 2020.     CrossRef
  • Impact of Physical Activity on Overall Survival and Liver Cirrhosis Incidence in Steatotic Liver Disease: Insights from a Large Cohort Study Using Inverse Probability of Treatment Weighting
    Keungmo Yang, Beom Sun Chung, Tom Ryu
    Nutrients.2024; 16(15): 2532.     CrossRef
  • Reply to correspondence on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
    Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
    Clinical and Molecular Hepatology.2024; 30(4): 1037.     CrossRef
  • Correspondence to editorial on “Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets”
    Yingzhou Shi, Guandou Yuan, Xiude Fan, Chao Xu
    Clinical and Molecular Hepatology.2024; 30(4): 987.     CrossRef
  • 8,290 View
  • 99 Download
  • 8 Web of Science
  • Crossref

Original Article

Artificial intelligence, epidemiology, methodology, or others

Protein-centric omics analysis reveals circulating complements linked to non-viral liver diseases as potential therapeutic targets
Yingzhou Shi, Hang Dong, Shiwei Sun, Xiaoqin Wu, Jiansong Fang, Jianbo Zhao, Junming Han, Zongyue Li, Huixiao Wu, Luna Liu, Wanhong Wu, Yang Tian, Guandou Yuan, Xiude Fan, Chao Xu
Clin Mol Hepatol 2024;30(1):80-97.
Published online December 7, 2023
DOI: https://doi.org/10.3350/cmh.2023.0343
Background/Aims
To evaluate the causal correlation between complement components and non-viral liver diseases and their potential use as druggable targets.
Methods
We conducted Mendelian randomization (MR) to assess the causal role of circulating complements in the risk of non-viral liver diseases. A complement-centric protein interaction network was constructed to explore biological functions and identify potential therapeutic options.
Results
In the MR analysis, genetically predicted levels of complement C1q C chain (C1QC) were positively associated with the risk of autoimmune hepatitis (odds ratio 1.125, 95% confidence interval 1.018–1.244), while complement factor H-related protein 5 (CFHR5) was positively associated with the risk of primary sclerosing cholangitis (PSC;1.193, 1.048– 1.357). On the other hand, CFHR1 (0.621, 0.497–0.776) and CFHR2 (0.824, 0.703–0.965) were inversely associated with the risk of alcohol-related cirrhosis. There were also significant inverse associations between C8 gamma chain (C8G) and PSC (0.832, 0.707–0.979), as well as the risk of metabolic dysfunction-associated steatotic liver disease (1.167, 1.036–1.314). Additionally, C1S (0.111, 0.018–0.672), C7 (1.631, 1.190–2.236), and CFHR2 (1.279, 1.059–1.546) were significantly associated with the risk of hepatocellular carcinoma. Proteins from the complement regulatory networks and various liver diseaserelated proteins share common biological processes. Furthermore, potential therapeutic drugs for various liver diseases were identified through drug repurposing based on the complement regulatory network.
Conclusions
Our study suggests that certain complement components, including C1S, C1QC, CFHR1, CFHR2, CFHR5, C7, and C8G, might play a role in non-viral liver diseases and could be potential targets for drug development.

Citations

Citations to this article as recorded by  Crossref logo
  • КЛІНІКО-МОРФОЛОГІЧНІ АСПЕКТИ ПЕРВИННОГО НЕАЛКОГОЛЬНОГО СТЕАТОГЕПАТИТУ ЗА НАЯВНОСТІ КОМОРБІДНОЇ ПАТОЛОГІЇ ЖОВЧНОГО МІХУРА
    О. Ю. Фофанова, В. В. Феденько, З. Я. Гурик, Е. О. Кіндратів, І. Г. Лаб'як
    Art of Medicine.2025; : 113.     CrossRef
  • Immune activation contributes recovery following pulmonary impairments by silica nanoparticles
    Caixia Guo, Xinying Zhao, Yan Li, Donglei Wang, Hailin Xu, Songqing Lv, Xueyan Li, Yanbo Li
    Journal of Hazardous Materials.2025; 496: 139403.     CrossRef
  • Plasma complement proteins as biomarkers and therapeutic targets in chronic kidney disease: a Mendelian randomization analysis
    Yu-Peng Xu, Zheng-Qi Song, Ming-Li Chen, Yang-Li Fang, Hui-Di Zhang
    Renal Failure.2025;[Epub]     CrossRef
  • Tissue-specific isoform usage and gene expression revealed through RNA-seq and ATAC-seq in developing cattle
    Sarem F. Khilji, Shangqian Xie, Gabrielle M. Becker, Katie A. Shira, Morgan R. Stegemiller, Julia L. Woods, Janet E. Williams, Lauren E. Christensen, Denise E. Konetchy, Darren E. Hagen,, Gordon K. Murdoch, Stephanie D. McKay, Brenda M. Murdoch
    BMC Genomics.2025;[Epub]     CrossRef
  • Starting the journey: Understanding the roles of complement proteins in liver diseases through mendelian randomization
    Mohammad Saeid Rezaee-Zavareh, Naomy Kim, Ju Dong Yang
    Clinical and Molecular Hepatology.2024; 30(2): 150.     CrossRef
  • Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis
    Zelin Tian, Junbo Song, Jiang She, Weixiang He, Shanshan Guo, Bingchen Dong
    Apoptosis.2024; 29(9-10): 1632.     CrossRef
  • Hepatocyte nuclear factor 4α is a critical factor for the production of complement components in the liver
    Carlos Ichiro Kasano-Camones, Satomi Yokota, Maiko Ohashi, Noriaki Sakamoto, Daichi Ito, Yoshifumi Saito, Ryo Uchida, Kazumi Ninomiya, Yusuke Inoue
    In Vitro Cellular & Developmental Biology - Animal.2024; 60(10): 1174.     CrossRef
  • 10,600 View
  • 261 Download
  • 10 Web of Science
  • Crossref

Reviews

Artificial intelligence, epidemiology, methodology, or others

A decade of liver organoids: Advances in disease modeling
Yue Liu, Jian-Ying Sheng, Chun-Fang Yang, Junjun Ding, Yun-Shen Chan
Clin Mol Hepatol 2023;29(3):643-669.
Published online March 6, 2023
DOI: https://doi.org/10.3350/cmh.2022.0428
Liver organoids are three-dimensional cellular tissue models in which cells interact to form unique structures in culture. During the past 10 years, liver organoids with various cellular compositions, structural features, and functional properties have been described. Methods to create these advanced human cell models range from simple tissue culture techniques to complex bioengineering approaches. Liver organoid culture platforms have been used in various research fields, from modeling liver diseases to regenerative therapy. This review discusses how liver organoids are used to model disease, including hereditary liver diseases, primary liver cancer, viral hepatitis, and nonalcoholic fatty liver disease. Specifically, we focus on studies that used either of two widely adopted approaches: differentiation from pluripotent stem cells or epithelial organoids cultured from patient tissues. These approaches have enabled the generation of advanced human liver models and, more importantly, the establishment of patient-tailored models for evaluating disease phenotypes and therapeutic responses at the individual level.

Citations

Citations to this article as recorded by  Crossref logo
  • Advances in 3D Organoids and Organ‐on‐a‐Chip Systems for Biomedical Research
    Vignesh Sakthivel, Santhanam Sanjai Dharshan, S. Karthick Raja Namasivayam, Jesu Arockiaraj
    Journal of Biomedical Materials Research Part A.2026;[Epub]     CrossRef
  • Liver organoids: From 3D printing to biomedical applications
    Ying Shi, Xin Han, Zheng Zhang, Jiangtao Xu, Guozhen Liu
    BMEMat.2025;[Epub]     CrossRef
  • Computational and experimental advances in liver-on-a-chip technology for cancer research: a systematic review
    Violeta Carvalho, Mariana Ferreira, Raquel O. Rodrigues, Senhorinha F. C. F. Teixeira, Rui A. Lima
    Biophysical Reviews.2025; 17(1): 151.     CrossRef
  • Revolutionizing liver fibrosis research: the promise of 3D organoid models in understanding and treating chronic liver disease
    Umashanker Navik, Sumeet Kumar Singh, Amit Khurana, Ralf Weiskirchen
    Expert Review of Gastroenterology & Hepatology.2025; 19(2): 105.     CrossRef
  • Liver organoids: Current advances and future applications for hepatology
    Yohan Kim, Minseok Kang, Michael Girma Mamo, Michael Adisasmita, Meritxell Huch, Dongho Choi
    Clinical and Molecular Hepatology.2025; 31(Suppl): S327.     CrossRef
  • Modeling hepatic steatosis with human adult stem cell-derived liver organoids
    Liuyang Zhu, Sen Liu, Ze Wang, Yueyue Yang, Pinsheng Han, Wen Tong, Tianyu Zhao, Libo Wang, Tao Cui, Long Yang, Yamin Zhang
    iScience.2025; 28(5): 112344.     CrossRef
  • “Armed in-vitro retina”-generating microglial retinal organoids, where are we now?
    Yaohong Liu, Lixiong Gao, Wenqian Chen, Yuhan Yan, Zi Ye, Zhaohui Li
    Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
  • Primary Human Tissue Models for Metabolic Dysfunction‐Associated Liver Disease ‐ toward Streamlining Drug Discovery with Patient‐Derived Assays
    Sonia Youhanna, Nayere Taebnia, Yingxin Liang, Ningtao Cheng, Yi Wang, Maurice Michel, Volker M. Lauschke
    Advanced Biology.2025;[Epub]     CrossRef
  • Psychosomatic Disorders, Epigenome, and Gut Microbiota
    Hamid Mostafavi Abdolmaleky, Ahmad Pirani, Giuseppe Pettinato
    Cells.2025; 14(24): 1959.     CrossRef
  • Generation and characterization of mature hepatocyte organoids for liver metabolic studies
    Yuchen Liu, Yaxing Zhou, James Ahodantin, Yu Jin, Juanjuan Zhu, Zhonghe Sun, Xiaolin Wu, Lishan Su, Yingzi Yang
    Journal of Cell Science.2024;[Epub]     CrossRef
  • Generation of in vivo-like multicellular liver organoids by mimicking developmental processes: A review
    Ayumu Okumura, Kenji Aoshima, Naoki Tanimizu
    Regenerative Therapy.2024; 26: 219.     CrossRef
  • Ex Vivo Tools and Models in MASLD Research
    Rallia-Iliana Velliou, Eirini Giannousi, Christiana Ralliou, Eva Kassi, Antonios Chatzigeorgiou
    Cells.2024; 13(22): 1827.     CrossRef
  • Advanced In Vitro Models for Preclinical Drug Safety: Recent Progress and Prospects
    Dileep G. Nair, Ralf Weiskirchen
    Current Issues in Molecular Biology.2024; 47(1): 7.     CrossRef
  • Breast cancer organoids derived from patients: A platform for tailored drug screening
    Yen-Dun Tony Tzeng, Jui-Hu Hsiao, Ling-Ming Tseng, Ming-Feng Hou, Chia-Jung Li
    Biochemical Pharmacology.2023; 217: 115803.     CrossRef
  • 16,658 View
  • 373 Download
  • 14 Web of Science
  • Crossref

Artificial intelligence, epidemiology, methodology, or others

Wnt signaling in liver regeneration, disease, and cancer
Gengyi Zou, Jae-Il Park
Clin Mol Hepatol 2023;29(1):33-50.
Published online July 4, 2022
DOI: https://doi.org/10.3350/cmh.2022.0058
The liver exhibits the highest recovery rate from acute injuries. However, in chronic liver disease, the long-term loss of hepatocytes often leads to adverse consequences such as fibrosis, cirrhosis, and liver cancer. The Wnt signaling plays a pivotal role in both liver regeneration and tumorigenesis. Therefore, manipulating the Wnt signaling has become an attractive approach to treating liver disease, including cancer. Nonetheless, given the crucial roles of Wnt signaling in physiological processes, blocking Wnt signaling can also cause several adverse effects. Recent studies have identified cancer-specific regulators of Wnt signaling, which would overcome the limitation of Wnt signaling target approaches. In this review, we discussed the role of Wnt signaling in liver regeneration, precancerous lesion, and liver cancer. Furthermore, we summarized the basic and clinical approaches of Wnt signaling blockade and proposed the therapeutic prospects of cancer-specific Wnt signaling blockade for liver cancer treatment.

Citations

Citations to this article as recorded by  Crossref logo
  • Correspondence to letter to the editor on “GULP1 as a novel diagnostic and predictive biomarker in hepatocellular carcinoma”
    Hyung Seok Kim, Soon Sun Kim, Jae Youn Cheong, Jung Woo Eun
    Clinical and Molecular Hepatology.2026; 32(1): e103.     CrossRef
  • Blood flow‐induced angiocrine signals promote organ growth and regeneration
    Paula Follert, Linda Große‐Segerath, Eckhard Lammert
    BioEssays.2025;[Epub]     CrossRef
  • In vitro β-catenin attenuation by a mefloquine-loaded core–shell nano emulsion strategy to suppress liver cancer cells
    Priyadarshini Mohapatra, Natarajan Chandrasekaran
    Nanoscale Advances.2025; 7(3): 748.     CrossRef
  • YAP/TAZ as master regulators in liver regeneration and disease: insights into mechanisms and therapeutic targets
    Bingyu Ye, Meijuan Yue, Hu Chen, Caifang Sun, Yongle Shao, Qinpeng Jin, Chunyan Zhang, Guoying Yu
    Molecular Biology Reports.2025;[Epub]     CrossRef
  • Protein Coronation-Induced Cancer Staging-Dependent Multilevel Cytotoxicity: An All-Humanized Study in Blood Vessel Organoids
    Chan Wang, Yingyi Quan, Jiang Jiang, Han Yu, Jia Liu, Wei Tang, Xinyue Li, Shouju Wang, Da Huo, Guang-Liang Jiang, Yang Yang, Qingqing Ding
    ACS Nano.2025; 19(1): 345.     CrossRef
  • Wnt Pathway-Targeted Therapy in Gastrointestinal Cancers: Integrating Benchside Insights with Bedside Applications
    Anirudh Nayak, Hannah Streiff, Ivan Gonzalez, Oluwabomi Oluwatomi Adekoya, Itzcoatl Silva, Anitha Kota Shenoy
    Cells.2025; 14(3): 178.     CrossRef
  • Molecular mechanisms in liver repair and regeneration: from physiology to therapeutics
    Xiao Ma, Tengda Huang, Xiangzheng Chen, Qian Li, Mingheng Liao, Li Fu, Jiwei Huang, Kefei Yuan, Zhen Wang, Yong Zeng
    Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
  • Cell competition as an emerging mechanism and therapeutic target in cancer
    Dakai Yang, Wenyue Sun, Lu Gao, Kai Zhao, Qin Zhuang, Yun Cai
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(5): 167769.     CrossRef
  • Wnt signaling pathways in biology and disease: mechanisms and therapeutic advances
    Chen Xue, Qingfei Chu, Qingmiao Shi, Yifan Zeng, Juan Lu, Lanjuan Li
    Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
  • Influencing factors and mechanism of hepatocyte regeneration
    Xiaoyi Zhang, Shenghao Li, Liyuan Hao, Fukang Jia, Fei Yu, Xiaoyu Hu
    Journal of Translational Medicine.2025;[Epub]     CrossRef
  • AEBP1 or ACLP, which is the key factor in inflammation and fibrosis?
    Zhang Runtian, Han Wenqiang, Shen Zimeng, Wang Tianyu, Zhong Jingquan
    International Journal of Biological Macromolecules.2025; 310: 143554.     CrossRef
  • Nicotinamide N-Methyltransferase (NNMT) and Liver Cancer: From Metabolic Networks to Therapeutic Targets
    Shi-Yan Lai, Xiao-Juan Zhu, Wei-Dong Sun, Shuang-Zhou Bi, Chen-Ying Zhang, An Liu, Jiang-Hua Li
    Biomolecules.2025; 15(5): 719.     CrossRef
  • Glycyrrhizic acid promotes liver regeneration through activating β-catenin in acetaminophen-induced liver injury
    Rong Cao, Hui Gong, Shuang Xia, Zhiyu Hu, Xiaoxiang Fan, Bowen Zhai, Linna Guo, Chunguang Xia, Zhichao Jiang, Miao Yan
    Journal of Ethnopharmacology.2025; 349: 119895.     CrossRef
  • The Association Between Hepatocellular Carcinoma and Gastrointestinal Adenocarcinoma: Is This a New Syndrome in Patients With Cirrhosis? A Case Series
    Fabrizio Bronte, Fabio D'Amato, Maria Rosa Barcellona, Giuseppe Bronte, Giuseppe Malizia, Salvatore Ialuna, Giorgio Fusco, Francesco Verderame, Enrico Bronte, Maria Grazia Bavetta
    Cancer Reports.2025;[Epub]     CrossRef
  • Baicalin Alleviates Piglet Immunosuppression Induced by Glaesserella parasuis via Promoting CD163/Tumor Necrosis Factor-like Weak Inducer of Apoptosis-Mediated Autophagy
    Shulin Fu, Ronghui Luo, Jingyang Li, Yunjian Fu, Qiaoli Dong, Siyu Liu, Yamin Sun, Ling Guo, Jin Hu, Yinsheng Qiu
    Biomolecules.2025; 15(5): 722.     CrossRef
  • The protective role of vitamin C against linezolid-induced hepato-renal toxicity in a rat model
    Shaimaa M. Azzam, Hend Mohamed Anwar, Ahmed H. Abd El-Slam, Marwa S. M. Diab, Halima Mohamed Ibrahim, Abdalrahman Mohammed Yousef, Fatma Mahmoud Sabry, Ibrahim A. Darwish, Kalidasan Kaliyamoorthy, Gad Elsayed Mohamed Salem, Heba M. A. Elsanhory
    Frontiers in Pharmacology.2025;[Epub]     CrossRef
  • High-efficient discovering the potent anti-Notum agents from herbal medicines for combating glucocorticoid-induced osteoporosis
    Yuqing Song, Feng Zhang, Jia Guo, Yufan Fan, Hairong Zeng, Mengru Sun, Jun Qian, Shenglan Qi, Zihan Chen, Xudong Jin, Yunqing Song, Tian Tian, Zhi Qian, Yao Sun, Zhenhao Tian, Baoqing Yu, Guangbo Ge
    Acta Pharmaceutica Sinica B.2025; 15(8): 4174.     CrossRef
  • Matrine targets β-catenin and blocks the formation of β-catenin/TCF7L2 complex to promote ferroptosis and inhibit metastasis in triple-negative breast cancer
    Yazhou Sang, Yue Hu, Ruohan Liang, Yueyue Zhang, Hongyuan Du, Huilan Zhang, Juan Chen, Yaqiong Zhang, Xuan Cao
    Phytomedicine.2025; 145: 157044.     CrossRef
  • Advances in the Study of RNA Deconjugating Enzyme DDX5 in Cancer
    静 宋
    World Journal of Cancer Research.2025; 15(03): 124.     CrossRef
  • SERPINH1 promotes malignant progression of laryngeal squamous cell carcinoma via COL7A1-mediated Wnt/β-catenin signaling
    Feinan He, Jinqiu Li, Weifang Tong, Sanchun Wang, Hongyan Wang, Baishuo Huang, Bo Teng
    Cellular Signalling.2025; 135: 112043.     CrossRef
  • Liver regeneration after partial hepatectomy: Triggers and mechanisms
    Bakari Korchilava, Tamar Khachidze, Nino Megrelishvili, Lika Svanadze, Manana Kakabadze, Keti Tsomaia, Memed Jintcharadze, Dimitri Kordzaia
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Targeting Wnt-driven metabolic adaptations in cancer: integrating glycolysis, glutaminolysis, IDO1-mediated immune evasion, and therapeutic delivery strategies
    Eric Flores-Hernández, Grace Binder, Kuo-Ching Mei, Nydia Tejeda-Muñoz
    Frontiers in Cell and Developmental Biology.2025;[Epub]     CrossRef
  • Therapeutic Advances in Signaling Channels and Their Associated Targets in the Development of Liver Fibrosis
    芳卓 朱
    Journal of Clinical Personalized Medicine.2025; 04(05): 48.     CrossRef
  • WNT signaling in cancer: molecular mechanisms and potential therapies
    Jiaqi Liang, Yiming Pan, Jingru Yang, Dequan Zeng, Jing Li
    Molecular Biomedicine.2025;[Epub]     CrossRef
  • Clinicopathological insights and management of liver metastases: Current advances and future perspectives
    Noura A A Ebrahim, Thoraya A Farghaly, Ahmed Abdo El-Sherif, Ahmed M Fahmy, Moamen O Othman, Neveen S Tahoun, Omnia Mohamed Korany, Aya Arafat, Reham Oreaba, Soliman M A Soliman
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Intestinal LKB1 Loss Drives a Premalignant Program Along the Serrated Cancer Pathway
    S.F. Plugge, H. Ma, J.Y. van der Vaart, J. Sprangers, F.H.M. Morsink, D. Xanthakis, C. Jamieson, K.B.W. Stroot, A.R. Keijzer, T. Margaritis, T. Candelli, R. Straver, J. de Ridder, F.C.P. Holstege, W.W.J. de Leng, G.J.A. Offerhaus, A. Merenda, M.M. Maurice
    Gastroenterology.2025;[Epub]     CrossRef
  • Elucidating the role of SIRT2 in hepatocellular carcinoma through multi-omics and deep learning
    Changan Chen, Tingmei Yang, Caiyuan Yu, Lijiao Cui, Bingjun Cai, Zhenkai Li, Shicai Ye, Yijie Weng
    Discover Oncology.2025;[Epub]     CrossRef
  • Hirudin suppresses hematogenous metastasis by targeting desmosome junction transition in circulating tumor cell clusters via HIF-1α–DSG2 signaling
    Jueyao Zou, Junfeng Shi, Qiong Chen, Ziyan Zhu, Tongyao Hu, Zhengyu Zhang, Zhiqiang Pan, Fei Xu, Yong Zhu, Yuanyuan Wu, Yang Zhao, Aiyun Wang, Yin Lu, Yanhong Pan, Wenxing Chen
    Experimental & Molecular Medicine.2025; 57(12): 2798.     CrossRef
  • Conversion Therapy and Liver Regeneration in Liver Cancer
    Xiaoqin Wu
    Journal of Biosciences and Medicines.2025; 13(12): 374.     CrossRef
  • Signaling pathways of liver regeneration: Biological mechanisms and implications
    Chunyan Zhang, Caifang Sun, Yabin Zhao, Bingyu Ye, GuoYing Yu
    iScience.2024; 27(1): 108683.     CrossRef
  • miR-199a-5p modulates choroidal neovascularization by regulating Wnt7b/Wnt/β-catenin signaling pathway
    Yu Geng, HaiRong Hua, Yuan Xia, Jie Zhou, Jian He, XingYu Xu, JianFeng Zhao
    Journal of Molecular Histology.2024; 55(3): 359.     CrossRef
  • Unraveling the crosstalk: circRNAs and the wnt signaling pathway in cancers of the digestive system
    Yu Zhang, Cheng Zhang, Chuanhui Peng, Junjun Jia
    Non-coding RNA Research.2024; 9(3): 853.     CrossRef
  • Advances in precision gene editing for liver fibrosis: From technology to therapeutic applications
    Peng Ji, Yan Li, Zihan Wang, Siyu Jia, Xinyi Jiang, Hui Chen, Qun Wang
    Biomedicine & Pharmacotherapy.2024; 177: 117003.     CrossRef
  • HNF4α improves hepatocyte regeneration by upregulating PXR
    Shantong Qiu, Yangyang Pan, Yan Cui, Mei Li, Tao Yue, Sisi Pu, Qian Zhang, Meng Wang
    The FASEB Journal.2024;[Epub]     CrossRef
  • A male mouse model for metabolic dysfunction-associated steatotic liver disease and hepatocellular carcinoma
    Byung-Kwan Jeong, Won-Il Choi, Wonsuk Choi, Jieun Moon, Won Hee Lee, Chan Choi, In Young Choi, Sang-Hyun Lee, Jung Kuk Kim, Young Seok Ju, Pilhan Kim, Young-Ah Moon, Jun Yong Park, Hail Kim
    Nature Communications.2024;[Epub]     CrossRef
  • Unveiling the anticancer effect of traditional Chinese herbal medicine
    Naoki Asano
    World Journal of Gastroenterology.2024; 30(30): 3626.     CrossRef
  • Unveiling the anticancer effect of traditional Chinese herbal medicine
    Naoki Asano
    World Journal of Gastroenterology.2024; 30(30): 3625.     CrossRef
  • Novel biomarkers and drug correlations of non-canonical WNT signaling in prostate and breast cancer
    Yongming Huang, Meiyin Fan, Yushuai Liu, Xiaoying Jiang, Kevin Du, Alice Wu, Qingyi Li, Yingying Wu, Jiaqian Liang, Keshan Wang
    Discover Oncology.2024;[Epub]     CrossRef
  • NSUN2 regulates Wnt signaling pathway depending on the m5C RNA modification to promote the progression of hepatocellular carcinoma
    Huiwu Xing, Xinyu Gu, Yingru Liu, Lixia Xu, Yuting He, Chen Xue
    Oncogene.2024; 43(47): 3469.     CrossRef
  • Discovery of CLKs inhibitors for the treatment of non-small cell lung cancer
    Tianxing Hu, Jiali Huang, Rui Chen, Hui Zhang, Mai Liu, Renbing Wang, Wenyi Zhou, Dechun Huang, Mingkang Cao, Depeng Li, Zhiyu Li, Hongxi Wu, Jinlei Bian
    European Journal of Medicinal Chemistry.2024; 280: 116952.     CrossRef
  • Roles of deubiquitinases in urologic cancers (Review)
    Liangpei Wu, Jiahui Wang, Lin Chai, Jun Chen, Xiaofeng Jin
    Oncology Letters.2024;[Epub]     CrossRef
  • Modulation of the central nervous system immune response and neuroinflammation via Wnt signaling in health and neurodegenerative diseases
    Kevin Fang
    Ibrain.2024; 10(4): 462.     CrossRef
  • Yiqi Liangxue Jiedu Prescription Inhibited the Canonical Wnt Pathway to Prevent Hepatocellular Precancerous Lesions
    Yuling Liang, Yuqing Xie, Zhibo Dang, Mengge Li, Lihua Yu, Xinhui Wang, Peng Wang, Zhiyun Yang
    Journal of Hepatocellular Carcinoma.2024; Volume 11: 2293.     CrossRef
  • Wnt Signaling Activation in Gingival Epithelial Cells and Macrophages of Experimental Periodontitis
    Ying Chen, Yang Hu
    Dentistry Journal.2023; 11(5): 129.     CrossRef
  • Targeting signaling pathways in osteosarcoma: Mechanisms and clinical studies
    Ziyu Ji, Jianlin Shen, Yujian Lan, Qian Yi, Huan Liu
    MedComm.2023;[Epub]     CrossRef
  • Therapeutic strategies to improve liver regeneration after hepatectomy
    Hayeong Jeong, Chanbin Lee, Min Jae Lee, Youngmi Jung
    Experimental Biology and Medicine.2023; 248(15): 1313.     CrossRef
  • Integrated analysis of tumor microenvironment features to establish a diagnostic model for papillary thyroid cancer using bulk and single-cell RNA sequencing technology
    Yizeng Wang, Wenbin Song, Yingxi Li, Zhaoyi Liu, Ke Zhao, Lanning Jia, Xiaoning Wang, Ruoyu Jiang, Yao Tian, Xianghui He
    Journal of Cancer Research and Clinical Oncology.2023; 149(18): 16837.     CrossRef
  • Milk thistle nano-micelle formulation promotes cell cycle arrest and apoptosis in hepatocellular carcinoma cells through modulating miR-155-3p /SOCS2 /PHLDA1 signaling axis
    Saghar Rahnama, Zahra Moazezi Tehrankhah, Fatemeh Mohajerani, Faezeh Shah Mohammadi, Zahra Yousefi Yeganeh, Farhood Najafi, Sadegh Babashah, Majid Sadeghizadeh
    BMC Complementary Medicine and Therapies.2023;[Epub]     CrossRef
  • Associations of Wnt5a expression with liver injury in chronic hepatitis B virus infection
    Xiang-Fen Ji, Qi Zhou, Jing-Wei Wang, Fei Sun, Shuai Gao, Kai Wang
    BMC Infectious Diseases.2023;[Epub]     CrossRef
  • Unveiling the power of microenvironment in liver regeneration: an in-depth overview
    Yuelei Hu, Ruilin Wang, Ni An, Chen Li, Qi Wang, Yannan Cao, Chao Li, Juan Liu, Yunfang Wang
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • 15,912 View
  • 320 Download
  • 43 Web of Science
  • Crossref

Alcohol-related liver disease

Subclinical versus advanced forms of alcohol-related liver disease: Need for early detection
Concepción Gómez-Medina, Luma Melo, David Martí-Aguado, Ramón Bataller
Clin Mol Hepatol 2023;29(1):1-15.
Published online April 15, 2022
DOI: https://doi.org/10.3350/cmh.2022.0017
Alcohol-related liver disease (ALD) consists of a wide spectrum of clinical manifestations and pathological features, ranging from asymptomatic patients to decompensated cirrhosis and hepatocellular carcinoma. Patients with heavy alcohol intake and advanced fibrosis often develop a subacute form of liver failure called alcohol-induced hepatitis (AH). Globally, most patients with ALD are identified at late stages of the disease, limiting therapeutic interventions. Thus, there is a need for early detection of ALD patients, which is lacking in most countries. The identification of alcohol misuse is hampered by the existence of alcohol underreporting by many patients. There are useful biomarkers that can detect recent alcohol use. Moreover, there are several non-invasive techniques to assess the presence of advanced fibrosis among patients with alcohol misuse, which could identify patients at high risk of liver related events or early death. In this review, we discuss differences between early stages of ALD and AH as the cornerstone of advanced forms. A global overview of epidemiological, anthropometric, clinical, analytical, histological, and molecular differences is summarized in this article. We propose that campaigns aimed at identifying patients with subclinical forms can prevent the development of life-threatening forms.

Citations

Citations to this article as recorded by  Crossref logo
  • Rifaximin treatment in patients with severe alcohol-associated hepatitis: A multicenter, randomized controlled, open-label, pilot trial
    Do Seon Song, Jin Mo Yang, Young Kul Jung, Hyung Joon Yim, Hee Yeon Kim, Chang Wook Kim, Soon Sun Kim, Jae Youn Cheong, Hae Lim Lee, Sung Won Lee, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim
    Annals of Hepatology.2025; 30(1): 101749.     CrossRef
  • Liver diseases: epidemiology, causes, trends and predictions
    Can Gan, Yuan Yuan, Haiyuan Shen, Jinhang Gao, Xiangxin Kong, Zhaodi Che, Yangkun Guo, Hua Wang, Erdan Dong, Jia Xiao
    Signal Transduction and Targeted Therapy.2025;[Epub]     CrossRef
  • Potential benefits of orally deliverable silymarin-loaded spirulina platensis in mitigating alcoholic liver disease
    Sijia Hao, Yueqi Lv, Yuxiao Wang, Kangjing Liu, Xiaoting Yu, Mingqian Tan
    Food Research International.2025; 212: 116508.     CrossRef
  • Clinical characteristics of MASLD/MetALD/MAFLD/NAFLD and the relative risk analysis on metabolic disorders
    Hong-ye Peng, Chun-li Lu, Mo Zhao, Xiao-qiang Huang, Shu-xia Huang, Zi-wen Zhuo, Jing Liu, Yan-ping Lu, Wen-liang Lv
    BMC Gastroenterology.2025;[Epub]     CrossRef
  • Serum β-klotho is a potential biomarker for diagnosing alcoholic liver disease and differentiating from nonalcoholic fatty liver disease
    Chengmei Fang, Xin Miao, Chuyan Peng, Zhenguo Xie, Fuzhen Zhao, Tian Chen, Wenjin Zhang, Xiaofei Bi, Xuan An, Guicheng Wu
    PeerJ.2025; 13: e19779.     CrossRef
  • Alcohol-associated liver disease: Epidemiology and management
    Helena Hernández-Évole, Natalia Jiménez-Esquivel, Elisa Pose, Ramón Bataller
    Annals of Hepatology.2024; 29(1): 101162.     CrossRef
  • Diagnostic performance of non-invasive tests in patients with MetALD in a health check-up cohort
    Joo Hyun Oh, Sang Bong Ahn, Seon Cho, Eun-Hee Nah, Eileen L. Yoon, Dae Won Jun
    Journal of Hepatology.2024; 81(5): 772.     CrossRef
  • Expansion of effector regulatory T cells in steroid responders of severe alcohol-associated hepatitis
    Min Woo Kang, Soon Kyu Lee, Eun Ji Jang, Jong Geun Park, Deok Hwa Seo, Ji Won Han, Jae Sung Yoo, Jung Hyun Kwon, Soon Woo Nam, Jeong Won Jang, Jong Young Choi, Seung Kew Yoon, Pil Soo Sung
    Liver Transplantation.2024; 30(9): 877.     CrossRef
  • Non-Invasive Biomarkers for Differentiating Alcohol Associated Hepatitis from Acute Decompensation in Patients with ALD
    Mina Ignat, Horia Stefanescu
    Journal of Clinical Medicine.2024; 13(13): 3747.     CrossRef
  • KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
    Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, D
    Clinical and Molecular Hepatology.2024; 30(Suppl): S5.     CrossRef
  • The prognostic impact of psychiatric intervention on alcohol-associated liver disease: The UK Biobank cohort study
    Keungmo Yang, Sunghwan Kim, Hyun Yang, Sheng-Min Wang, Bumseok Jeong, Hyun Kook Lim, Si Hyun Bae
    Clinical and Molecular Hepatology.2024; 30(4): 929.     CrossRef
  • Liver stiffness as a dynamic predictor of decompensation and mortality in alcohol-related liver disease
    Tamer A. Addissouky
    Discover Medicine.2024;[Epub]     CrossRef
  • ADRB2 serves as a novel biomarker and attenuates alcoholic hepatitis via the SIRT1/PGC-1α/PPARα pathway: integration of WGCNA, machine learning and experimental validation
    Li Song, Shuo Huang, Honghao Yan, Qing Ma, Qihan Luo, Jiang Qiu, Minxia Chen, Zongyuan Li, He Jiang, Yufan Chen, Fangming Chen, Yu Du, Haozhe Fu, Lisha Zhao, Kanglu Zhao, Ping Qiu
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Current and future treatment for alcoholic‐related liver diseases
    Eileen L. Yoon, Won Kim
    Journal of Gastroenterology and Hepatology.2023; 38(8): 1218.     CrossRef
  • Alcohol consumption and the risk of liver disease: a nationwide, population-based study
    Sang Yi Moon, Minkook Son, Yeo Wool Kang, Myeongseok Koh, Jong Yoon Lee, Yang Hyun Baek
    Frontiers in Medicine.2023;[Epub]     CrossRef
  • 16,320 View
  • 214 Download
  • 14 Web of Science
  • Crossref

Letter to the Editor

Autoimmune liver disease

The major diagnostic role of autoantibodies in the diagnosis of autoimmune hepatitis, a disease of all ages
Linda Beenet
Clin Mol Hepatol 2021;27(3):510-511.
Published online March 22, 2021
DOI: https://doi.org/10.3350/cmh.2021.0058

Citations

Citations to this article as recorded by  Crossref logo
  • Working Algorithms and Detection Methods of Autoantibodies in Autoimmune Liver Disease: A Nationwide Study
    Guillermo Muñoz-Sánchez, Albert Pérez-Isidro, Iñaki Ortiz de Landazuri, Antonio López-Gómez, Luz Yadira Bravo-Gallego, Milagros Garcia-Ormaechea, Maria Rosa Julià, Odette Viñas, Estíbaliz Ruiz-Ortiz
    Diagnostics.2022; 12(3): 697.     CrossRef
  • 8,023 View
  • 172 Download
  • 1 Web of Science
  • Crossref

Original Article

Steatotic liver disease

Loss-of-function HSD17B13 variants, non-alcoholic steatohepatitis and adverse liver outcomes: Results from a multi-ethnic Asian cohort
Yi-Wen Ting, Amanda Shen-Yee Kong, Shamsul Mohd Zain, Wah-Kheong Chan, Hwa-Li Tan, Zahurin Mohamed, Yuh-Fen Pung, Rosmawati Mohamed
Clin Mol Hepatol 2021;27(3):486-498.
Published online February 23, 2021
DOI: https://doi.org/10.3350/cmh.2020.0162
Background/Aims
17β-hydroxysteroid dehydrogenase 13 (HSD17B13) variants were recently reported to have significantly lower odds of non-alcoholic fatty liver disease (NAFLD). This is a two-part study that aimed to evaluate the association of HSD17B13 variants with NAFLD and its histological severity, and to identify the association of the variants with clinical outcomes in a cohort of biopsy-proven NAFLD patients.
Methods
Consecutive biopsy-proven NAFLD patients and controls without fatty liver were recruited for this study between 2009 and 2014. Genotyping for HSD17B13 variants was performed using rhAmp assays. A total of 165 patients with NAFLD were monitored up until August 2019. Clinical outcomes were recorded.
Results
HSD17B13 rs72613567 TA allele and rs6834314 G allele were associated with lower odds of non-alcoholic steatohepatitis (NASH) in the overall cohort and among ethnic Chinese, but not among ethnic Malays or Indians (P<0.05). During a mean follow-up of 89 months, 32 patients (19.4%) experienced at least one clinical outcome (cardiovascular events, n=22; liver-related complications, n=6; extra-hepatic malignancy, n=5; and mortality, n=6). The rs72613567 homozygous TA allele and the rs6834314 homozygous G allele were independently associated with a lower incidence of liver-related complications (hazard ratio [HR], 0.004; 95% confidence interval [CI], 0.00–0.64; P=0.033 and HR, 0.01; 95% CI, 0.00–0.97; P=0.048, respectively) and were associated with lower grade of hepatocyte ballooning among the ethnic Chinese.
Conclusion
HSD17B13 rs72613567 and rs6834314 variants were inversely associated with NAFLD and NASH, and were associated with lower incidence of adverse liver outcomes in a cohort of multi-ethnic Asian patients with NAFLD.

Citations

Citations to this article as recorded by  Crossref logo
  • RNA-based drugs: current, imminent and possible therapeutic applications
    Sebastiano A. Torrisi, Federica Geraci, Lidia Diolosà, Angelina De Luca, Luca Falzone, Filippo Drago, Massimo Libra, Gian Marco Leggio
    Pharmacology & Therapeutics.2026; 277: 108958.     CrossRef
  • Ethnic differences in metabolic and histologic features among White, Hispanic, Black and Asian patients with metabolic-associated Steatotic liver disease: A network meta-analysis
    Limin Lin, Jiaming Lai, Ling Luo, Junzhao Ye, Bihui Zhong
    Annals of Hepatology.2025; 30(2): 101780.     CrossRef
  • Unraveling Mechanisms of Genetic Risks in Metabolic Dysfunction–Associated Steatotic Liver Diseases: A Pathway to Precision Medicine
    Xiang Zhang, Kyong-Mi Chang, Jun Yu, Rohit Loomba
    Annual Review of Pathology: Mechanisms of Disease .2025; 20(1): 375.     CrossRef
  • Role of genetic variants and DNA methylation of lipid metabolism-related genes in metabolic dysfunction-associated steatotic liver disease
    Jun-Jie Wang, Xiao-Yuan Chen, Yi-Rong Zhang, Yan Shen, Meng-Lin Zhu, Jun Zhang, Jun-Jie Zhang
    Frontiers in Physiology.2025;[Epub]     CrossRef
  • Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
    Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos-Molina
    American Journal of Physiology-Cell Physiology.2025; 328(5): C1637.     CrossRef
  • Meta‐Analysis: Effects of Steatotic Liver Disease‐Associated Genetic Risk Alleles on Longitudinal Outcomes
    Matthew Kubina, Vitchapong Prasitsumrit, Jarell Tan, Joo Wei Ethan Quek, Dhiraj Peddu, Ankit Mishra, Pojsakorn Danpanichkul, Jake P. Mann, Eric Trépo, Stephan Buch, Daniel Q. Huang, Cheng Han Ng, Mark D. Muthiah, Yu Jun Wong, Karn Wijarnpreecha, Vincent L
    Alimentary Pharmacology & Therapeutics.2025; 62(3): 244.     CrossRef
  • Phase I randomized double-blind study of an RNA interference therapeutic targeting HSD17B13 for metabolic dysfunction-associated steatohepatitis
    Arun J. Sanyal, Jorg Taubel, Prajakta Badri, Sarah Bond, Nune Makarova, Weizhi Zhao, Swati Duggal, Farshad Kajbaf, Benjamin A. Olenchock, John M. Gansner
    Journal of Hepatology.2025; 83(4): 838.     CrossRef
  • The Distribution and Survival Association of Genetic Polymorphisms in Thai Patients with Hepatocellular Carcinoma According to Underlying Liver Disease
    Theint Cho Zin Aung, Bootsakorn Boonkaew, Maneerat Chayanupatkul, Kittiyod Poovorawan, Natthaya Chuaypen, Pisit Tangkijvanich
    Genes.2025; 16(7): 808.     CrossRef
  • Metabolic and genetic mechanisms of metabolic dysfunction-associated steatotic liver disease: an integrative perspective from molecular pathways to clinical challenges
    Jingyuan Ma, Yanna Ma, Xing Wan, Junchen Li, Yunshu Zhang, Jifeng Liu, Yunhai Gao
    Frontiers in Endocrinology.2025;[Epub]     CrossRef
  • 17-Beta-Hydroxysteroid Dehydrogenase 13 Loss of Function Does Not Confer Protection to Nonalcoholic Fatty Liver Disease in Indian Population
    Bale Govardhan, V. Kulkarni Anand, Padaki Nagaraja Rao, P. Balachandran Menon, Sharma Mithun, Mitnala Sasikala, T.R. Sowmya, Sekaran Anuradha, C. Pawar Smita, D. Nageshwar Reddy, Vishnubhotla Ravikanth
    Journal of Clinical and Experimental Hepatology.2024; 14(4): 101371.     CrossRef
  • GLP-1 receptor agonists in the treatment of diabetic non–alcoholic steatohepatitis patients
    Ernest A. Adeghate
    Expert Opinion on Pharmacotherapy.2024; 25(3): 223.     CrossRef
  • Emerging roles of RNA‐binding proteins in fatty liver disease
    Oluwafolajimi Adesanya, Diptatanu Das, Auinash Kalsotra
    WIREs RNA.2024;[Epub]     CrossRef
  • Are we ready for genetic testing in metabolic dysfunction‐associated steatotic liver disease?
    Adele Tulone, Grazia Pennisi, Carlo Ciccioli, Giuseppe Infantino, Claudia La Mantia, Roberto Cannella, Francesco Mercurio, Salvatore Petta
    United European Gastroenterology Journal.2024; 12(5): 638.     CrossRef
  • Genetic predisposition to metabolic dysfunction-associated fatty liver disease
    O.E. Abaturov, A.O. Nikulina
    CHILD`S HEALTH.2024; 19(3): 162.     CrossRef
  • Interaction Between PNPLA3 and SIRT5 Genetic Variants in Association with Liver Fibrosis Severity in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease
    Kamonchanok Moonlisarn, Pornjira Somnark, Bootsakorn Boonkaew, Chalermarat Bunchorntavakul, Pisit Tangkijvanich
    Genes.2024; 15(11): 1370.     CrossRef
  • Non-alcoholic fatty liver disease establishment and progression: genetics and epigenetics as relevant modulators of the pathology
    Camila Cristiane Pansa, Letícia Ramos Molica, Karen C. M. Moraes
    Scandinavian Journal of Gastroenterology.2023; 58(5): 521.     CrossRef
  • Review article: the role of HSD17B13 on global epidemiology, natural history, pathogenesis and treatment of NAFLD
    Maral Amangurbanova, Daniel Q. Huang, Rohit Loomba
    Alimentary Pharmacology & Therapeutics.2023; 57(1): 37.     CrossRef
  • Geographical similarity and differences in the burden and genetic predisposition of NAFLD
    Terry Cheuk‐Fung Yip, Eduardo Vilar‐Gomez, Salvatore Petta, Yusuf Yilmaz, Grace Lai‐Hung Wong, Leon A. Adams, Victor de Lédinghen, Silvia Sookoian, Vincent Wai‐Sun Wong
    Hepatology.2023; 77(4): 1404.     CrossRef
  • Correspondence on Letter regarding “Auranofin attenuates hepatic steatosis and fibrosis in nonalcoholic fatty liver disease via NRF2 and NF-κB signaling pathways”
    Seung Min Lee, Dae Won Jun
    Clinical and Molecular Hepatology.2023; 29(1): 171.     CrossRef
  • Discovery of a Novel Potent and Selective HSD17B13 Inhibitor, BI-3231, a Well-Characterized Chemical Probe Available for Open Science
    Sven Thamm, Marina K. Willwacher, Gary E. Aspnes, Tom Bretschneider, Nicholas F. Brown, Silke Buschbom-Helmke, Thomas Fox, Emanuele M. Gargano, Daniel Grabowski, Christoph Hoenke, Damian Matera, Katja Mueck, Stefan Peters, Sophia Reindl, Doris Riether, Ma
    Journal of Medicinal Chemistry.2023; 66(4): 2832.     CrossRef
  • Comparison between obese and non-obese nonalcoholic fatty liver disease
    Wah-Kheong Chan
    Clinical and Molecular Hepatology.2023; 29(Suppl): S58.     CrossRef
  • Clinical and histologic factors associated with discordance between steatosis grade derived from histology vs. MRI‐PDFF in NAFLD
    Beom K. Kim, Nicole Bernstein, Daniel Q. Huang, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Khang Nguyen, Leyna Nguyen, Tracy Le, Egbert Madamba, Lisa Richards, Mark A. Valasek, Cynthia Behling, Claude B. Sirlin, Atsushi Nakajim
    Alimentary Pharmacology & Therapeutics.2023; 58(2): 229.     CrossRef
  • Polymorphisms of HSD17B13, GCKR, HFE, and CP as factors of the development of non-alcoholic fatty liver disease and comorbid diseases
    O. V. Smirnova, D. V. Lagutinskaya
    Meditsinskiy sovet = Medical Council.2023; (8): 119.     CrossRef
  • Food Network Analysis in Non-Obese Patients with or without Steatosis
    Rossella Donghia, Pasqua Letizia Pesole, Sergio Coletta, Caterina Bonfiglio, Giovanni De Pergola, Sara De Nucci, Roberta Rinaldi, Gianluigi Giannelli
    Nutrients.2023; 15(12): 2713.     CrossRef
  • Associations between genetic variants of HSD17B13 and fasting plasma glucose in Chinese children
    Ping-ping Zhang, Jie-yun Song, Li Li, Miao Xu, Hui Wang, Hai-jun Wang
    Nutrition, Metabolism and Cardiovascular Diseases.2023; 33(9): 1778.     CrossRef
  • Advances in genetic variation in metabolism-related fatty liver disease
    Fan Shi, Mei Zhao, Shudan Zheng, Lihong Zheng, Haiqiang Wang
    Frontiers in Genetics.2023;[Epub]     CrossRef
  • Diagnostic Modalities of Non-Alcoholic Fatty Liver Disease: From Biochemical Biomarkers to Multi-Omics Non-Invasive Approaches
    Eirini Martinou, Marinos Pericleous, Irena Stefanova, Vasha Kaur, Angeliki M. Angelidi
    Diagnostics.2022; 12(2): 407.     CrossRef
  • Therapeutic RNA-silencing oligonucleotides in metabolic diseases
    Algera Goga, Markus Stoffel
    Nature Reviews Drug Discovery.2022; 21(6): 417.     CrossRef
  • Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
    Antonio Gil-Gómez, Ángela Rojas, María R. García-Lozano, Rocío Muñoz-Hernández, Rocío Gallego-Durán, Douglas Maya-Miles, Rocío Montero-Vallejo, Sheila Gato, Javier Gallego, Rubén Francés, Germán Soriano, Javier Ampuero, Manuel Romero-Gómez
    International Journal of Molecular Sciences.2022; 23(19): 11840.     CrossRef
  • Update on genetics and epigenetics in metabolic associated fatty liver disease
    Xiaopeng Zhu, Mingfeng Xia, Xin Gao
    Therapeutic Advances in Endocrinology and Metabolism.2022;[Epub]     CrossRef
  • No evidence for a causal link between Helicobacter pylori infection and nonalcoholic fatty liver disease: A bidirectional Mendelian randomization study
    Yuwei Liu, Hongqin Xu, ZiHan Zhao, Yutong Dong, Xiaomei Wang, Junqi Niu
    Frontiers in Microbiology.2022;[Epub]     CrossRef
  • Association of HSD17B13 rs72613567: TA allelic variant with liver disease: review and meta-analysis
    Shan Tang, Jing Zhang, Ting-Ting Mei, Wen-Yan Zhang, Su-Jun Zheng, Hai-Bin Yu
    BMC Gastroenterology.2021;[Epub]     CrossRef
  • An analysis of polygenic risk scores for non-alcoholic fatty liver disease
    Dae Won Jun
    Clinical and Molecular Hepatology.2021; 27(3): 446.     CrossRef
  • 11,419 View
  • 282 Download
  • 32 Web of Science
  • Crossref

Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Alcohol-related liver disease

Liver-lung axes in alcohol-related liver disease
Gavin E. Arteel
Clin Mol Hepatol 2020;26(4):670-676.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0174
Alcohol-related liver disease (ALD) and alcohol-related susceptibility to acute lung injury are the leading causes of morbidity and mortality due to chronic alcohol abuse. Most commonly, alcohol-induced injury to both organs are evaluated independently, although they share many parallel mechanisms of injury. Moreover, recent studies indicate that there is a potential liver lung axis that may contribute to organ pathology. This mini-review explores established and potential mechanisms of organ-organ crosstalk in ALD and alcohol-related lung injury.

Citations

Citations to this article as recorded by  Crossref logo
  • Is type 2 diabetes a link between lung function and metabolic dysfunction–associated steatotic liver disease? Insights from population studies and Mendelian randomization
    Runmin Cao, Yurun Zhang, Ling Cao, Honghe Jiang
    European Journal of Gastroenterology & Hepatology.2025; 37(5): 652.     CrossRef
  • Beyond the Brain: Exploring the multi-organ axes in Parkinson’s disease pathogenesis
    Tingting Liu, Haojie Wu, Jianshe Wei
    Journal of Advanced Research.2025;[Epub]     CrossRef
  • Emerging evidence of inter-organ interaction on drug transporters under liver injury
    Ling Jiang, Ying Deng, Ruijing Mu, Wenke Feng, Xiaonan Liu, Li Liu
    Chinese Journal of Natural Medicines.2025; 23(6): 687.     CrossRef
  • Exosomes From Intestinal Epithelial Cells Promote Hepatic Differentiation of Liver Progenitor Cells in Gut‐Liver‐on‐a‐Chip Models
    Liang Ye, Shi Li, Guofang Bi, Binghui Li, Zhai Cai, Meixian Jin, Ying Zhang, Wanren Yang, Yang Li, Shao Li, Wei Hu, Yi Gao, Mingxin Pan, Shuqin Zhou, Chao Zhang, Huichang Bi, Qing Peng
    Advanced Science.2025;[Epub]     CrossRef
  • Serum LCAT as a Gender-Neutral Biomarker for Early Osteoporosis: A Multicenter Cohort Validation Study
    Yali Wen, Shoujun Cheng, Liming Gou, Weihong Zhou, Yishan Li, Ruoxuan Wang, Ji Wu, Xuening Dai, Ming Gao, Lei Wang, Bin Xue, Yinhe Wang
    International Journal of General Medicine.2025; Volume 18: 4131.     CrossRef
  • Purinergic and extracellular vesicle signaling in alcohol-induced blood–brain barrier breakdown and neuroimmune activation
    Namdev S. Togre, Priyanka S. Bhoj, Naveen Mekala, Rebecca Hancock, Jayshil Trivedi, Yuri Persidsky
    Brain, Behavior, and Immunity.2025; 130: 106115.     CrossRef
  • Lipid Metabolic Changes and Mitochondrial Stress in Ethanol-Treated Alveolar Type II Epithelial Cells: Initial Events Leading to Alcoholic Chronic Lung Disease
    Mukund Srinivasan, Bhupendra S. Kaphalia
    Cells.2025; 14(22): 1817.     CrossRef
  • Emerging role of liver-bone axis in osteoporosis
    Hongliang Gao, Xing Peng, Ning Li, Liming Gou, Tao Xu, Yuqi Wang, Jian Qin, Hui Liang, Peiqi Ma, Shu Li, Jing Wu, Xihu Qin, Bin Xue
    Journal of Orthopaedic Translation.2024; 48: 217.     CrossRef
  • Organ crosstalk and dysfunction in sepsis
    André Borges, Luís Bento
    Annals of Intensive Care.2024;[Epub]     CrossRef
  • New insights in the pathogenesis of alcohol-related liver disease: The metabolic, immunologic, and neurologic pathways☆
    Tom Ryu, Kyurae Kim, Sung Eun Choi, Katherine Po Sin Chung, Won-Il Jeong
    Liver Research.2023; 7(1): 1.     CrossRef
  • Confined Cascade Metabolic Reprogramming Nanoreactor for Targeted Alcohol Detoxification and Alcoholic Liver Injury Management
    Xudong Geng, Xuancheng Du, Weijie Wang, Chengmei Zhang, Xiangdong Liu, Yuanyuan Qu, Mingwen Zhao, Weifeng Li, Mingzhen Zhang, Kangsheng Tu, Yong-Qiang Li
    ACS Nano.2023; 17(8): 7443.     CrossRef
  • Dynamics of pathomorphological changes in the liver of rats at different stages of experimental alcohol damage
    V. I. Didenko, Y. A. Gaidar, D. F. Mylostiva, I. A. Klenina, А. A. Halinskyi, O. P. Petishko, O. I. Hrabovska, А. N. Halinska
    Regulatory Mechanisms in Biosystems.2023; 14(1): 131.     CrossRef
  • The Pan-liver Network Theory
    Yaxing Zhang, Xian-Ming Fang
    Chinese Journal of Physiology.2023; 66(6): 401.     CrossRef
  • Protective Effects of Honey-Processed Astragalus on Liver Injury and Gut Microbiota in Mice Induced by Chronic Alcohol Intake
    Jingxuan Zhou, Nanhai Zhang, Liang Zhao, Mohamed Mohamed Soliman, Wei Wu, Jingming Li, Feng Zhou, Liebing Zhang, Rana Muhammad Aadil
    Journal of Food Quality.2022; 2022: 1.     CrossRef
  • Obesity Reshapes the Microbial Population Structure along the Gut-Liver-Lung Axis in Mice
    Apostolos Galaris, Dionysios Fanidis, Elli-Anna Stylianaki, Vaggelis Harokopos, Alexandra-Styliani Kalantzi, Panagiotis Moulos, Antigone S. Dimas, Pantelis Hatzis, Vassilis Aidinis
    Biomedicines.2022; 10(2): 494.     CrossRef
  • Hydrochloride Berberine ameliorates alcohol-induced liver injury by regulating inflammation and lipid metabolism
    Xiumei Ke, Ruoyu Zhang, Pan Li, Ling Zuo, Meng Wang, Junxuan Yang, Jianwei Wang
    Biochemical and Biophysical Research Communications.2022; 610: 49.     CrossRef
  • Alcoholic liver disease: a new insight into the pathogenesis of liver disease
    Seol Hee Park, Young-Sun Lee, Jaemin Sim, Seonkyung Seo, Wonhyo Seo
    Archives of Pharmacal Research.2022; 45(7): 447.     CrossRef
  • Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients
    Seul Ki Han, Moon Young Kim, Seong Hee Kang, Ki Tae Suk, Soon Koo Baik
    Hepatology International.2021; 15(5): 1207.     CrossRef
  • 11,583 View
  • 154 Download
  • 18 Web of Science
  • Crossref

Long non-coding RNAs in liver diseases: Focusing on nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease
Sen Han, Ting Zhang, Praveen Kusumanchi, Nazmul Huda, Yanchao Jiang, Zhihong Yang, Suthat Liangpunsakul
Clin Mol Hepatol 2020;26(4):705-714.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0166
Long non-coding RNAs (lncRNAs), a class of transcribed RNA molecules with the lengths exceeding 200 nucleotides, are not translated into protein. They can modulate protein-coding genes by controlling transcriptional and posttranscriptional processes. The dysregulation of lncRNAs has been related to various pathological disorders. In this review, we summarized the current knowledge of lncRNAs and their implications in the pathogenesis of three common liver diseases: nonalcoholic fatty liver disease, alcohol-related liver disease, and cholestatic liver disease. Future studies to further define the role of lncRNAs and their mechanisms in various types of liver diseases should be explored. An improved understanding from these studies will provide us a useful perspective leading to mechanism-based intervention by targeting specific lncRNAs for the treatment of liver diseases.

Citations

Citations to this article as recorded by  Crossref logo
  • LncRNA H19 promoted alcohol-associated liver disease through dysregulation of alternative splicing and methionine metabolism
    Zhihong Yang, Yanchao Jiang, Jing Ma, Li Wang, Sen Han, Nazmul Huda, Praveen Kusumanchi, Hui Gao, Themis Thoudam, Zhaoli Sun, Suthat Liangpunsakul
    Hepatology.2025; 81(5): 1485.     CrossRef
  • Molecular mechanisms of lncRNA NEAT1 in the pathogenesis of liver-related diseases, with special focus on therapeutic approaches
    Yahui Wang, Gaurav Sanghvi, Suhas Ballal, RSK Sharma, Piyus Kumar Pathak, Aman Shankhyan, Jiaxuan Sun, Qingmin Chen, Yu Ma, Lei Huang, Yahui Liu
    Pathology - Research and Practice.2025; 269: 155867.     CrossRef
  • Dynamic role of long noncoding RNA in liver diseases: pathogenesis and diagnostic aspects
    Ningning Chen, Yunxia Li, Xiaoying Li
    Clinical and Experimental Medicine.2025;[Epub]     CrossRef
  • Physiological Mechanisms Vulnerable to Alcohol‐Induced Alterations: Role in Chronic Comorbidities
    Liz Simon, Kaitlin E. Couvillion, Meagan E. Donovan, Eden M. Gallegos, Flavia M. Souza‐Smith, Patricia E. Molina
    Comprehensive Physiology.2025;[Epub]     CrossRef
  • The Role of miRNA and Long Noncoding RNA in Cholestatic Liver Diseases
    Yudian Zhang, Ying Liu, Wen Huo, Longfei He, Bowen Li, Hui Wang, Fanyin Meng, Chenggang Duan, Bingru Zhou, Jinbo Wu, Rong Chen, Juan Xing, Ying Wan
    The American Journal of Pathology.2024; 194(6): 879.     CrossRef
  • LncRNA taurine upregulated gene 1 in liver disease
    Zihao Fan, Hao Pan, Na Qu, Xin Wang, Lianrui Cao, Lijiang Chen, Mingxia Liu
    Clinica Chimica Acta.2024; 560: 119752.     CrossRef
  • Long Non-Coding RNAs in Non-Alcoholic Fatty Liver Disease; Friends or Foes?
    Sina Kalantari Soltanieh, Sahar Khastar, Irwanjot Kaur, Abhishek Kumar, Jaya Bansal, Ata Fateh, Deepak Nathiya, Beneen Husseen, Mansour Rajabivahid, Mahmoud Dehghani-Ghorbi, Reza Akhavan-Sigari
    Cell Biochemistry and Biophysics.2024; 83(1): 279.     CrossRef
  • LncRNA ZFAS1 ameliorates injury led by non-alcoholic fatty liver disease via suppressing lipid peroxidation and inflammation
    Lu Liu, Sen Sun, Xiaohua Li
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(1): 102067.     CrossRef
  • The function of long non-coding RNA in non-alcoholic fatty liver disease
    Lianrui Cao, Na Qu, Xin Wang, Lijiang Chen, Mingxia Liu
    Clinics and Research in Hepatology and Gastroenterology.2023; 47(3): 102095.     CrossRef
  • LncRNA and circRNA in Patients with Non-Alcoholic Fatty Liver Disease: A Systematic Review
    Qingmin Zeng, Chang-Hai Liu, Dongbo Wu, Wei Jiang, Nannan Zhang, Hong Tang
    Biomolecules.2023; 13(3): 560.     CrossRef
  • Post-translational modifications of histone and non-histone proteins in epigenetic regulation and translational applications in alcohol-associated liver disease: Challenges and research opportunities
    Wiramon Rungratanawanich, Jacob W. Ballway, Xin Wang, Kyoung-Jae Won, James P. Hardwick, Byoung-Joon Song
    Pharmacology & Therapeutics.2023; 251: 108547.     CrossRef
  • Elucidating the Influence of MPT-driven necrosis-linked LncRNAs on immunotherapy outcomes, sensitivity to chemotherapy, and mechanisms of cell death in clear cell renal carcinoma
    Jinbang Huang, Mengtao Liu, Haiqing Chen, Jinhao Zhang, Xixi Xie, Lai Jiang, Shengke Zhang, Chenglu Jiang, Jieying Zhang, Qinhong Zhang, Guanhu Yang, Hao Chi, Gang Tian
    Frontiers in Oncology.2023;[Epub]     CrossRef
  • Transcriptomic Analysis Reveals the Messenger RNAs Responsible for the Progression of Alcoholic Cirrhosis
    Zhihong Yang, Sen Han, Ting Zhang, Praveen Kusumanchi, Nazmul Huda, Kelsey Tyler, Kristina Chandler, Nicholas J. Skill, Wanzhu Tu, Mu Shan, Yanchao Jiang, Jessica L. Maiers, Kristina Perez, Jing Ma, Suthat Liangpunsakul
    Hepatology Communications.2022; 6(6): 1361.     CrossRef
  • Management of liver diseases: Current perspectives
    Gautam Ray
    World Journal of Gastroenterology.2022; 28(40): 5818.     CrossRef
  • Research Progress on the Mechanism Between Polycystic Ovary Syndrome and Abnormal Endometrium
    Zhu Xue, Juanli Li, Jiaxing Feng, Han Han, Jing Zhao, Jiao Zhang, Yanhua Han, Xiaoke Wu, Yuehui Zhang
    Frontiers in Physiology.2021;[Epub]     CrossRef
  • 9,441 View
  • 115 Download
  • 16 Web of Science
  • Crossref

Original Article

COVID-19

Clinical outcomes of coronavirus disease 2019 in patients with pre-existing liver diseases: A multicenter study in South Korea
Yu Rim Lee, Min Kyu Kang, Jeong Eun Song, Hyun Jung Kim, Young Oh Kweon, Won Young Tak, Se Young Jang, Jung Gil Park, Changhyeong Lee, Jae Seok Hwang, Byoung Kuk Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim, Soo Young Park
Clin Mol Hepatol 2020;26(4):562-576.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0126
Background/Aims
Although coronavirus disease 2019 (COVID-19) has spread rapidly worldwide, the implication of pre-existing liver disease on the outcome of COVID-19 remains unresolved.

Methods
A total of 1,005 patients who were admitted to five tertiary hospitals in South Korea with laboratory-confirmed COVID-19 were included in this study. Clinical outcomes in COVID-19 patients with coexisting liver disease as well as the predictors of disease severity and mortality of COVID-19 were assessed.

Results
Of the 47 patients (4.7%) who had liver-related comorbidities, 14 patients (1.4%) had liver cirrhosis. Liver cirrhosis was more common in COVID-19 patients with severe pneumonia than in those with non-severe pneumonia (4.5% vs. 0.9%, P=0.006). Compared to patients without liver cirrhosis, a higher proportion of patients with liver cirrhosis required oxygen therapy; were admitted to the intensive care unit; had septic shock, acute respiratory distress syndrome, or acute kidney injury; and died (P<0.05). The overall survival rate was significantly lower in patients with liver cirrhosis than in those without liver cirrhosis (log-rank test, P=0.003). Along with old age and diabetes, the presence of liver cirrhosis was found to be an independent predictor of severe disease (odds ratio, 4.52; 95% confidence interval [CI], 1.20–17.02;P=0.026) and death (hazard ratio, 2.86; 95% CI, 1.04–9.30; P=0.042) in COVID-19 patients.

Conclusions
This study suggests liver cirrhosis is a significant risk factor for COVID-19. Stronger personal protection and more intensive treatment for COVID-19 are recommended in these patients.

Citations

Citations to this article as recorded by  Crossref logo
  • Global geographic and socioeconomic disparities in COVID-associated acute kidney injury: a systematic review and meta-analysis
    Danyang Dai, Pedro Franca Gois, Digby Simpson, Souhayel Hedfi, Sally Shrapnel, Jason Donald Pole
    Journal of Global Health.2025;[Epub]     CrossRef
  • Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors
    Levente Zsichla, Viktor Müller
    Viruses.2023; 15(1): 175.     CrossRef
  • SARS-CoV-2 induced liver injury: Incidence, risk factors, impact on COVID-19 severity and prognosis in different population groups
    George D Liatsos
    World Journal of Gastroenterology.2023; 29(16): 2397.     CrossRef
  • COVID-19 and severity of liver diseases: Possible crosstalk and clinical implications
    Mohammad T. Imam, Ziyad S. Almalki, Abdullah R. Alzahrani, Saeed S. Al-Ghamdi, Alaa H. Falemban, Ibrahim M. Alanazi, Naiyer Shahzad, Munira Muhammad Alrooqi, Qaiser Jabeen, Imran Shahid
    International Immunopharmacology.2023; 121: 110439.     CrossRef
  • Clinical Effect of Hepatitis B Virus on COVID-19 Infected Patients: A Nationwide Population-Based Study Using the Health Insurance Review & Assessment Service Database
    Jung Wan Choe, Young Kul Jung, Hyung Joon Yim, Gi Hyeon Seo
    Journal of Korean Medical Science.2022;[Epub]     CrossRef
  • Heterogeneity and Risk of Bias in Studies Examining Risk Factors for Severe Illness and Death in COVID-19: A Systematic Review and Meta-Analysis
    Abraham Degarege, Zaeema Naveed, Josiane Kabayundo, David Brett-Major
    Pathogens.2022; 11(5): 563.     CrossRef
  • COVID-19 Severity and Mortality Among Chronic Liver Disease Patients: A Systematic Review and Meta-Analysis
    Ramya Nagarajan, Yuvaraj Krishnamoorthy, Sathish Rajaa, Vishnu Shankar Hariharan
    Preventing Chronic Disease.2022;[Epub]     CrossRef
  • Forms of cholangitis to be considered after SARS-CoV-2 infection
    Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2022; 28(4): 929.     CrossRef
  • A systems biology approach for investigating significantly expressed genes among COVID-19, hepatocellular carcinoma, and chronic hepatitis B
    Babak Sokouti
    Egyptian Journal of Medical Human Genetics.2022;[Epub]     CrossRef
  • Autoimmune liver disease represented as primary biliary cholangitis after SARS-CoV-2 infection: A need for population-based cohort study
    Soon Kyu Lee, Jung Hyun Kwon, Nara Yoon, Soon Woo Nam, Pil Soo Sung
    Clinical and Molecular Hepatology.2022; 28(4): 926.     CrossRef
  • Prognostic Impact of Myosteatosis on Mortality in Hospitalized Patients with COVID-19
    Min-Kyu Kang, Yu-Rim Lee, Jeung-Eun Song, Young-Oh Kweon, Won-Young Tak, Se-Young Jang, Jung-Gil Park, Soo-Young Park
    Diagnostics.2022; 12(9): 2255.     CrossRef
  • The association of chronic liver disorders with exacerbation of symptoms and complications related to COVID‐19: A systematic review and meta‐analysis of cohort studies
    Maryam Afraie, Pardis Mohammadzedeh, Mobin Azami, Sorour Khateri, Kamran Zamani, Farhad Moradpour, Yousef Moradi
    The Clinical Respiratory Journal.2022; 16(12): 777.     CrossRef
  • COVID-19 With Preexisting Hypercoagulability Digestive Disease
    Mingshan Jiang, Jingxi Mu, Silan Shen, Hu Zhang
    Frontiers in Medicine.2021;[Epub]     CrossRef
  • A narrative review on characterization of acute respiratory distress syndrome in COVID-19-infected lungs using artificial intelligence
    Jasjit S. Suri, Sushant Agarwal, Suneet K. Gupta, Anudeep Puvvula, Mainak Biswas, Luca Saba, Arindam Bit, Gopal S. Tandel, Mohit Agarwal, Anubhav Patrick, Gavino Faa, Inder M. Singh, Ronald Oberleitner, Monika Turk, Paramjit S. Chadha, Amer M. Johri, J. M
    Computers in Biology and Medicine.2021; 130: 104210.     CrossRef
  • COVID‐19 in hospitalized liver transplant recipients: An early systematic review and meta‐analysis
    Kumar Jayant, Isabella Reccia, Francesco Virdis, Jordan S. Pyda, Piotr J. Bachul, Diego di Sabato, Rolf N. Barth, John Fung, Talia Baker, Piotr Witkowski
    Clinical Transplantation.2021;[Epub]     CrossRef
  • Management of Patients with Chronic Liver Disease: The Era of the COVID-19 Pandemic
    Yu Rim Lee
    The Korean Journal of Gastroenterology.2021; 77(4): 156.     CrossRef
  • Patients with cirrhosis during the COVID-19 pandemic: Current evidence and future perspectives
    Hung-Yuan Su, Yin-Chou Hsu
    World Journal of Clinical Cases.2021; 9(13): 2951.     CrossRef
  • Italian association for the study of the liver position statement on SARS-CoV2 vaccination
    Francesco Paolo Russo, Salvatore Piano, Raffaele Bruno, Patrizia Burra, Massimo Puoti, Mario Masarone, Sara Montagnese, Francesca Romana Ponziani, Salvatore Petta, Alessio Aghemo
    Digestive and Liver Disease.2021; 53(6): 677.     CrossRef
  • Angiotensin-converting enzyme 2 receptors, chronic liver diseases, common medications, and clinical outcomes in coronavirus disease 2019 patients
    Wattana Leowattana
    World Journal of Virology.2021; 10(3): 86.     CrossRef
  • Impact of COVID-19 on liver
    Yu-Jang Su, Chen-Wang Chang, Ming-Jen Chen, Yen-Chun Lai
    World Journal of Clinical Cases.2021; 9(27): 7998.     CrossRef
  • Update on liver disease management during the pandemic of coronavirus disease 2019 (COVID-19): 2021 KASL guideline
    Ju-Yeon Cho, Young-Sun Lee, Soon Sun Kim, Do Seon Song, Jeong-Hoon Lee, Ji Hoon Kim
    Clinical and Molecular Hepatology.2021; 27(4): 515.     CrossRef
  • Clinical outcomes in COVID-19 and cirrhosis: a systematic review and meta-analysis of observational studies
    Paul Middleton, Catherine Hsu, Mark P Lythgoe
    BMJ Open Gastroenterology.2021; 8(1): e000739.     CrossRef
  • Multicenter Analysis of Clinical Features and Prognosis of COVID-19 Patients with Hepatic Impairment
    Jeong Eun Song, Min Kyu Kang, Yu Rim Lee, Chang Hyeong Lee, Jung Gil Park, Young Oh Kweon, Won Young Tak, Soo Young Park, Se Young Jang, Jae Seok Hwang, Byoung Kuk Jang, Won Young Jang, Jeong Ill Suh, Woo Jin Chung, Byung Seok Kim
    Gut and Liver.2021; 15(4): 606.     CrossRef
  • Critical Update on the Diagnosis and Management of COVID-19 in Advanced Cirrhosis and Liver Transplant Recipients
    Cyriac Abby Philips, Mohamed Rela, Arvinder Singh Soin, Subhash Gupta, Sudhindran Surendran, Philip Augustine
    Journal of Clinical and Translational Hepatology.2021; 000(000): 000.     CrossRef
  • 11,651 View
  • 190 Download
  • 23 Web of Science
  • Crossref

Special topic: Alcoholic liver diseases
The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Alcohol-related liver disease

Roles of the complement system in alcohol-induced liver disease
Yi Zhou, Guandou Yuan, Fudi Zhong, Songqing He
Clin Mol Hepatol 2020;26(4):677-685.
Published online October 1, 2020
DOI: https://doi.org/10.3350/cmh.2020.0094
Alcohol-induced liver disease (ALD) is a complex disorder, with a disease spectrum ranging from steatosis to steatohepatitis, cirrhosis, and hepatocellular carcinoma. Although the pathogenesis of ALD is incompletely understood and currently no effective drugs are available for ALD, several lines of evidence suggest that complement activation and oxidative stress play crucial roles in the pathogenesis of ALD. Complement activation can regulate the production of ROS and influence oxidative stress in ALD. Precise regulation of the complement system in ALD may be a rational and novel avenue to postpone and even reverse the progression of disease and simultaneously promote the repair of liver injury. In this mini-review, we briefly summarize the recent research progress, especially focusing on the role of complement and oxidative stress-induced transfer RNA-derived fragments, which might help us to better understand the pathogenesis of ALD and provide aid in the development of novel therapeutic strategies for ALD.

Citations

Citations to this article as recorded by  Crossref logo
  • The activation of microglia by the complement system in neurodegenerative diseases
    He Zhao, Yayun Lv, Jiasen Xu, Xiaoyu Song, Qi Wang, Xiaoyu Zhai, Xiaohui Ma, Jingjing Qiu, Limei Cui, Yan Sun
    Ageing Research Reviews.2025; 104: 102636.     CrossRef
  • Novel insights into cuproptosis in alcoholic liver disease using bioinformatics analysis and experimental validation
    Tongtong Pan, Shijia Wu, Shouhao Wang, Xiaodong Wang, Dazhi Chen, Yongping Chen
    International Immunopharmacology.2025; 146: 113828.     CrossRef
  • Can serum C3/C4 complement ratio be used in the differential diagnosis of central nervous system demyelinating diseases?
    Melike Cakan, Bariscan Cimen, Nazire Pınar Acar-Ozen, Yildirim Sara, Rana Karabudak, Aslı Tuncer
    Multiple Sclerosis and Related Disorders.2025; 95: 106312.     CrossRef
  • Research progress on the roles of complement in liver injury
    Li-Li Ou, Jin-Lian Jiang, Man-Lu Guo, Jin-Hua Wu, Wei-Wei Zhong, Yi-Huai He
    World Journal of Hepatology.2025;[Epub]     CrossRef
  • Gardenin A alleviates alcohol-induced oxidative stress and inflammation in HepG2 and Caco2 cells via AMPK/Nrf2 pathway
    Prashsti Chadha, Hiral Aghara, Delna Johnson, Dhrubjyoti Sharma, Mitalben Odedara, Manali Patel, Hemant Kumar, Vijay Thiruvenkatam, Palash Mandal
    Bioorganic Chemistry.2025; 161: 108543.     CrossRef
  • Flavonoid Polyphenols as Therapeutic Agents for Fatty Liver Disease: Mechanisms, Microbiome Interactions, and Metabolic Insights
    Lei Li, Yanling Jin, Tiangang Li, Bijun Lv, Difen Yuan, Xiaoya Li, Jiali Yuan
    Molecular Nutrition & Food Research.2025;[Epub]     CrossRef
  • Reactive Oxygen Species as Key Molecules in the Pathogenesis of Alcoholic Fatty Liver Disease and Nonalcoholic Fatty Liver Disease: Future Perspectives
    Zhiqing Zhang, Hong Yang, Fei Han, Peng Guo
    Current Issues in Molecular Biology.2025; 47(6): 464.     CrossRef
  • Comparative mRNA profile analysis from NAc of adolescent male mice after binge-like alcohol exposure eliciting deficits in context fear extinction learning
    Mario E. Lloret Torres, Arelys Rivas Jiménez, Eduardo L. Tosado Rodríguez, Kiara Cardona Jordan, Xiany X. Lay Rivera, Yaren L. Peña Señeriz, Joseph L. Capella Muñiz, Marieliz Dieppa Rodríguez, Daniel F. Ruiz Bolívar, Jovangelis González Del Toro, John A.
    PLOS One.2025; 20(6): e0322576.     CrossRef
  • Discovering Heterogeneous Leukocytes Subsets Associated With Alcoholic Steatohepatitis by scRNAseq Analysis
    Haribalan Perumalsamy, Sehee Park, Ji Eun Kim, Xiao Xiao, Hye Young Kim, Dae Won Jun, Tae‐Hyun Yoon
    MedComm.2025;[Epub]     CrossRef
  • Inflammatory liver diseases and susceptibility to sepsis
    Hong Lu
    Clinical Science.2024; 138(7): 435.     CrossRef
  • Water decoction of Pericarpium citri reticulatae and Amomi fructus ameliorates alcohol-induced liver disease involved in the modulation of gut microbiota and TLR4/NF-κB pathway
    Xing-Min Zhang, Yue-Chang Huang, Bai-Zhong Chen, Qian Li, Pan-Pan Wu, Wen-Hua Chen, Ri-Hui Wu, Chen Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Alcohol and Periodontal Disease: A Narrative Review
    Utsav H Gandhi, Amit Benjamin, Shreya Gajjar, Tanvi Hirani, Khushboo Desai, Bansariben B Suhagia, Rahnuma Ahmad, Susmita Sinha, Mainul Haque, Santosh Kumar
    Cureus.2024;[Epub]     CrossRef
  • Hepatocyte-derived Fetuin-A promotes alcohol-associated liver disease in mice by inhibiting autophagy-lysosome degradation of TLR and M2 macrophage polarization
    Shibang Lu, Hu Jin, Tiantian Nong, Dongxiao Li, Kang Long, Yanjun Chen, Yan Li, Hao Xing, Tingcai Pan, Songqing He, Keqing Jiang, Fudi Zhong
    Free Radical Biology and Medicine.2024; 224: 506.     CrossRef
  • DNA methylome analysis reveals epigenetic alteration of complement genes in advanced metabolic dysfunction-associated steatotic liver disease
    Amal Magdy, Hee-Jin Kim, Hanyong Go, Jun Min Lee, Hyun Ahm Sohn, Keeok Haam, Hyo-Jung Jung, Jong-Lyul Park, Taekyeong Yoo, Eun-Soo Kwon, Dong Hyeon Lee, Murim Choi, Keon Wook Kang, Won Kim, Mirang Kim
    Clinical and Molecular Hepatology.2024; 30(4): 824.     CrossRef
  • Shear Wave Dispersion Elastography in ALD and MASLD: Comparative Pathophysiology and Clinical Potential—A Narrative Review
    Tommaso Dionisi, Linda Galasso, Luigiandrea Antuofermo, Francesco Antonio Mancarella, Giorgio Esposto, Irene Mignini, Maria Elena Ainora, Antonio Gasbarrini, Giovanni Addolorato, Maria Assunta Zocco
    Journal of Clinical Medicine.2024; 13(24): 7799.     CrossRef
  • Compound Probiotic Ameliorates Acute Alcoholic Liver Disease in Mice by Modulating Gut Microbiota and Maintaining Intestinal Barrier
    Haixia Liu, Xing Kang, Xiaodan Yang, Hao Yang, Xiaoyu Kuang, Peng Ren, Huan Yan, Xiaorong Shen, Yongbo Kang, Lin Li, Xiaohui Wang, Linzhi Guo, Mingwei Tong, Weiping Fan
    Probiotics and Antimicrobial Proteins.2023; 15(1): 185.     CrossRef
  • Hepatoprotective Effect of Kaempferol: A Review of the Dietary Sources, Bioavailability, Mechanisms of Action, and Safety
    Maulana Yusuf Alkandahri, Barolym Tri Pamungkas, Zulpakor Oktoba, Mareetha Zahra Shafirany, Lela Sulastri, Maya Arfania, Ebta Narasukma Anggraeny, Ade Pratiwi, Fitri Dwi Astuti, Indriyani, Siti Yuliani Dewi, Salsa Zulfa Hamidah, Srinivas Mutalik
    Advances in Pharmacological and Pharmaceutical Sciences.2023; 2023: 1.     CrossRef
  • Antioxidant and hepatoprotective activities of methanolic extract of Fimbristylis miliacea (L.) Vahl
    Roni Roy, Jony Roy, Israt Jahan Liya, Jamiuddin Ahmed, Afroza Akter, Mohammad Anwarul Basher
    Phytomedicine Plus.2023; 3(2): 100449.     CrossRef
  • Hydrogen gas ameliorates acute alcoholic liver injury via anti-inflammatory and antioxidant effects and regulation of intestinal microbiota
    Haixia Liu, Xing Kang, Peng Ren, Xiaoyu Kuang, Xiaodan Yang, Hao Yang, Xiaorong Shen, Huan Yan, Yongbo Kang, Fan Zhang, Xiaohui Wang, Linzhi Guo, Weiping Fan
    International Immunopharmacology.2023; 120: 110252.     CrossRef
  • RNA alternative splicing impacts the risk for alcohol use disorder
    Rudong Li, Jill L. Reiter, Andy B. Chen, Steven X. Chen, Tatiana Foroud, Howard J. Edenberg, Dongbing Lai, Yunlong Liu
    Molecular Psychiatry.2023; 28(7): 2922.     CrossRef
  • Interorgan communication with the liver: novel mechanisms and therapeutic targets
    Jiulu Zhao, Xi Zhang, Yuan Li, Jizhang Yu, Zhang Chen, Yuqing Niu, Shuan Ran, Song Wang, Weicong Ye, Zilong Luo, Xiaohan Li, Yanglin Hao, Junjie Zong, Chengkun Xia, Jiahong Xia, Jie Wu
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • Métabolisme de l’alcool
    N. Dali-Youcef, J.-L. Schlienger
    EMC - Pathologie professionnelle et de l 'environnement.2023; 42(3): 1.     CrossRef
  • Métabolisme de l’alcool
    N. Dali-Youcef, J.-L. Schlienger
    EMC - Hépatologie.2023; 38(2): 1.     CrossRef
  • Immune cells in alcohol-related liver disease
    Honghai Xu, Hua Wang
    Liver Research.2022; 6(1): 1.     CrossRef
  • Complement in Acute Liver Failure: The Right Timing to Give a Sincere Compliment
    Susanne N. Weber, Frank Lammert
    Cellular and Molecular Gastroenterology and Hepatology.2021; 11(5): 1546.     CrossRef
  • Complement System in Alcohol-Associated Liver Disease
    Lazara Elena Santiesteban-Lores, Milena Carvalho Carneiro, Lourdes Isaac, Lorena Bavia
    Immunology Letters.2021; 236: 37.     CrossRef
  • Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression
    Ming-Ling Chang, Zinger Yang, Sien-Sing Yang
    International Journal of Molecular Sciences.2020; 21(21): 8308.     CrossRef
  • 12,468 View
  • 163 Download
  • 24 Web of Science
  • Crossref

Alcohol-related liver disease

Programmed cell death in alcohol-associated liver disease
Tatsunori Miyata, Laura E. Nagy
Clin Mol Hepatol 2020;26(4):618-625.
Published online September 21, 2020
DOI: https://doi.org/10.3350/cmh.2020.0142
Alcohol-associated liver disease (ALD), which ranges from mild disease to alcohol-associated hepatitis and cirrhosis, is the most prevalent type of chronic liver disease and a leading cause of morbidity and mortality worldwide. Accumulating evidence reveals that programmed cell death (PCD) plays a crucial role in progression of ALD involving crosstalk between hepatocytes and immune cells. Multiple pathways of PCD, including apoptosis, necroptosis, autophagy, pyroptosis and ferroptosis, are reported in ALD. Interestingly, PCD pathways are intimately linked and interdependent, making it difficult to therapeutically target a single pathway. This review clarifies the multiple types of PCD occurring in liver and focuses on crosstalk between hepatocytes and innate immune cells in ALD.

Citations

Citations to this article as recorded by  Crossref logo
  • The Role of Natural Products in Liver Cancer: Focus on Angiogenesis, Inflammation, Oxidative Stress, and Apoptosis
    Nuray Üremiş, Muhammed Mehdi Üremiş
    Molecular Nutrition & Food Research.2026;[Epub]     CrossRef
  • MetALD: Clinical aspects, pathophysiology and treatment
    Jordi Gratacós-Ginès, Silvia Ariño, Pau Sancho-Bru, Ramon Bataller, Elisa Pose
    JHEP Reports.2025; 7(2): 101250.     CrossRef
  • Pyroptosis, ferroptosis, and autophagy in immune therapy: perspective for immunotherapy of endometrial cancer
    Liangxin Ren, Qixia Yu, Yao Pan, Fengling Li, Yaqin Yang, Qin Tian
    Molecular & Cellular Toxicology.2025; 21(3): 443.     CrossRef
  • Hepatic microRNA-320 restrains ferroptosis to mitigate acute-on-chronic alcohol-induced liver injury
    Wenjun Li, Li Liu, Shengying Qian, Yingfen Chen, Ru Ya, Ningning Ma, Yawen Hao, Shujun Ge, Xiaoxiao Zhang, Liu Yang, Yong He
    Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.2025; 1871(4): 167748.     CrossRef
  • Selenomethionine Alleviates Alcohol-Induced Liver Injury by Inhibiting Ferroptosis
    Feng Chen, Zhenhua Zhou, Jinxian Fu, Chang Gao
    Digestive Diseases and Sciences.2025; 70(5): 1779.     CrossRef
  • Rhamnetin‐3‐O‐α‐L‐Rhamnoside Attenuates Alcoholic Liver Injury in Mice via Regulation of the Autophagy/Ferroptosis Pathway
    Jiangtao Zhou, Borong Zhao, Fan Yang, Dandan Deng, Jiayu Chang, Lihan Yan, Hong Yang, Fei Yang, Liwen Han, Guan’e Yang, Xiaolong Ji
    Journal of Food Biochemistry.2025;[Epub]     CrossRef
  • Longitudinal paired liver biopsies and transcriptome profiling in alcohol-associated hepatitis reveal dynamic changes in cellular senescence
    Daniel Rodrigo-Torres, Alastair M Kilpatrick, Sofia Ferreira-Gonzalez, Rhona E Aird, Stephen Rahul Atkinson, Victoria L Gadd, Tak Yung Man, Luke D Tyson, Gopal Krishna R Dhondalay, Nikhil Vergis, Gavin E Arteel, Mark R Thursz, Laura Martinez-Gili, Stuart
    Gut.2025; 74(9): 1500.     CrossRef
  • The Ways to Die: Cell Death in Liver Pathophysiology
    Peng Cao, Hartmut Jaeschke, Hong-Min Ni, Wen-Xing Ding
    Seminars in Liver Disease.2025; 45(03): 397.     CrossRef
  • Constitutive Hepatic mTORC1 Activation Aggravates Alcohol-Induced Liver Injury via Endoplasmic Reticulum Stress–Mediated Ferroptosis
    Lin Xu, Yuanyuan Zhao, Yang Yang, Enbo Qi, Boao Liu, Peili Zhuang, Shiyi Song, Tingmin Chang, Zhiguo Chen, Xiaohong Kang, Xiwen Xiong
    The American Journal of Pathology.2025; 195(7): 1209.     CrossRef
  • Life-threatening risk factors contribute to the development of diseases with the highest mortality through the induction of regulated necrotic cell death
    Zsuzsa Muszka, Viktória Jenei, Rebeka Mácsik, Evgeniya Mezhonova, Silina Diyab, Réka Csősz, Attila Bácsi, Anett Mázló, Gábor Koncz
    Cell Death & Disease.2025;[Epub]     CrossRef
  • Causal relationship analysis of MRI measurements of major human internal organs and liver disease
    Huanyu Wu, Danjing Zhou, Jinggang Zhu, Jianchun Tu
    European Journal of Medical Research.2025;[Epub]     CrossRef
  • Gardenin A alleviates alcohol-induced oxidative stress and inflammation in HepG2 and Caco2 cells via AMPK/Nrf2 pathway
    Prashsti Chadha, Hiral Aghara, Delna Johnson, Dhrubjyoti Sharma, Mitalben Odedara, Manali Patel, Hemant Kumar, Vijay Thiruvenkatam, Palash Mandal
    Bioorganic Chemistry.2025; 161: 108543.     CrossRef
  • Zinc Deficiency Induces Hepatic Oxidative Stress, Inflammation, and Programmed Cell Death in Mice
    ZhaoLong Cai, HongRu Wang, Fuxin Han, JingJing Wang, Hongli LV, Xue-jiao Gao, Meng-yao Guo
    Biological Trace Element Research.2025;[Epub]     CrossRef
  • Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs): A Pan-Steatotic Liver Disease Treatment?
    Lampros Chrysavgis, Niki-Gerasimoula Mourelatou, Evangelos Cholongitas
    Biomedicines.2025; 13(7): 1516.     CrossRef
  • Effects of soluble epoxide hydrolase inhibition on liver injury and gut microbiota in mice chronically fed ethanol
    Dennis R. Warner, Jeffrey B. Warner, Yasmeen Abdelfadil, Josiah E. Hardesty, Rui Treves, Chao Lei, Hannah E. Hanford, Craig J. McClain, Irina A. Kirpich
    Alcohol, Clinical and Experimental Research.2025; 49(8): 1730.     CrossRef
  • Research progress on the hepatoprotective effect, pharmacokinetic properties, and hepatotoxicity of geniposide
    Songyuan Tang, Guangli Yan, Ling Kong, Hui Sun, Chang Liu, Ying Han, Xijun Wang
    Acupuncture and Herbal Medicine.2025; 5(2): 136.     CrossRef
  • Ferroptosis and gut microbiota: A new horizon in alcohol-associated liver disease management
    Yue Chen, Wenkang Gao, Kailin Cai, Ling Yang, Huikuan Chu
    Cellular and Molecular Life Sciences.2025;[Epub]     CrossRef
  • Ampelopsis grossedentata protects against ethanol-induced acute duodenal injury by inhibiting TNF-triggered caspases-dependent apoptosis in mice
    Chao-Yue Sun, Wan-Qing Li, Jing-Wen Lu, Ao-Yue Zhang, Qing-Xia Chu, Li Tang, Wei Gao, Jin-Jie Cai, Ying Lu, Dong Liu
    Journal of Ethnopharmacology.2025; 353: 120462.     CrossRef
  • Yogurt alleviates alcohol-induced hepatocyte pyroptosis and inflammation via autophagy/P62/Nrf2/ROS/NLRP3 pathway
    Shuang Guan, Yuanmeng Wang, Ranran Zhang, Xinyu Yao, Shujing Lu, Xuming Deng, Jing Lu
    Journal of Dairy Science.2025; 108(10): 10489.     CrossRef
  • アルコール関連肝疾患について
    一義 今
    Nihon Ika Daigaku Igakkai Zasshi.2025; 21(3): 211.     CrossRef
  • Hepatocyte-Specific Transcriptional Responses to Liver-Targeted Delivery of a Soluble Epoxide Hydrolase Inhibitor in a Mouse Model of Alcohol-Associated Liver Disease
    Dennis R. Warner, Jeffrey B. Warner, Josiah E. Hardesty, Yasmeen Abdelfadil, Chirag Soni, Philip Bauer, Claudio Maldonado, Craig J. McClain, Irina A. Kirpich
    Biology.2025; 14(9): 1267.     CrossRef
  • Physiological Mechanisms Vulnerable to Alcohol‐Induced Alterations: Role in Chronic Comorbidities
    Liz Simon, Kaitlin E. Couvillion, Meagan E. Donovan, Eden M. Gallegos, Flavia M. Souza‐Smith, Patricia E. Molina
    Comprehensive Physiology.2025;[Epub]     CrossRef
  • Mung bean (Vigna radiata L.) ethanol extract alleviates alcoholic liver injury with modulation of the gut microbiota and spermidine elevation
    Yixin Liu, Yi Ruan, Anhui Zhao, Zhiying Bian, Jing Bai, Shuqi Niu, Songtao Wang, Zhangjun Huang, Xiaonian Cao, Caihong Shen, Sijing Liu, Jinlin Guo
    Food & Function.2025; 16(21): 8564.     CrossRef
  • Ameliorative Potential of Menstrual Blood-derived Endometrial Stem Cells in Alcohol-induced Fatty Liver Disease
    Yan Jiang, Qingyang Huo, Jingwen Gao, Beilin Kou, Narazah Mohd Yusoff, Emmanuel Jairaj Moses, Juntang Lin
    Current Stem Cell Research & Therapy.2025; 20(8): 869.     CrossRef
  • Pharmacotherapy to Prevent Alcohol Relapse in Alcohol-Associated Liver Disease
    Wei Zhang, Soo Young Hwang, Jay Luther
    Current Gastroenterology Reports.2025;[Epub]     CrossRef
  • Identification of an IRF–ZBP1–caspase-8–NINJ1 axis in driving PANoptosis and pathology during alcohol-associated liver disease
    Qiang Qin, Wen Chen, Clay D. King, Sivakumar Prasanth Kumar, Chadi A. El Farran, Peter Vogel, Rebecca E. Tweedell, Thirumala-Devi Kanneganti
    Proceedings of the National Academy of Sciences.2025;[Epub]     CrossRef
  • Hepatic Transcriptome and Its Regulation Following Soluble Epoxide Hydrolase Inhibition in Alcohol-Associated Liver Disease
    Jeffrey B. Warner, Josiah E. Hardesty, Ying L. Song, Alison T. Floyd, Zhongbin Deng, Audriy Jebet, Liqing He, Xiang Zhang, Craig J. McClain, Bruce D. Hammock, Dennis R. Warner, Irina A. Kirpich
    The American Journal of Pathology.2024; 194(1): 71.     CrossRef
  • Efferocytosis in liver disease
    Hongxue Shi, Mary P. Moore, Xiaobo Wang, Ira Tabas
    JHEP Reports.2024; 6(1): 100960.     CrossRef
  • Functional genetic variants of the disulfidptosis-relatedINF2gene predict survival of hepatitis B virus-related hepatocellular carcinoma
    Junjie Wei, Qiuping Wen, Shicheng Zhan, Ji Cao, Yanji Jiang, Jiawei Lian, Yuejiao Mai, Moqin Qiu, Yingchun Liu, Peiqin Chen, Qiuling Lin, Xiaoxia Wei, Yuying Wei, Qiongguang Huang, Ruoxin Zhang, Songqing He, Guandou Yuan, Qingyi Wei, Zihan Zhou, Hongping
    Carcinogenesis.2024; 45(4): 199.     CrossRef
  • Cell Death in Liver Disease and Liver Surgery
    Christian Stoess, Yeon-Kyung Choi, Janset Onyuru, Helmut Friess, Hal Hoffman, Daniel Hartmann, Ariel Feldstein
    Biomedicines.2024; 12(3): 559.     CrossRef
  • Hepatoprotective Effect of Allium ochotense Extracts on Chronic Alcohol-Induced Fatty Liver and Hepatic Inflammation in C57BL/6 Mice
    Min Ji Go, Jong Min Kim, Hyo Lim Lee, Tae Yoon Kim, Ju Hui Kim, Han Su Lee, In Young Kim, Seon Jeong Sim, Ho Jin Heo
    International Journal of Molecular Sciences.2024; 25(6): 3496.     CrossRef
  • Ethanol‐Induced Hepatic Ferroptosis Is Mediated by PERK‐Dependent MAMs Formation: Preventive Role of Quercetin
    Hongkun Lin, Xiaoping Guo, Jingjing Liu, Yuhan Tang, Li Chen, Huimin Chen, Ying Zhao, Lili Wang, Hongxia Li, Jiasheng Yu, Ping Yao
    Molecular Nutrition & Food Research.2024;[Epub]     CrossRef
  • Deletion of Mixed Lineage Kinase Domain Like Pseudokinase Aggravates Chronic Alcohol-Induced Liver Injury via Increasing Apoptosis
    Keon Hwi Im, Waqar Khalid Saeed, Eun Bin Kim, A. Hyeon Lee, Ji Eun Kim, Seung Min Lee, Xuanyuan hanning, Hyun Sung Kim, Dae Won Jun, Eileen L. Yoon
    Digestive Diseases and Sciences.2024; 69(5): 1701.     CrossRef
  • Alcohol-Associated Liver Disease Outcomes: Critical Mechanisms of Liver Injury Progression
    Natalia A. Osna, Irina Tikhanovich, Martí Ortega-Ribera, Sebastian Mueller, Chaowen Zheng, Johannes Mueller, Siyuan Li, Sadatsugu Sakane, Raquel Carvalho Gontijo Weber, Hyun Young Kim, Wonseok Lee, Souradipta Ganguly, Yusuke Kimura, Xiao Liu, Debanjan Dha
    Biomolecules.2024; 14(4): 404.     CrossRef
  • Hovenia dulcis: a Chinese medicine that plays an essential role in alcohol-associated liver disease
    Yi-Xiang He, Meng-Nan Liu, Yang-Yang Wang, Hao Wu, Mei Wei, Jin-Yi Xue, Yuan Zou, Xin Zhou, Hui Chen, Zhi Li
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Loss of GCN5L1 exacerbates damage in alcoholic liver disease through ferroptosis activation
    Chenxi Yang, Ye Yang, Xiuya Hu, Qiqi Tang, Jiaqi Zhang, Peiyu Zhang, Xin Lu, Juan Xu, Sai Li, Zhengni Dong, Lu Zhu, Lingdi Wang
    Liver International.2024; 44(8): 1924.     CrossRef
  • An integrated network pharmacology approach reveals that Ampelopsis grossedentata improves alcoholic liver disease via TLR4/NF-κB/MLKL pathway.
    Ping Qiu, Ai Mi, Chunlan Hong, Shuo Huang, Qing Ma, Qihan Luo, Jiang Qiu, He Jiang, Yufan Chen, Fangming Chen, Honghao Yan, Jinkai Zhao, Yu Kong, Yu Du, Changyu Li, Desong Kong, Thomas Efferth, Dayong Lou
    Phytomedicine.2024; : 155658.     CrossRef
  • TRPV1/cPLA2/AA pathway contributes to ferroptosis-mediated acute liver injury in heatstroke
    Youyong Tang, Chenxin Liu, Riqing Wei, Ru Li, Zhiwei Li, Keying Zhang, Xiaofeng Zhao, Qiang Ma
    International Immunopharmacology.2024; 138: 112539.     CrossRef
  • Inhibition of ethanol-induced eNAMPT secretion attenuates liver ferroptosis through BAT-Liver communication
    Yujia Zhou, Nengzhi Pang, Wenli Li, Qiuyan Li, Jing Luo, Yingying Gu, Qianrong Hu, Yi Jie Ding, Yan Sun, Jie Pan, Mengqi Gao, Ying Xiao, Sixi Ma, Yanxu Hao, Huichun Xing, Evendro Fei Fang, Wenhua Ling, Zhenfeng Zhang, Lili Yang
    Redox Biology.2024; 75: 103274.     CrossRef
  • Consequence of alcohol intoxication-mediated efferocytosis impairment
    Subhashini Brahadeeswaran, Ramasamy Tamizhselvi
    Frontiers in Immunology.2024;[Epub]     CrossRef
  • Hepatic Extracellular Matrix and Its Role in the Regulation of Liver Phenotype
    Gavin E. Arteel
    Seminars in Liver Disease.2024; 44(03): 343.     CrossRef
  • Galangin Alleviates Alcohol-Provoked Liver Injury Associated with Gut Microbiota Disorder and Intestinal Barrier Dysfunction in Mice
    Yanan Zhao, Bin Li, Hongting Deng, Chang Zhang, Yitong Wang, Lei Chen, Hui Teng
    Journal of Agricultural and Food Chemistry.2024; 72(40): 22336.     CrossRef
  • The pharmacological management of alcohol-related cirrhosis: what’s new?
    Nipun Verma, Ashwin P Vinod, Ashwani K. Singal
    Expert Opinion on Pharmacotherapy.2024; 25(14): 1923.     CrossRef
  • Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
    Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
    Clinical and Molecular Hepatology.2024; 30(4): 620.     CrossRef
  • Targeted Delivery to Dying Cells Through P-Selectin–PSGL-1 Axis: A Promising Strategy for Enhanced Drug Efficacy in Liver Injury Models
    Te-Sheng Lien, Der-Shan Sun, Hsin-Hou Chang
    Cells.2024; 13(21): 1778.     CrossRef
  • Pentraxin-3 modulates hepatocyte ferroptosis and the innate immune response in LPS-induced liver injury
    Huitong Wang, Zhaojie Su, Yunyun Qian, Baojie Shi, Hao Li, Wenbin An, Yi Xiao, Cheng Qiu, Zhixiang Guo, Jianfa Zhong, Xia Wu, Jiajia Chen, Ying Wang, Wei Zeng, Linghui Zhan, Jie Wang
    Molecular Biomedicine.2024;[Epub]     CrossRef
  • Ferroptosis and liver diseases
    Xin LI, Liang TAO, Meijuan ZHONG, Qian WU, Junjia MIN, Fudi WANG
    Journal of Zhejiang University (Medical Sciences).2024; 53(6): 747.     CrossRef
  • ГЕПАТОЦИТАРНЫЙ АПОПТОЗ В РАЗВИТИИ ОСТРОЙ ХРОНИЧЕСКОЙ ПЕЧЕНОЧНОЙ НЕДОСТАТОЧНОСТИ ПРИ ДЕКОМПЕНСИРОВАННОМ АЛКОГОЛЬНОМ ЦИРРОЗЕ ПЕЧЕНИ
    Ольга Петровна Дуданова, Алиса Сергеевна Родина, Ирина Валерьевна Курбатова, Марина Эдуардовна Шубина, Людмила Владимировна Топчиева
    University therapeutic journal.2024; 6(4): 166.     CrossRef
  • Ferroptosis contributes to ethanol-induced hepatic cell death via labile iron accumulation and GPx4 inactivation
    Jiao Luo, Ge Song, Ningning Chen, Mengyue Xie, Xuan Niu, Shuyue Zhou, Yanan Ji, Xiaoxiao Zhu, Wanli Ma, Qianqian Zhang, Dianke Yu
    Cell Death Discovery.2023;[Epub]     CrossRef
  • Macrophage‐derived MLKL in alcohol‐associated liver disease: Regulation of phagocytosis
    Xiaoqin Wu, Xiude Fan, Megan R. McMullen, Tatsunori Miyata, Adam Kim, Vai Pathak, Jianguo Wu, Le Z. Day, Josiah E. Hardesty, Nicole Welch, Jaividhya Dasarathy, Daniela S. Allende, Arthur J. McCullough, Jon M. Jacobs, Daniel M. Rotroff, Srinivasan Dasarath
    Hepatology.2023; 77(3): 902.     CrossRef
  • Loss of long-chain acyl-CoA synthetase 1 promotes hepatocyte death in alcohol-induced steatohepatitis
    Haibo Dong, Wei Zhong, Wenliang Zhang, Liuyi Hao, Wei Guo, Ruichao Yue, Xinguo Sun, Zhaoli Sun, Ramon Bataller, Zhanxiang Zhou
    Metabolism.2023; 138: 155334.     CrossRef
  • Liver Iron Loading in Alcohol-Associated Liver Disease
    Najma Ali, Kevin Ferrao, Kosha J. Mehta
    The American Journal of Pathology.2023; 193(10): 1427.     CrossRef
  • Resolvin D1 attenuated liver injury caused by chronic ethanol and acute LPS challenge in mice
    Josiah E. Hardesty, Jeffrey B. Warner, Ying L. Song, Eric C. Rouchka, Craig J. McClain, Dennis R. Warner, Irina A. Kirpich
    The FASEB Journal.2023;[Epub]     CrossRef
  • Recent Advances in Understanding of Pathogenesis of Alcohol-Associated Liver Disease
    Xiaoqin Wu, Xiude Fan, Tatsunori Miyata, Adam Kim, Christina K. Cajigas-Du Ross, Semanti Ray, Emily Huang, Moyinoluwa Taiwo, Rakesh Arya, Jianguo Wu, Laura E. Nagy
    Annual Review of Pathology: Mechanisms of Disease.2023; 18(1): 411.     CrossRef
  • PTTG1 alleviates acute alcoholic liver injury by inhibiting endoplasmic reticulum stress‐induced hepatocyte pyroptosis
    Shiuan Tien, Haoxiong Zhou, Qi Zhou, Huiling Liu, Bin Wu, Yunwei Guo
    Liver International.2023; 43(4): 840.     CrossRef
  • Emerging roles and therapeutic potentials of ferroptosis: from the perspective of 11 human body organ systems
    Yaochong Tan, Xueting Dong, Donglin Zhuang, Buzi Cao, Hua Jiang, Qingnan He, Mingyi Zhao
    Molecular and Cellular Biochemistry.2023; 478(12): 2695.     CrossRef
  • Mincle-GSDMD-mediated release of IL-1β small extracellular vesicles from hepatic macrophages in ethanol-induced liver injury
    Quanri Zhang, Weiwei Liu, Katarzyna Bulek, Han Wang, Megan R. McMullen, Xiaoqin Wu, Nicole Welch, Renliang Zhang, Jaividhya Dasarathy, Srinivasan Dasarathy, Laura E. Nagy, Xiaoxia Li
    Hepatology Communications.2023;[Epub]     CrossRef
  • Hepatic progesterone receptor membrane component 1 attenuates ethanol-induced liver injury by reducing acetaldehyde production and oxidative stress
    Seong-Lae Jo, In-Jeoung Baek, Je-Won Ko, Hyo-Jung Kwun, Hyun-Jin Shin, Eui-Ju Hong
    American Journal of Physiology-Gastrointestinal and Liver Physiology.2023; 324(6): G442.     CrossRef
  • GPR116 promotes ferroptosis in sepsis-induced liver injury by suppressing system Xc–/GSH/GPX4
    Ying Wang, Ting Wang, Qian Xiang, Na Li, Jun Wang, Jiahao Liu, Yan Zhang, Tao Yang, Jinjun Bian
    Cell Biology and Toxicology.2023; 39(6): 3015.     CrossRef
  • Retinoic Acid Receptor β Loss in Hepatocytes Increases Steatosis and Elevates the Integrated Stress Response in Alcohol-Associated Liver Disease
    Marta Melis, Steven E. Trasino, Xiao-Han Tang, Andrew Rappa, Tuo Zhang, Lihui Qin, Lorraine J. Gudas
    International Journal of Molecular Sciences.2023; 24(15): 12035.     CrossRef
  • The intersection between alcohol-related liver disease and nonalcoholic fatty liver disease
    Luis Antonio Díaz, Juan Pablo Arab, Alexandre Louvet, Ramón Bataller, Marco Arrese
    Nature Reviews Gastroenterology & Hepatology.2023; 20(12): 764.     CrossRef
  • Vitamin D deficiency exacerbates alcohol-related liver injury via gut barrier disruption and hepatic overload of endotoxin
    Akihiko Shibamoto, Kosuke Kaji, Norihisa Nishimura, Takahiro Kubo, Satoshi Iwai, Fumimasa Tomooka, Junya Suzuki, Yuki Tsuji, Yukihisa Fujinaga, Hideto Kawaratani, Tadashi Namisaki, Takemi Akahane, Hitoshi Yoshiji
    The Journal of Nutritional Biochemistry.2023; 122: 109450.     CrossRef
  • Effect of Lauric acid against ethanol-induced hepatotoxicity by modulating oxidative stress/apoptosis signalling and HNF4α in Wistar albino rats
    Arunraj Namachivayam, Abilash Valsala Gopalakrishnan
    Heliyon.2023; 9(11): e21267.     CrossRef
  • Alcohol induces hepatocytes necroptosis through the LC3/RIPK1/RIPK3 pathway
    Yuelin Chen, Meitong Liu, Hongdi Wei, Jiakang Guo, Shengzhuo Zhang, Xiujuan Bu, Shanshan Chen, Duoduo Zhang, Shuang Guan
    Food and Chemical Toxicology.2023; 182: 114124.     CrossRef
  • Progressive dysfunction of the immune system as a factor preventing recoverable regeneration of the liver in chronic fibrosing diseases
    Н.А. Онищенко, А.О. Никольская, М.Ю. Шагидулин
    Zhurnal «Patologicheskaia fiziologiia i eksperimental`naia terapiia».2023; 67(3): 109.     CrossRef
  • Atezolizumab and Bevacizumab Combination Therapy in the Treatment of Advanced Hepatocellular Cancer
    Ignacio Ventura, Lorena Sanchiz, María Ester Legidos-García, María Teresa Murillo-Llorente, Marcelino Pérez-Bermejo
    Cancers.2023; 16(1): 197.     CrossRef
  • Bile Acid–Mediated Activation of Brown Fat Protects From Alcohol-Induced Steatosis and Liver Injury in Mice
    Mingjie Fan, Yangmeng Wang, Lihua Jin, Zhipeng Fang, Jiangling Peng, Jui Tu, Yanjun Liu, Eryun Zhang, Senlin Xu, Xiaoqian Liu, Yuqing Huo, Zhaoli Sun, Xiaojuan Chao, Wen-Xing Ding, Qingfeng Yan, Wendong Huang
    Cellular and Molecular Gastroenterology and Hepatology.2022; 13(3): 809.     CrossRef
  • Crosstalk between Oxidative Stress and Inflammatory Liver Injury in the Pathogenesis of Alcoholic Liver Disease
    Yoon Mee Yang, Ye Eun Cho, Seonghwan Hwang
    International Journal of Molecular Sciences.2022; 23(2): 774.     CrossRef
  • Alcohol-Associated Tissue Injury: Current Views on Pathophysiological Mechanisms
    Liz Simon, Flavia M. Souza-Smith, Patricia E. Molina
    Annual Review of Physiology.2022; 84(1): 87.     CrossRef
  • Phosphoproteomics identifies pathways underlying the role of receptor‐interaction protein kinase 3 in alcohol‐associated liver disease and uncovers apoptosis signal‐regulating kinase 1 as a target
    Vaibhav Singh, Emily Huang, Vai Pathak, Belinda B. Willard, Daniela S. Allende, Laura E. Nagy
    Hepatology Communications.2022; 6(8): 2022.     CrossRef
  • Silibinin inhibits ethanol- or acetaldehyde-induced ferroptosis in liver cell lines
    Xiao-Yu Song, Peng-Cheng Liu, Wei-Wei Liu, Jia Zhou, Toshihiko Hayashi, Kazunori Mizuno, Shunji Hattori, Hitomi Fujisaki, Takashi Ikejima
    Toxicology in Vitro.2022; 82: 105388.     CrossRef
  • Natural History of Alcohol-Associated Liver Disease: Understanding the Changing Landscape of Pathophysiology and Patient Care
    Jasmohan S. Bajaj, Laura E. Nagy
    Gastroenterology.2022; 163(4): 840.     CrossRef
  • Progress in research of alcoholic liver disease
    Shang Zeng, San-Qiang Li, Qian-Hui Li
    World Chinese Journal of Digestology.2022; 30(12): 535.     CrossRef
  • Plasticity of monocytes and macrophages in cirrhosis of the liver
    Anne Geng, Emilio Flint, Christine Bernsmeier
    Frontiers in Network Physiology.2022;[Epub]     CrossRef
  • Advancements in the Alcohol-Associated Liver Disease Model
    Lin Zhu, Hai-Di Li, Jie-Jie Xu, Juan-Juan Li, Miao Cheng, Xiao-Ming Meng, Cheng Huang, Jun Li
    Biomolecules.2022; 12(8): 1035.     CrossRef
  • Leonurine Alleviates Alcoholic Steatohepatitis Through the TLR4/NF-κB Signalling Pathway
    Taocheng Zhou, Qian Fang, Junnan Cai, Xue Wu, Xiongwen Lv
    Revista Brasileira de Farmacognosia.2022; 32(4): 593.     CrossRef
  • Cellular Bioenergetics: Experimental Evidence for Alcohol-induced Adaptations
    Liz Simon, Patricia E Molina
    Function.2022;[Epub]     CrossRef
  • Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives
    Yoonji Ha, Inju Jeong, Tae Hyun Kim
    Biomedicines.2022; 10(10): 2530.     CrossRef
  • Rhizophora mucronata Lam. (Mangrove) Bark Extract Reduces Ethanol-Induced Liver Cell Death and Oxidative Stress in Swiss Albino Mice: In Vivo and In Silico Studies
    Chitra Jairaman, Zeyad I. Alehaideb, Syed Ali Mohamed Yacoob, Sahar S. Alghamdi, Rasha S. Suliman, Anuradha Venkataraman, Bandar Alghanem, Senthilkumar Sivanesan, Rajagopalan Vijayaraghavan, Saranya Rameshbabu, Shree Mukilan Pari, Sabine Matou-Nasri
    Metabolites.2022; 12(11): 1021.     CrossRef
  • Macrophages in Chronic Liver Failure: Diversity, Plasticity and Therapeutic Targeting
    Arjuna Singanayagam, Evangelos Triantafyllou
    Frontiers in Immunology.2021;[Epub]     CrossRef
  • Different functions of vitamin E homologues in the various types of cell death induced by oxysterols
    Atsuki Suzuki, Yasuomi Urano, Tomohisa Ishida, Noriko Noguchi
    Free Radical Biology and Medicine.2021; 176: 356.     CrossRef
  • The Emerging Role of Ferroptosis in Liver Diseases
    Si Chen, Jun-yao Zhu, Xin Zang, Yong-zhen Zhai
    Frontiers in Cell and Developmental Biology.2021;[Epub]     CrossRef
  • 17,583 View
  • 302 Download
  • 75 Web of Science
  • Crossref

Reviews

Microbiome

Fecal microbiota transplantation in alcohol related liver diseases
Saggere Muralikrishna Shasthry
Clin Mol Hepatol 2020;26(3):294-301.
Published online June 23, 2020
DOI: https://doi.org/10.3350/cmh.2020.0057
The current standard of care for severe alcoholic hepatitis (SAH) has several limitations in that only up to one-third of patients are eligible for steroid therapy. Additionally, steroids have their own issues: a portion of patients do not respond, while there is doubtful long-term benefit in those who do and a large proportion are ineligible to receive steroids entirely and hence have no definitive options for treatment. As such, there is a large gap between the problem and the available solutions. Alcohol causes dysbiosis and also disrupts gut barrier function, consequently promoting the translocation of microbial lipopolysaccharide into the portal circulation and liver. Therefore, probiotics, prebiotics, antibiotics, or transplantation of gut microbiota are likely to attenuate the dysbiosis-related liver insult. Fecal microbiota transplantation (FMT) is expected to have a role in managing alcoholic liver disease in general and SAH in particular by correcting dysbiosis, the primary insult. Results from mouse studies have suggested beyond doubt that alcohol-related liver injury is transferrable and also treatable by adopting FMT from suitable donors. Initial human trials from our center have affirmed benefits in human subjects with SAH as well, with both improvements in disease severity and as well as the rate of survival. Further studies addressing the head-to-head comparison of steroids and FMT are ongoing. Available preliminary data are promising and FMT and/or gut microbial modulation might become the standard of care in the near future for managing alcohol-related liver diseases, especially alcoholic hepatitis, with greater applicability, improved acceptability, and minimal side effects.

Citations

Citations to this article as recorded by  Crossref logo
  • Alcohol-Related Liver Disease
    Haripriya Maddur, Steven Flamm
    Clinics in Liver Disease.2026; 30(1): 45.     CrossRef
  • Puerarin ameliorates alcoholic liver disease by regulating intestinal flora and MAPK/Nrf2 signalling pathways
    Zicheng Wang, Yingying Yu, Wanjun Shao, Yuhao Zhao, Zhe Li, Jiaming Han, Jingyu Wen, Yongchun Meng, Ying Lin, Shaoping Wang
    Ecotoxicology and Environmental Safety.2026; 309: 119699.     CrossRef
  • Prospective study on time-to-tertiary care in alcohol-associated hepatitis: space–time coordinates as prognostic tool and therapeutic target
    Ľubomír Skladaný, Daniela Žilinčanová, Natália Kubánek, Svetlana Adamcová Selčanová, Daniel Havaj, Lukáš Laffers, Michal Žilinčan, Alvi H Islam, Juan Pablo Arab, Tomáš Koller
    Alcohol and Alcoholism.2025;[Epub]     CrossRef
  • The crosstalk between gut microbiota and microbiota-derived metabolites in hepatocellular carcinoma
    Sang Jun Yoon, Seul Ki Han, Tae Suk Kim, Ki Tae Suk, Dae Hee Choi, Young Don Kim, Moon Young Kim, Gab Jin Cheon, Soon Koo Baik, Dong Joon Kim
    Critical Reviews in Microbiology.2025; 51(6): 1315.     CrossRef
  • Prolonged Intestinal Ethanol Absorption and Oxidative Stress: Revisiting the Gut–Liver Axis in Alcohol-Associated Disease
    Beom Sun Chung, Keungmo Yang, Chihyun Park, Tom Ryu
    International Journal of Molecular Sciences.2025; 26(12): 5442.     CrossRef
  • Correction of vaginal microbiocenosis in bacterial vaginosis. Promising areas
    G.O. Grechkanev, I.O. Strelets, N.N. Nikishov, E.V. Sinitsina, A.N. Nikishova
    Russian Bulletin of Obstetrician-Gynecologist.2025; 25(4): 44.     CrossRef
  • Alcohol-Induced Oxidative Stress and Gut–Liver–Brain Crosstalk: Expanding the Paradigm from ALD to MetALD
    Jeong-Yoon Lee, Young-Min Jee, Keungmo Yang, Tom Ryu
    Antioxidants.2025; 14(10): 1196.     CrossRef
  • A systematic review and meta-analysis on the efficacy of fecal microbiome transplantation in patients with severe alcohol-associated hepatitis
    Evance Pakuwal, Jin Lin Tan, Richard J. Woodman, Amanda J. Page, Andrea M. Stringer, Mohamed Asif Chinnaratha
    European Journal of Gastroenterology & Hepatology.2025; 37(11): 1260.     CrossRef
  • Fecal Microbiota Transplant in Alcoholic Liver Disease: A Review of Current Literature
    Alexander Grieme, Yizhong Wu, Kalee Moore, Manuel Garza, Eric R. Smith, Erica Yatsynovich, Thomas J. Egeland, Rajesh Shah
    Therapeutics.2025; 3(1): 2.     CrossRef
  • Intestinal microbiome-targeted therapies improve liver function in alcohol-related liver disease by restoring bifidobacteria: a systematic review and meta-analysis
    Xin Chi, Xiu Sun, Danying Cheng, Shunai Liu, Calvin Q. Pan, Huichun Xing
    Frontiers in Pharmacology.2024;[Epub]     CrossRef
  • Chronic Liver Disease and Promising Therapeutic Strategy: A Concise Review
    Han Yu, Zhijun Wang, Gang Zhao
    Pharmacognosy Magazine.2024; 20(4): 1031.     CrossRef
  • Inflammatory liver diseases and susceptibility to sepsis
    Hong Lu
    Clinical Science.2024; 138(7): 435.     CrossRef
  • Fecal microbiota transplantation from female donors restores gut permeability and reduces liver injury and inflammation in middle-aged male mice exposed to alcohol
    Arantza Lamas-Paz, Mariana Mesquita, Marcos Garcia-Lacarte, Olga Estévez-Vázquez, Raquel Benedé-Ubieto, Alejandro H. Gutierrez, Hanghang Wu, Hector Leal Lasalle, Javier Vaquero, Rafael Bañares, Eduardo Martínez-Naves, Sergio Roa, Yulia A. Nevzorova, Gonza
    Frontiers in Nutrition.2024;[Epub]     CrossRef
  • Digestive dynamics: Unveiling interplay between the gut microbiota and the liver in macronutrient metabolism and hepatic metabolic health
    Mrunmayee R. Kandalgaonkar, Virender Kumar, Matam Vijay‐Kumar
    Physiological Reports.2024;[Epub]     CrossRef
  • Inflammatory Response in the Pathogenesis and Treatment of Hepatocellular Carcinoma: A Double-Edged Weapon
    Linda Galasso, Lucia Cerrito, Valeria Maccauro, Fabrizio Termite, Irene Mignini, Giorgio Esposto, Raffaele Borriello, Maria Elena Ainora, Antonio Gasbarrini, Maria Assunta Zocco
    International Journal of Molecular Sciences.2024; 25(13): 7191.     CrossRef
  • Faecal microbiota transplantation associated adverse events
    Rafal Patryn, Natalia Kazmierczak-Wojtas, Lucyna Bulas, Olga Boretska, Monika Szkultecka-Debek, Mariola Drozd, Tomasz Blicharski
    Current Issues in Pharmacy and Medical Sciences.2024; 37(3): 171.     CrossRef
  • Immunological mechanisms in steatotic liver diseases: An overview and clinical perspectives
    Mengyao Yan, Shuli Man, Long Ma, Lanping Guo, Luqi Huang, Wenyuan Gao
    Clinical and Molecular Hepatology.2024; 30(4): 620.     CrossRef
  • 3PM-guided innovation in treatments of severe alcohol-associated hepatitis utilizing fecal microbiota transplantation
    Lubomir Skladany, Natalia Kubanek, Svetlana Adamcova Selcanova, Daniela Zilincanova, Daniel Havaj, Karolina Sulejova, Katarina Soltys, Lucia Messingerova, Michal Lichvar, Lukas Laffers, Michal Zilincan, Eva Honsova, Peter Liptak, Peter Banovcin, Jan Bures
    EPMA Journal.2024; 15(4): 677.     CrossRef
  • Mapping the relationship between alcohol use disorder and gut microbiota: a 20-year bibliometric study
    Ao Xiang, Yonglong Chang, Li Shi, Xuhui Zhou
    Frontiers in Microbiology.2024;[Epub]     CrossRef
  • Cell-to-cell and organ-to-organ crosstalk in the pathogenesis of alcohol-associated liver disease
    Hui Gao, Yanchao Jiang, Ge Zeng, Nazmul Huda, Themis Thoudam, Zhihong Yang, Suthat Liangpunsakul, Jing Ma
    eGastroenterology.2024; 2(4): e100104.     CrossRef
  • Conventional type 1 dendritic cells protect against gut barrier disruption via maintaining Akkermansia muciniphila in alcoholic steatohepatitis
    Liuyi Hao, Wei Zhong, Jongmin Woo, Xiaoyuan Wei, Hao Ma, Haibo Dong, Wei Guo, Xinguo Sun, Ruichao Yue, Jiangchao Zhao, Qibin Zhang, Zhanxiang Zhou
    Hepatology.2023; 78(3): 896.     CrossRef
  • TRPV6 deficiency attenuates stress and corticosterone-mediated exacerbation of alcohol-induced gut barrier dysfunction and systemic inflammation
    Avtar S. Meena, Pradeep K. Shukla, Rupa Rao, Cherie Canelas, Joseph F. Pierre, RadhaKrishna Rao
    Frontiers in Immunology.2023;[Epub]     CrossRef
  • The Role of Microbiota in Liver Transplantation and Liver Transplantation-Related Biliary Complications
    Ulrich Wirth, Tianxiao Jiang, Josefine Schardey, Katharina Kratz, Mingming Li, Malte Schirren, Florian Kühn, Alexandr Bazhin, Jens Werner, Markus Guba, Christian Schulz, Joachim Andrassy
    International Journal of Molecular Sciences.2023; 24(5): 4841.     CrossRef
  • Gut Microbiota: A Future Clinical Magic Bullet to Manifest Pathogenic Disease in the Current Future
    Pooja Rani Mina
    Journal of Pure and Applied Microbiology.2023; 17(1): 51.     CrossRef
  • The human microbiome and gut–liver axis in people living with HIV
    Maria J. Duarte, Phyllis C. Tien, Ma Somsouk, Jennifer C. Price
    Current HIV/AIDS Reports.2023; 20(3): 170.     CrossRef
  • Exploring the diversity of blood microbiome during liver diseases: Unveiling Novel diagnostic and therapeutic Avenues
    Dinakaran Vasudevan, Arulraj Ramakrishnan, Ganesan Velmurugan
    Heliyon.2023; 9(11): e21662.     CrossRef
  • Fecal Microbiota Transplantation in Liver Cirrhosis
    Adrian Boicean, Victoria Birlutiu, Cristian Ichim, Olga Brusnic, Danusia Maria Onișor
    Biomedicines.2023; 11(11): 2930.     CrossRef
  • Advances in the management of alcohol-associated liver disease
    Ahmad Anouti, Thomas A Kerr, Mack C Mitchell, Thomas G Cotter
    Gastroenterology Report.2023;[Epub]     CrossRef
  • Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation
    Sergii Tkach, Andrii Dorofeyev, Iurii Kuzenko, Nadiya Boyko, Tetyana Falalyeyeva, Luigi Boccuto, Emidio Scarpellini, Nazarii Kobyliak, Ludovico Abenavoli
    Medicina.2022; 58(1): 84.     CrossRef
  • Intestinal Microbiota Contributes to the Improvement of Alcoholic Hepatitis in Mice Treated With Schisandra chinensis Extract
    Jun-Yan Xiang, Yan-Yu Chi, Jin-Xin Han, Xinyu Shi, Yong Cai, Hongyu Xiang, Qiuhong Xie
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Recent insights into the hepatoprotective effects of lactic acid bacteria in alcoholic liver disease
    Xiaoqian Sun, Jingjing Shi, Lingyu Kong, Qiyuan Shen, Xiaoqun Zeng, Zhen Wu, Yuxing Guo, Daodong Pan
    Trends in Food Science & Technology.2022; 125: 91.     CrossRef
  • Predictive and Prognostic Roles of Gut Microbial Variation in Liver Transplant
    Hon Jen Wong, Wen Hui Lim, Cheng Han Ng, Darren Jun Hao Tan, Glenn K. Bonney, Alfred W. C. Kow, Daniel Q. Huang, Mohammad Shadab Siddiqui, Mazen Noureddin, Nicholas Syn, Mark D. Muthiah
    Frontiers in Medicine.2022;[Epub]     CrossRef
  • Principles of diagnosis and treatment of alcohol-induced liver fibrosis
    D. V. Garbuzenko
    Meditsinskiy sovet = Medical Council.2022; (7): 104.     CrossRef
  • TRPV6 channel mediates alcohol-induced gut barrier dysfunction and systemic response
    Avtar S. Meena, Pradeep K. Shukla, Briar Bell, Francesco Giorgianni, Rebeca Caires, Carlos Fernández-Peña, Sarka Beranova, Eitaro Aihara, Marshall H. Montrose, Mehdi Chaib, Liza Makowski, Indira Neeli, Marko Z. Radic, Valeria Vásquez, Jonathan H. Jaggar,
    Cell Reports.2022; 39(11): 110937.     CrossRef
  • Utilizing Gut Microbiota to Improve Hepatobiliary Tumor Treatments: Recent Advances
    Hao Qin, Baowen Yuan, Wei Huang, Yan Wang
    Frontiers in Oncology.2022;[Epub]     CrossRef
  • Alcohol-Related Liver Disease: An Overview on Pathophysiology, Diagnosis and Therapeutic Perspectives
    Yoonji Ha, Inju Jeong, Tae Hyun Kim
    Biomedicines.2022; 10(10): 2530.     CrossRef
  • Pathophysiological Prerequisites and Therapeutic Potential of Fecal Microbiota Transplantation in Severe Alcoholic Hepatitis
    D. V. Garbuzenko
    The Russian Archives of Internal Medicine.2022; 12(5): 352.     CrossRef
  • Finding a Balance in the Vaginal Microbiome: How Do We Treat and Prevent the Occurrence of Bacterial Vaginosis?
    Rebecca Jane Joseph, Hooi-Leng Ser, Yi-He Kuai, Loh Teng-Hern Tan, Valliammai Jayanthi Thirunavuk Arasoo, Vengadesh Letchumanan, Lijing Wang, Priyia Pusparajah, Bey-Hing Goh, Nurul-Syakima Ab Mutalib, Kok-Gan Chan, Learn-Han Lee
    Antibiotics.2021; 10(6): 719.     CrossRef
  • From intestinal dysbiosis to alcohol-associated liver disease
    Beatriz Garcia Mendes, Bernd Schnabl
    Clinical and Molecular Hepatology.2020; 26(4): 595.     CrossRef
  • Alcohol and hepatocarcinogenesis
    Makiko Taniai
    Clinical and Molecular Hepatology.2020; 26(4): 736.     CrossRef
  • 12,523 View
  • 253 Download
  • 37 Web of Science
  • Crossref

Liver fibrosis, cirrhosis, and portal hypertension

Hepatic venous pressure gradient: clinical use in chronic liver disease
Ki Tae Suk
Clin Mol Hepatol 2014;20(1):6-14.
Published online March 26, 2014
DOI: https://doi.org/10.3350/cmh.2014.20.1.6

Portal hypertension is a severe consequence of chronic liver diseases and is responsible for the main clinical complications of liver cirrhosis. Hepatic venous pressure gradient (HVPG) measurement is the best available method to evaluate the presence and severity of portal hypertension. Clinically significant portal hypertension is defined as an increase in HVPG to >10 mmHg. In this condition, the complications of portal hypertension might begin to appear. HVPG measurement is increasingly used in the clinical fields, and the HVPG is a robust surrogate marker in many clinical applications such as diagnosis, risk stratification, identification of patients with hepatocellular carcinoma who are candidates for liver resection, monitoring of the efficacy of medical treatment, and assessment of progression of portal hypertension. Patients who had a reduction in HVPG of ≥20% or to ≤12 mmHg in response to drug therapy are defined as responders. Responders have a markedly decreased risk of bleeding/rebleeding, ascites, and spontaneous bacterial peritonitis, which results in improved survival. This review provides clinical use of HVPG measurement in the field of liver disease.

Citations

Citations to this article as recorded by  Crossref logo
  • Comparison of Carvedilol and Propranolol in Reducing the Portal Vein Pressure
    Wendou Hu, Shunyu Yao, Min Qiao
    Journal of Clinical Gastroenterology.2026; 60(1): 77.     CrossRef
  • Value of Spleen Dynamic Contrast-enhanced Ultrasound Parameters in Predicting Hepatic Vein Pressure Gradient for Patients With Liver Cirrhosis
    Tie Zhou, Yan Zhou, Lin Zhao, Yanmin Kan, Jianmin Ding, Cheng Sun, Xiang Jing
    Journal of Clinical Gastroenterology.2026; 60(2): 182.     CrossRef
  • The evolution of non-invasive strategies in cirrhosis management—from screening to precision monitoring: Editorial on “Fibrosis-4plus score: a novel machine learning-based tool for screening high-risk varices in compensated cirrhosis (CHESS2004): an inter
    Haiyu Wang, Jinjun Chen
    Clinical and Molecular Hepatology.2026; 32(1): 403.     CrossRef
  • Standard technique in Japan for measuring hepatic venous pressure gradient
    Yusuke Imai, Yohei Koizumi, Yoichi Hiasa, Masashi Hirooka, Yoshio Tokumoto, Osamu Yoshida, Fumio Chikamori
    Journal of Gastroenterology.2025; 60(1): 24.     CrossRef
  • Metabolomic Changes Associated With the Change in HVPG After DAAs Therapy in HCV Cirrhotic Patients
    Ana Virseda‐Berdices, Rubén Martín‐Escolano, Juan Berenguer, Juan González‐García, Oscar Brochado‐Kith, David Rojo, Cristina Díez, Víctor Hontañon, Leire Pérez‐Latorre, Luis Ibañez‐Samaniego, Elba Llop‐Herrera, Antonio Olveira, Amanda Fernández‐Rodríguez,
    Liver International.2025;[Epub]     CrossRef
  • Secondary Prophylaxis of Cirrhotic Gastric Variceal Bleeding: Addition of Non‐Selective Beta‐Blockers to Endoscopic Combined Treatment
    Ling Wu, Xiaoquan Huang, Feng Li, Siyu Jiang, Liyuan Ni, Yingjie Ai, Detlef Schuppan, Shiyao Chen
    United European Gastroenterology Journal.2025; 13(4): 586.     CrossRef
  • Hepatic Venous Pressure Gradient Measurement and its Limitation
    Nadera Altork, Spyridon Peppas, Atoosa Rabiee
    Current Hepatology Reports.2025;[Epub]     CrossRef
  • Shared Features of Obliterative Portal Venopathy, Normal Liver, and Chronic Liver Disease: A Histologic and Morphometric Analysis
    Peizi Li, Thomas D. Schiano, Swan N. Thung, Stephen C. Ward, M. Isabel Fiel
    Modern Pathology.2025; 38(6): 100739.     CrossRef
  • CT-Derived spleen volume accurately diagnoses severe portal hypertension at HVPG thresholds of 16 mmhg
    Xinyu Chen, Jiamei Zhou, Yicheng Lin, Kefeng Jia, Jiajun Tian, Fenghui Li, Rong Lv, Weili Yin, Fang Wang, Ping Zhu, Chao Yang, Jiayin Wang, Tao Wang, Junqing Yan, Ying Liu, Qing Ye, Huiling Xiang
    Scientific Reports.2025;[Epub]     CrossRef
  • Application of 4D Flow MRI in Quantitative Evaluation of Portal Hypertension in Cirrhosis
    琼 胡
    Advances in Clinical Medicine.2025; 15(05): 287.     CrossRef
  • Comparison of Carvedilol to Propranolol in Reduction of Hepatic Venous Pressure Gradient in Liver Cirrhosis: A Meta‐Analysis
    Amey Joshi, Hafsa Arshad Azam Raja, Poulami Roy, Fakhar Latif, Rahul George Reji, Novonil Deb, Ryan K. Mui, Ahmed Shady
    Journal of Gastroenterology and Hepatology.2025; 40(6): 1409.     CrossRef
  • Strengthening the Assessment of Antifibrotic Therapy in Compensated Cirrhosis
    Sheng Li, Xiao Wu
    Liver International.2025;[Epub]     CrossRef
  • Role of liver ARFI (acoustic radiation force impulse) to predict esophageal varices in chronic parenchymal liver disease
    Devanand Bala Lakshmoji, Jayaprakash Natarajan, Thilagarajan Sangilikalai, Rajakumar Rathnasamy, Nagul Udayasankar, Sudhan Rackimuthu
    Egyptian Journal of Radiology and Nuclear Medicine.2025;[Epub]     CrossRef
  • Comment on "Stage‑specific impact of portal hypertension on outcomes after liver resection in hepatocellular carcinoma"
    Hongmiao Xia, Yu Zhou
    Hepatology International.2025;[Epub]     CrossRef
  • Noninvasive Prediction Models of First Decompensation in Compensated Advanced Chronic Liver Disease: A Meta-Analysis
    Angus W. Jeffrey, James Chen, Andrew Chin, Emmanuel A. Tsochatzis, Avik Majumdar, Luis Calzadilla-Bertot, Michael C. Wallace, Gary P. Jeffrey, Leon A. Adams
    Clinical Gastroenterology and Hepatology.2025;[Epub]     CrossRef
  • Endo-hepatology: Bridging the gap between lumen and liver
    Walaa Abdelhamed, Mohamed El-Kassas
    World Journal of Gastroenterology.2025;[Epub]     CrossRef
  • Therapeutic Potential of the β3-Adrenergic Receptor and Its Ligands in Cardiovascular Diseases
    Marcel Kempiński, Paweł Jańczak, Adrianna Porębska, Patrycja Sandra Zawadzka, Paulina Jastrzębska, Marcin Mateusz Granat, Małgorzata Wojciechowska
    International Journal of Molecular Sciences.2025; 26(24): 11844.     CrossRef
  • Use of invasive cardiopulmonary exercise testing to diagnose preload reserve failure in patients with liver disease
    Carolyn G. Ahlers, Priyesh Patel, Kishan Parikh, Marat Fudim
    ESC Heart Failure.2024; 11(1): 587.     CrossRef
  • Endohepatology in clinical practice: EUS-guided portal pressure measurement combined with EUS-guided liver biopsy and variceal screening and treatment in outpatients
    Sung Kim, Scot Lewey, Laura Meuller, Douglas G. Adler
    Endoscopic Ultrasound.2024; 13(2): 89.     CrossRef
  • Predictors and Outcomes of Post-transjugular Intrahepatic Portosystemic Shunt Liver Failure in Patients with Cirrhosis
    Amar Mukund, Ashish Aravind, Ankur Jindal, Harsh Vardhan Tevethia, Yashwant Patidar, Shiv K. Sarin
    Digestive Diseases and Sciences.2024; 69(3): 1025.     CrossRef
  • Red cell distribution width/platelet ratio estimates the 3-year risk of decompensation in Metabolic Dysfunction-Associated Steatotic Liver Disease-induced cirrhosis
    Marcello Dallio, Mario Romeo, Paolo Vaia, Salvatore Auletta, Simone Mammone, Marina Cipullo, Luigi Sapio, Angela Ragone, Marco Niosi, Silvio Naviglio, Alessandro Federico
    World Journal of Gastroenterology.2024; 30(7): 685.     CrossRef
  • Prognostic Indicators of Overall Survival in Hepatocellular Carcinoma Patients Undergoing Liver Resection
    Cristina-Paula Ursu, Andra Ciocan, Ștefan Ursu, Răzvan Alexandru Ciocan, Claudia Diana Gherman, Ariana-Anamaria Cordoș, Dan Vălean, Rodica Sorina Pop, Luminița Elena Furcea, Bogdan Procopeț, Horia Ștefănescu, Emil Ioan Moiș, Nadim Al Hajjar, Florin Graur
    Cancers.2024; 16(7): 1427.     CrossRef
  • The impact of hepatic and splenic volumetric assessment in imaging for chronic liver disease: a narrative review
    Numan Kutaiba, William Chung, Mark Goodwin, Adam Testro, Gary Egan, Ruth Lim
    Insights into Imaging.2024;[Epub]     CrossRef
  • Metabolomics reveals altered metabolites in cirrhotic patients with severe portal hypertension in Tibetan population
    Yanting Ye, Chao Xia, Hong Hu, Shihang Tang, Hui Huan
    Frontiers in Medicine.2024;[Epub]     CrossRef
  • Physical exercise in liver diseases
    Yunwei Zhang, Chunyan Cao, Chaofan Li, Russell G. Witt, Hai Huang, Allan Tsung, Hongji Zhang
    Hepatology.2024;[Epub]     CrossRef
  • Advanced cystic fibrosis liver disease: Endovascular, endoscopic, radiologic, and surgical considerations
    Sirish K. Palle, Daniel H. Leung
    Pediatric Pulmonology.2024;[Epub]     CrossRef
  • CIRSE Standards of Practice on Transjugular Intrahepatic Portosystemic Shunts
    Pierleone Lucatelli, Antonín Krajina, Romaric Loffroy, Roberto Miraglia, Claus Christian Pieper, Stéphanie Franchi-Abella, Bianca Rocco
    CardioVascular and Interventional Radiology.2024; 47(12): 1710.     CrossRef
  • Portal pressure is of significant prognostic value in primary biliary cholangitis
    Thomas W. Warnes, Stephen A. Roberts, Alexander Smith, Victor M. Cope, Patricia Vales, Raymond McMahon
    Liver International.2023; 43(1): 139.     CrossRef
  • Endoscopic ultrasound-guided vascular interventions: An overview of current and emerging techniques
    Ahmed Youssef Altonbary
    International Journal of Gastrointestinal Intervention.2023; 12(1): 16.     CrossRef
  • Clinical significance of measuring hepatic venous pressure gradient on transjugular liver biopsy for patients with pre-cirrhotic bridging fibrosis liver disease
    Tuan Vu, Hanel Eberly, Amy Zheng, Aidan Hintze, Kathryn L. McGillen, Jeffrey Cruz, Benjamin Shin
    Clinical Imaging.2023; 96: 44.     CrossRef
  • The Efficacy of Carvedilol in Comparison to Propranolol in Reducing the Hepatic Venous Pressure Gradient and Decreasing the Risk of Variceal Bleeding in Adult Cirrhotic Patients: A Systematic Review
    Lana Dardari, Maher Taha, Purva Dahat, Stacy Toriola, Travis Satnarine, Zareen Zohara, Ademiniyi Adelekun, Kofi D Seffah, Korlos Salib, Ana P Arcia Franchini
    Cureus.2023;[Epub]     CrossRef
  • Prediction and surveillance of de novo HCC in patients with compensated advanced chronic liver disease after hepatitis C virus eradication with direct antiviral agents
    Ashraf Elbahrawy, Hassan Atalla, Abdulla A. Mahmoud, Ahmed Eliwa, Alaa Alsawak, Mohamed Alboraie, Ali Madian, Ahmed Alashker, Sadek Mostafa, Ahmed Alwassief, Hussein H. Aly
    Frontiers in Virology.2023;[Epub]     CrossRef
  • Methods for assessing portal hypertension
    S.M. Chooklin, S.S. Chuklin
    EMERGENCY MEDICINE.2023; 19(6): 393.     CrossRef
  • Advances in the management of complications from cirrhosis
    Jasleen Singh, Mark Ebaid, Sammy Saab
    Gastroenterology Report.2023;[Epub]     CrossRef
  • The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis
    Thomas Reiberger
    Hepatology Communications.2022; 6(5): 950.     CrossRef
  • Artificial intelligence in the diagnosis of cirrhosis and portal hypertension
    Xiaoguo Li, Ning Kang, Xiaolong Qi, Yifei Huang
    Journal of Medical Ultrasonics.2022; 49(3): 371.     CrossRef
  • Value of Liver Function Tests in Cirrhosis
    Praveen Sharma
    Journal of Clinical and Experimental Hepatology.2022; 12(3): 948.     CrossRef
  • Clinical Applications of 4D Flow MRI in the Portal Venous System
    Thekla H. Oechtering, Grant S. Roberts, Nikolaos Panagiotopoulos, Oliver Wieben, Scott B. Reeder, Alejandro Roldán-Alzate
    Magnetic Resonance in Medical Sciences.2022; 21(2): 340.     CrossRef
  • β-arrestin-2 predicts the clinical response to β-blockers in cirrhotic portal hypertension patients: A prospective study
    Sameh A Lashen, Mohammed M Shamseya, Marwa A Madkour, Radwa M Abdel Salam, Sanaa S Mostafa
    World Journal of Hepatology.2022; 14(2): 429.     CrossRef
  • Endoscopic Ultrasound-Guided Porto-systemic Pressure Gradient Measurement Correlates with Histological Hepatic Fibrosis
    Alyssa Y. Choi, Kenneth J. Chang, Jason B. Samarasena, John G. Lee, Xiaodong Li, Wenchang Guo, Vishal S. Chandan, Ke-Qin Hu
    Digestive Diseases and Sciences.2022; 67(12): 5685.     CrossRef
  • Hemorheological and biochemical study in patients with liver cirrhosis
    Christian Alejandra Sarabia Aldana, Luis Medina-Torres, Fausto Calderas, Luis Antonio Ramírez-Torres, Diola-Marina Núñez-Ramírez, Edtson Emilio Herrera-Valencia, Ma. Josefa Bernad-Bernad, Octavio Manero
    Physics of Fluids.2022;[Epub]     CrossRef
  • The severity of portal hypertension by a non-invasive assessment: acoustic structure quantification analysis of liver parenchyma
    Wen-Bin Cai, Ji-Kai Yin, Qiao-ying Li, Yi-Lin Yang, Yun-You Duan, Li Zhang
    BMC Medical Imaging.2022;[Epub]     CrossRef
  • Tolerance and acceptance of hepatic venous pressure gradient measurement in cirrhosis (CHESS1904): An international multicenter study
    Jun‐Hui Sun, He Zhao, Haijun Zhang, Lei Li, Necati Örmeci, Zi‐Niu Yu, Xun Li, Shuangxi Li, Xujun Yang, Huaping Wei, Xiaoliang Zhu, Zhengcong Zhang, Yajin Wang, Zhongwei Zhao, Jianting Mao, Qiaohong Wu, Xiaole Sun, Huiling Xiang, Kefeng Jia, Chao Yang, Wei
    Portal Hypertension & Cirrhosis.2022; 1(1): 7.     CrossRef
  • Evaluation of Hepatic Hemodynamics (Hepatic Venous Pressure Gradient) During Right Heart Catheterization: A Comprehensive Review
    Guillermo Cueto-Robledo, Abril Tapia-Paredes, Marisol Garcia-Cesar, Maria-Berenice Torres-Rojas, Rodrigo-Alejandro Flores-Romero, Ernesto Roldan-Valadez
    Current Problems in Cardiology.2022; 47(9): 101278.     CrossRef
  • Use of biochemical parameters for non-invasive screening of oesophageal varices in comparison to elastography-based approach in patients with compensated advanced chronic liver disease
    Anita Madir, Ivica Grgurevic, Lovorka Derek, Adriana Unic, Sanda Mustapic, Marko Zelenika, Tomislav Bokun, Frane Pastrovic, Kristian Podrug, Marko Lucijanic
    Biochemia medica.2022; 32(2): 280.     CrossRef
  • Porto-Sinusoidal Vascular Disease in a Patient With Diffuse Aortitis and Massive Ascites
    Emily Lin, Brian T. Lee
    ACG Case Reports Journal.2022; 9(7): e00812.     CrossRef
  • Multiscale biomechanics and mechanotransduction from liver fibrosis to cancer
    Ning Li, Xiaoyu Zhang, Jin Zhou, Wang Li, Xinyu Shu, Yi Wu, Mian Long
    Advanced Drug Delivery Reviews.2022; 188: 114448.     CrossRef
  • Right Heart Catheterization (RHC): A Comprehensive Review of Provocation Tests and Hepatic Hemodynamics in Patients With Pulmonary Hypertension (PH)
    Leslie-Marisol Gonzalez-Hermosillo, Guillermo Cueto-Robledo, Ernesto Roldan-Valadez, Luis-Eugenio Graniel-Palafox, Marisol Garcia-Cesar, Maria-Berenice Torres-Rojas, Berenice Romero-Martinez, Karla-Yamilet Castro-Escalante
    Current Problems in Cardiology.2022; 47(12): 101351.     CrossRef
  • Diagnostic and interventional EUS in hepatology: An updated review
    Vaneet Jearth, Sridhar Sundaram, Surinder Singh Rana
    Endoscopic Ultrasound.2022; 11(5): 355.     CrossRef
  • The natural history of patients with compensated cirrhosis and elevated hepatic venous pressure gradient
    Andrew Wortham, Ali Khalifa, Don C. Rockey
    Portal Hypertension & Cirrhosis.2022; 1(2): 101.     CrossRef
  • The use of endoscopic ultrasound in the diagnosis and management of portal hypertension
    Wim Laleman, Emma Vanderschueren, Schalk Van der Merwe, Kenneth J. Chang
    Best Practice & Research Clinical Gastroenterology.2022; 60-61: 101811.     CrossRef
  • Covered transjugular intrahepatic portosystemic stent-shunt vs large volume paracentesis in patients with cirrhosis: A real-world propensity score-matched study
    Amritpal Dhaliwal, Homoyoon Merhzad, Salil Karkhanis, Dhiraj Tripathi
    World Journal of Clinical Cases.2022; 10(31): 11313.     CrossRef
  • Evolution of interventional endoscopic ultrasound
    Mark J Radlinski, Daniel S Strand, Vanessa M Shami
    Gastroenterology Report.2022;[Epub]     CrossRef
  • Calibration of an Electrical Analog Model of Liver Hemodynamics in Fontan Patients
    Elyar Abbasi Bavil, Matthew G. Doyle, Charlotte Debbaut, Rachel M. Wald, Luc Mertens, Thomas L. Forbes, Cristina H. Amon
    Journal of Biomechanical Engineering.2021;[Epub]     CrossRef
  • Accuracy of liver and spleen stiffness on magnetic resonance elastography for detecting portal hypertension: a systematic review and meta-analysis
    Ranjit Singh, Mitchell P. Wilson, Prayash Katlariwala, Mohammad H. Murad, Matthew D.F. McInnes, Gavin Low
    European Journal of Gastroenterology & Hepatology.2021; 32(2): 237.     CrossRef
  • Role of Endoscopic Ultrasound in Liver Disease: Where Do We Stand?
    Tajana Pavic, Ivana Mikolasevic, Dominik Kralj, Nina Blazevic, Anita Skrtic, Ivan Budimir, Ivan Lerotic, Davor Hrabar
    Diagnostics.2021; 11(11): 2021.     CrossRef
  • Massive duodenal variceal hemorrhage in a patient with prior Roux-en-Y gastric bypass
    Kiran Sinjali, Chris Bent
    Radiology Case Reports.2021; 16(11): 3304.     CrossRef
  • Portal hypertension in primary biliary cholangitis: prevalence, natural history and histological correlates
    Thomas W. Warnes, Stephen A. Roberts, Alexander Smith, Victor M. Cope, Patricia Vales, Najib Y. Haboubi, Raymond F. McMahon
    European Journal of Gastroenterology & Hepatology.2021; 33(12): 1595.     CrossRef
  • Endoscopic ultrasound-guided vascular interventions: Current insights and emerging techniques
    Rupinder Mann, Hemant Goyal, Abhilash Perisetti, Saurabh Chandan, Sumant Inamdar, Benjamin Tharian
    World Journal of Gastroenterology.2021; 27(40): 6874.     CrossRef
  • Artificial Intelligence in Imaging of Chronic Liver Diseases
    Carl F. Sabottke, Bradley M. Spieler, Ahmed W. Moawad, Khaled M. Elsayes
    Magnetic Resonance Imaging Clinics of North America.2021; 29(3): 451.     CrossRef
  • Hepatopulmonary syndrome is related to the development of acute-on-chronic liver failure and poor prognosis in cirrhotic patients
    Seul Ki Han, Moon Young Kim, Seong Hee Kang, Ki Tae Suk, Soon Koo Baik
    Hepatology International.2021; 15(5): 1207.     CrossRef
  • Invasive measurement of portal hypertension in the hemodynamics laboratory as an important element of qualification for the treatment of esophageal varices: A single-center experience
    Krystian Bojko, Adam Kern, Tomasz Arłukowicz, Leszek Gromadziński, Jerzy Górny, Dariusz Onichimowski, Rakesh Jalali, Damian Kabziński, Artur Zarzecki, Jacek Bil
    Polish Annals of Medicine.2021;[Epub]     CrossRef
  • Hepatic Venous Pressure Gradient
    Teodora Bochnakova
    Clinical Liver Disease.2021; 17(3): 144.     CrossRef
  • Hepatic venous-portal gradient (HVPG) measurement: pearls and pitfalls
    Qiqi Lu, Sum Leong, Kristen Alexa Lee, Ankur Patel, Jasmine Ming Er Chua, Nanda Venkatanarasimha, Richard HG Lo, Farah Gillan Irani, Kun Da Zhuang, Apoorva Gogna, Pik Eu Jason Chang, Hiang Keat Tan, Chow Wei Too
    The British Journal of Radiology.2021; 94(1124): 20210061.     CrossRef
  • An Uncommon Cause of Biliary Obstruction in a Patient With Budd-Chiari Syndrome
    Sheena Mago, Marianna Mavilia, Colin Thomas Swales
    ACG Case Reports Journal.2021; 8(5): e00597.     CrossRef
  • Massive gastrointestinal bleeding due to ectopic varix in distal duodenum: a case report
    Patrick Mallea, Aaron Allen, Maureen Kim Lynch, Elsbeth Jensen-Otsu, David Tompkins
    Journal of Community Hospital Internal Medicine Perspectives.2021; 11(3): 370.     CrossRef
  • HISTOSTEREOMETRIC ASPECTS OF FEATURES OF REMODELING OF THE VENTRICULAR STRUCTURES OF THE HEART IN THE CONDITIONS OF POSTRESECTION PORTAL HYPERTENSION
    N. M. Gdanska, M. S. Hnatjuk, L. V. Tatarchuk, N. Ja. Monastyrska
    Bulletin of Problems Biology and Medicine.2021; 4(1): 251.     CrossRef
  • Indian College of Radiology and Imaging Evidence-Based Guidelines for Interventions in Portal Hypertension and Its Complications
    Amar Mukund, Shaleen Rana, Chander Mohan, Naveen Kalra, Sanjay Saran Baijal
    Indian Journal of Radiology and Imaging.2021; 31(04): 917.     CrossRef
  • Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes
    Patricia P. Bloom, Amirkasra Mojtahed, Emily D. Bethea, Sally A. Knooihuizen, Jin Choi, Jules L. Dienstag, Raymond T. Chung, Chin Hur
    Digestive Diseases and Sciences.2020; 65(1): 312.     CrossRef
  • Clinical and Preclinical Imaging of Hepatosplenic Schistosomiasis
    Brice Masi, Teodora-Adriana Perles-Barbacaru, Monique Bernard, Angèle Viola
    Trends in Parasitology.2020; 36(2): 206.     CrossRef
  • Anesthesia for the Patient with Severe Liver Failure
    Aidan Spring, Jagroop S. Saran, Sinead McCarthy, Stuart A. McCluskey
    Anesthesiology Clinics.2020; 38(1): 35.     CrossRef
  • Anticholinergic Burden and Safety Outcomes in Older Patients with Chronic Hepatitis C: A Retrospective Cohort Study
    Patricia Amoros-Reboredo, Dolors Soy, Marta Hernandez-Hernandez, Sabela Lens, Conxita Mestres
    International Journal of Environmental Research and Public Health.2020; 17(11): 3776.     CrossRef
  • Exercise and physical activity in cirrhosis: opportunities or perils
    Annette Bellar, Nicole Welch, Srinivasan Dasarathy
    Journal of Applied Physiology.2020; 128(6): 1547.     CrossRef
  • Nonalcoholic fatty liver disease and portal hypertension
    Marvin Ryou, Nicholas Stylopoulos, Gyorgy Baffy
    Exploration of Medicine.2020; 1(3): 149.     CrossRef
  • PTFE-covered TIPS is an effective treatment for secondary preventing variceal rebleeding in cirrhotic patients with high risks
    Yongjie Zhou, Wen Zhang, Zihan Zhang, Jianjun Luo, Junying Gu, Qingxin Liu, Jingqin Ma, Zhiping Yan, Shiyao Chen, Jian Wang
    European Journal of Gastroenterology & Hepatology.2020; 32(9): 1235.     CrossRef
  • Accurate ultrasonography-based portal pressure assessment in patients with hepatocellular carcinoma
    Yu Zhang, Zhong Wang, Yi-Fan Wu, Zhen-Dong Yue, Hong-Wei Zhao, Lei Wang, Zhen-Hua Fan, Fu-Liang He, Fu-Quan Liu
    World Journal of Gastrointestinal Oncology.2020; 12(8): 931.     CrossRef
  • Noninvasive imaging assessment of portal hypertension
    Paul Kennedy, Octavia Bane, Stefanie J. Hectors, Aaron Fischman, Thomas Schiano, Sara Lewis, Bachir Taouli
    Abdominal Radiology.2020; 45(11): 3473.     CrossRef
  • Clinical Decompensation and Outcomes in Patients With Compensated Cirrhosis and a Hepatic Venous Pressure Gradient ≥20 mm Hg
    Ankur Jindal, Ankit Bhardwaj, Guresh Kumar, Shiv Kumar Sarin
    American Journal of Gastroenterology.2020; 115(10): 1624.     CrossRef
  • Acute-on-chronic liver failure as a major predictive factor for mortality in patients with variceal bleeding
    Jongbeom Shin, Jung Hwan Yu, Young-Joo Jin, Hyung Joon Yim, Young Kul Jung, Jin Mo Yang, Do Seon Song, Young Seok Kim, Sang Gyune Kim, Dong Joon Kim, Ki Tae Suk, Eileen L. Yoon, Sang Soo Lee, Chang Wook Kim, Hee Yeon Kim, Jae Young Jang, Soung Won Jeong
    Clinical and Molecular Hepatology.2020; 26(4): 540.     CrossRef
  • Application of Hepatic Venous Pressure Gradient to Predict Prognosis in Cirrhotic Patients with a Low Model for End-stage Liver Disease Score
    Young Chang, Ki Tae Suk, Soung Won Jeong, Jeong-Ju Yoo, Sang Gyune Kim, Young Seok Kim, Sae Hwan Lee, Hong Soo Kim, Seong Hee Kang, Soon Koo Baik, Dong Joon Kim, Moon Young Kim, Jae Young Jang
    Diagnostics.2020; 10(10): 805.     CrossRef
  • Anesthesia for the Patient with Severe Liver Failure
    Aidan Spring, Jagroop S. Saran, Sinead McCarthy, Stuart A. McCluskey
    Advances in Anesthesia.2020; 38: 251.     CrossRef
  • Varices on computed tomography are surrogate of clinically significant portal hypertension and can predict survival in compensated cirrhosis patients
    Dong Ho Lee, Jhii‐Hyun Ahn, Jin Wook Chung, Young Ju Kim, Seung‐Whan Cha, Moon Young Kim, Soon Koo Baik
    Journal of Gastroenterology and Hepatology.2019; 34(2): 450.     CrossRef
  • Potential mechanisms linking gut microbiota and portal hypertension
    Gyorgy Baffy
    Liver International.2019; 39(4): 598.     CrossRef
  • Endoscopic Ultrasound-Guided Interventions for the Measurement and Treatment of Portal Hypertension
    Jason B. Samarasena, Kenneth J. Chang
    Gastrointestinal Endoscopy Clinics of North America.2019; 29(2): 311.     CrossRef
  • Machine Learning-based Development and Validation of a Scoring System for Screening High-Risk Esophageal Varices
    Tien S. Dong, Amir Kalani, Elizabeth S. Aby, Long Le, Kayti Luu, Meg Hauer, Rahul Kamath, Keith D. Lindor, James H. Tabibian
    Clinical Gastroenterology and Hepatology.2019; 17(9): 1894.     CrossRef
  • The New Cutoff Value of the Hepatic Venous Pressure Gradient on Predicting Long-Term Survival in Cirrhotic Patients
    Tae Yeob Kim, Ki Tae Suk, Soung Won Jeong, Tom Ryu, Dong Joon Kim, Soon Koo Baik, Joo Hyun Sohn, Woo Kyoung Jeong, Eunhee Choi, Jae Young Jang, Moon Young Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • HVPG as a Predictor of Mortality in Non-Critically-Ill Cirrhotic Patients
    Jeong-Ju Yoo, Sang Gyune Kim
    Journal of Korean Medical Science.2019;[Epub]     CrossRef
  • Pulmonary arterial hypertension populations of special interest: portopulmonary hypertension and pulmonary arterial hypertension associated with congenital heart disease
    Laurent Savale, Alessandra Manes
    European Heart Journal Supplements.2019; 21(Supplement): K37.     CrossRef
  • Natural History of Cirrhosis of Liver after First Decompensation: A Prospective Study in India
    Apurva S. Shah, Deepak N. Amarapurkar
    Journal of Clinical and Experimental Hepatology.2018; 8(1): 50.     CrossRef
  • Impact of Bacterial Translocation on Hepatopulmonary Syndrome: A Prospective Observational Study
    Ki Tae Suk, Moon Young Kim, Soung Won Jeong, Jae Young Jang, Yoon Ok Jang, Soon Koo Baik
    Digestive Diseases and Sciences.2018; 63(1): 248.     CrossRef
  • Supersonic shear imaging for the diagnosis of liver fibrosis and portal hypertension in liver diseases: a meta-analysis
    Han Deng, Xingshun Qi, Tiansong Zhang, Xiaolong Qi, Eric M Yoshida, Xiaozhong Guo
    Expert Review of Gastroenterology & Hepatology.2018; 12(1): 91.     CrossRef
  • Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
    Gyorgy Baffy
    Digestive Diseases and Sciences.2018; 63(3): 563.     CrossRef
  • Endoscopic Ultrasound-Guided Portal Pressure Measurement and Interventions
    Jason B. Samarasena, Kenneth J. Chang
    Clinical Endoscopy.2018; 51(3): 222.     CrossRef
  • Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis
    Vijendra Kirnake, Anil Arora, Praveen Sharma, Mohan Goyal, Romesh Chawlani, Jay Toshniwal, Ashish Kumar
    Indian Journal of Gastroenterology.2018; 37(4): 335.     CrossRef
  • Non-invasive predictive model for hepatic venous pressure gradient based on a 3-dimensional computed tomography volume rendering technology
    Yujen Tseng, Lili Ma, Tiancheng Luo, Xiaoqing Zeng, Na Li, Yichao Wei, Ji Zhou, Feng Li, Shiyao Chen
    Experimental and Therapeutic Medicine.2018;[Epub]     CrossRef
  • 4D flow MR imaging of the portal venous system: a feasibility study in children
    Keyur Parekh, Michael Markl, Michael Rose, Susanne Schnell, Andrada Popescu, Cynthia K. Rigsby
    European Radiology.2017; 27(2): 832.     CrossRef
  • Anesthetic and operative considerations for laparoscopic liver resection
    Michael E. Egger, Vijaya Gottumukkala, Jonathan A. Wilks, Jose Soliz, Matthias Ilmer, Jean Nicolas Vauthey, Claudius Conrad
    Surgery.2017; 161(5): 1191.     CrossRef
  • Liver Stiffness Measured by Shear‐wave Elastography for Evaluating Intrahepatic Portal Hypertension in Children
    Hee Mang Yoon, So Yeon Kim, Kyung Mo Kim, Seak Hee Oh, Gi‐Young Ko, Yangsoon Park, Jin Seong Lee, Ah Young Jung, Young Ah Cho
    Journal of Pediatric Gastroenterology and Nutrition.2017; 64(6): 892.     CrossRef
  • Effect of viral suppression on hepatic venous pressure gradient in hepatitis C with cirrhosis and portal hypertension
    N. Afdhal, G. T. Everson, J. L. Calleja, G. W. McCaughan, J. Bosch, D. M. Brainard, J. G. McHutchison, S. De‐Oertel, D. An, M. Charlton, K. R. Reddy, T. Asselah, E. Gane, M. P. Curry, X. Forns
    Journal of Viral Hepatitis.2017; 24(10): 823.     CrossRef
  • Hepatic venous pressure gradient correlates with advanced hepatic fibrosis: a retrospective review
    Jonathan K. Vincent, Christopher Stark, Joseph T. Shields, Anant D. Bhave, Christopher S. Morris
    Abdominal Radiology.2017; 42(11): 2609.     CrossRef
  • Diagnostic efficacy of noninvasive liver fibrosis indexes in predicting portal hypertension in patients with cirrhosis
    Le Wang, Yuemin Feng, Xiaowen Ma, Guangchuan Wang, Hao Wu, Xiaoyu Xie, Chunqing Zhang, Qiang Zhu, Ming-Lung Yu
    PLOS ONE.2017; 12(8): e0182969.     CrossRef
  • A Pilot Study Evaluating the Safety of Intravenously Administered Human Amnion Epithelial Cells for the Treatment of Hepatic Fibrosis
    Rebecca Lim, Alexander Hodge, Gregory Moore, Euan M. Wallace, William Sievert
    Frontiers in Pharmacology.2017;[Epub]     CrossRef
  • Rifaximin and Propranolol Combination Therapy Is More Effective than Propranolol Monotherapy for the Reduction of Portal Pressure: An Open Randomized Controlled Pilot Study
    Yoo Li Lim, Moon Young Kim, Yoon Ok Jang, Soon Koo Baik, Sang Ok Kwon
    Gut and Liver.2017; 11(5): 702.     CrossRef
  • Prognostic Significance of Hemodynamic and Clinical Stages in the Prediction of Hepatocellular Carcinoma
    Ki Tae Suk, Eun Jin Kim, Dong Joon Kim, Hyo Sun Kim, Chang Seok Bang, Tae Young Park, Gwang Ho Baik, Sung Eun Kim, Ji Won Park, Sang Hoon Park, Myung Seok Lee, Hyoung Su Kim, Myoung Kuk Jang, Seung Ha Park, Eunhee Choi, Chang H. Kim, Hotaik Sung, Choong K
    Journal of Clinical Gastroenterology.2017; 51(3): 285.     CrossRef
  • The 2016 International Society for Heart Lung Transplantation listing criteria for heart transplantation: A 10-year update
    Mandeep R. Mehra, Charles E. Canter, Margaret M. Hannan, Marc J. Semigran, Patricia A. Uber, David A. Baran, Lara Danziger-Isakov, James K. Kirklin, Richard Kirk, Sudhir S. Kushwaha, Lars H. Lund, Luciano Potena, Heather J. Ross, David O. Taylor, Erik A.M
    The Journal of Heart and Lung Transplantation.2016; 35(1): 1.     CrossRef
  • Hepatic Venous Pressure Gradient Predicts Long-Term Mortality in Patients with Decompensated Cirrhosis
    Tae Yeob Kim, Jae Gon Lee, Joo Hyun Sohn, Ji Yeoun Kim, Sun Min Kim, Jinoo Kim, Woo Kyoung Jeong
    Yonsei Medical Journal.2016; 57(1): 138.     CrossRef
  • Indocyanine green retention test (ICG-r15) as a noninvasive predictor of portal hypertension in patients with different severity of cirrhosis
    Marie-Louise L. Pind, Flemming Bendtsen, Thomas Kallemose, Søren Møller
    European Journal of Gastroenterology & Hepatology.2016; 28(8): 948.     CrossRef
  • Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis
    Radan Bruha, Marie Jachymova, Jaromir Petrtyl, Karel Dvorak, Martin Lenicek, Petr Urbanek, Tomislav Svestka, Libor Vitek
    World Journal of Gastroenterology.2016; 22(12): 3441.     CrossRef
  • Evaluation of portal hypertension by real‐time shear wave elastography in cirrhotic patients
    Tae Yeob Kim, Woo Kyoung Jeong, Joo Hyun Sohn, Jinoo Kim, Min Yeong Kim, Yongsoo Kim
    Liver International.2015; 35(11): 2416.     CrossRef
  • von Willebrand factor as a novel noninvasive predictor of portal hypertension and esophageal varices in hepatitis B patients with cirrhosis
    Hao Wu, Shiping Yan, Guangchuan Wang, Shaobo Cui, Chunqing Zhang, Qiang Zhu
    Scandinavian Journal of Gastroenterology.2015; 50(9): 1160.     CrossRef
  • Staging of liver fibrosis or cirrhosis: The role of hepatic venous pressure gradient measurement
    Ki Tae Suk
    World Journal of Hepatology.2015; 7(3): 607.     CrossRef
  • Sarcopenia as a Useful Predictor for Long-Term Mortality in Cirrhotic Patients with Ascites
    Tae Yeob Kim, Min Yeong Kim, Joo Hyun Sohn, Sun Min Kim, Jeong Ah Ryu, Sanghyeok Lim, Youngsoo Kim
    Journal of Korean Medical Science.2014; 29(9): 1253.     CrossRef
  • 26,453 View
  • 401 Download
  • 116 Web of Science
  • Crossref
Original Articles
The usefulness of transient elastography to diagnose cirrhosis in patients with alcoholic Liver disease
Sang Gyune Kim, M.D., Young Seok Kim, M.D., Seung Won Jung, M.D., Hee Kyung Kim, M.D.1, Jae Young Jang, M.D., Jong Ho Moon, M.D., Hong Soo Kim, M.D., Joon Seong Lee, M.D., Moon Sung Lee, M.D., Chan Sup Shim, M.D., Boo Sung Kim, M.D.
Korean J Hepatol 2009;15(1):42-51.
Published online March 31, 2009
DOI: https://doi.org/10.3350/kjhep.2009.15.1.42
Backgrounds/Aims
It is not easy to differentiate between patients with cirrhosis and those with alcoholic liver disease. Liver biopsy is generally considered the gold standard for assessing hepatic fibrosis; however, this protocol frequently carries a risk of severe complications and false-negative results. Transient elastography (Fibroscan, Echosens, Paris, France), which is a noninvasive method of measuring liver stiffness, has become available for assessing liver fibrosis. Liver stiffness reportedly differs markedly with the cirrhosis etiology. The aim of this study was thus to determine the diagnostic accuracy of the Fibroscan in the detection of cirrhosis in patients with alcoholic liver disease. Methods: We enrolled 45 patients with alcoholic liver disease. Fibroscan, abdominal ultrasonography, aspartate aminotransferase/platelet ratio index (APRI), and liver biopsy were performed on all patients. Fibrosis stage was assessed using the Batts-Ludwig scoring system. Results: The stage of fibrosis (F1-F4) was distributed among the cohort as follows: 5 patients at F1, 4 patients at F2, 7 patients at F3, and 29 patients at F4. Liver stiffness differed significantly between each fibrosis stage (P<0.001). For the diagnosis of cirrhosis, the area under the receiver operating characteristic curve was 0.97 for transient elastography (95% confidence interval, CI, 0.93-1.01), 0.81 for ultrasonography (95% CI, 0.68-0.94), and 0.83 for APRI score (95% CI, 0.70-0.95). The optimal cut-off value of liver stiffness for detecting cirrhosis was 25.8 kPa, with a sensitivity of 90% and a specificity of 87%. Conclusions: Transient elastography is a useful method for diagnosing cirrhosis in patients with alcoholic liver disease. (Korean J Hepatol 2008;15:42-51)

Citations

Citations to this article as recorded by  Crossref logo
  • Noninvasive Tests in Assessment of Patients with Alcohol-Associated Liver Disease
    Lukas Otero Sanchez, Christophe Moreno
    Clinics in Liver Disease.2024; 28(4): 715.     CrossRef
  • KASL clinical practice guidelines for noninvasive tests to assess liver fibrosis in chronic liver disease
    Mi Na Kim, Ji Won Han, Jihyun An, Beom Kyung Kim, Young-Joo Jin, Seung-seob Kim, Minjong Lee, Han Ah Lee, Yuri Cho, Hee Yeon Kim, Yu Rim Shin, Jung Hwan Yu, Moon Young Kim, YoungRok Choi, Young Eun Chon, Eun Ju Cho, Eun Joo Lee, Sang Gyune Kim, Won Kim, D
    Clinical and Molecular Hepatology.2024; 30(Suppl): S5.     CrossRef
  • Diagnostic challenges in patients with alcohol-related liver disease
    Aleksander Krag, Tania Roskams, Massimo Pinzani, Sebastian Mueller
    Zeitschrift für Gastroenterologie.2022; 60(01): 45.     CrossRef
  • Assessment of liver disease in patients with chronic hepatitis C and unhealthy alcohol use
    Daniel Fuster, Xavier García-Calvo, Paola Zuluaga, Ferran Bolao, Robert Muga
    World Journal of Gastroenterology.2021; 27(23): 3223.     CrossRef
  • Noninvasive diagnosis in alcohol‐related liver disease
    Alia Hadefi, Delphine Degré, Eric Trépo, Christophe Moreno
    Health Science Reports.2020;[Epub]     CrossRef
  • Fibroscan Reliably Rules Out Advanced Liver Fibrosis and Significant Portal Hypertension in Alcoholic Patients
    Melissa Salavrakos, Hubert Piessevaux, Mina Komuta, Nicolas Lanthier, Peter Stärkel
    Journal of Clinical Gastroenterology.2019; 53(10): 772.     CrossRef
  • Liver Ultrasound Elastography: An Update to the World Federation for Ultrasound in Medicine and Biology Guidelines and Recommendations
    Giovanna Ferraioli, Vincent Wai-Sun Wong, Laurent Castera, Annalisa Berzigotti, Ioan Sporea, Christoph F Dietrich, Byung Ihn Choi, Stephanie R. Wilson, Masatoshi Kudo, Richard G. Barr
    Ultrasound in Medicine & Biology.2018; 44(12): 2419.     CrossRef
  • Non-invasive diagnosis of liver fibrosis in patients with alcohol-related liver disease by transient elastography: an individual patient data meta-analysis
    Eric Nguyen-Khac, Maja Thiele, Cosmin Voican, Pierre Nahon, Christophe Moreno, Jerome Boursier, Sebastian Mueller, Victor de Ledinghen, Peter Stärkel, Sang Gyune Kim, Michael Fernandez, Bjorn Madsen, Sylvie Naveau, Aleksander Krag, Gabriel Perlemuter, Mar
    The Lancet Gastroenterology & Hepatology.2018; 3(9): 614.     CrossRef
  • Prospective Evaluation of Liver Stiffness Using Transient Elastography in Alcoholic Patients Following Abstinence
    Elena Gianni, Paolo Forte, Valentina Galli, Giulia Razzolini, Gabriele Bardazzi, Vito Annese
    Alcohol and Alcoholism.2017; 52(1): 42.     CrossRef
  • Liver acoustic radiation force impulse (ARFI) in childhood obesity: comparison and correlation with biochemical markers
    Rajeev Kamble, Kushaljit S. Sodhi, Babu R. Thapa, Akshay K. Saxena, Anmol Bhatia, Devi Dayal, Niranjan Khandelwal
    Journal of Ultrasound.2017; 20(1): 33.     CrossRef
  • American Gastroenterological Association Institute Technical Review on the Role of Elastography in Chronic Liver Diseases
    Siddharth Singh, Andrew J. Muir, Douglas T. Dieterich, Yngve T. Falck-Ytter
    Gastroenterology.2017; 152(6): 1544.     CrossRef
  • Systematic review with meta‐analysis: diagnostic accuracy of transient elastography for staging of fibrosis in people with alcoholic liver disease
    C. S. Pavlov, G. Casazza, D. Nikolova, E. Tsochatzis, C. Gluud
    Alimentary Pharmacology & Therapeutics.2016; 43(5): 575.     CrossRef
  • Relationship between 25-Hydroxyvitamin D Levels and Liver Fibrosis as Assessed by Transient Elastography in Patients with Chronic Liver Disease
    Bong Jin Ko, Young Seok Kim, Sang Gyune Kim, Jung Hwan Park, Sae Hwan Lee, Soung Won Jeong, Jae Young Jang, Hong Soo Kim, Boo Sung Kim, Sun Mi Kim, Young Don Kim, Gab Jin Cheon, Bo Ra Lee
    Gut and Liver.2016; 10(5): 818.     CrossRef
  • Inflammation‐adapted liver stiffness values for improved fibrosis staging in patients with hepatitis C virus and alcoholic liver disease
    Sebastian Mueller, Stefan Englert, Helmut K. Seitz, Radu I. Badea, Andreas Erhardt, Bita Bozaari, Michel Beaugrand, Monica Lupșor‐Platon
    Liver International.2015; 35(12): 2514.     CrossRef
  • Cost-effectiveness of non-invasive methods for assessment and monitoring of liver fibrosis and cirrhosis in patients with chronic liver disease: systematic review and economic evaluation
    Catriona Crossan, Emmanuel A Tsochatzis, Louise Longworth, Kurinchi Gurusamy, Brian Davidson, Manuel Rodríguez-Perálvarez, Konstantinos Mantzoukis, Julia O’Brien, Evangelos Thalassinos, Vassilios Papastergiou, Andrew Burroughs
    Health Technology Assessment.2015; 19(9): 1.     CrossRef
  • Transient elastography using Fibroscan is the most reliable noninvasive method for the diagnosis of advanced fibrosis and cirrhosis in alcoholic liver disease
    Michael Fernandez, Eric Trépo, Delphine Degré, Thierry Gustot, Laurine Verset, Pieter Demetter, Jacques Devière, Michael Adler, Christophe Moreno
    European Journal of Gastroenterology & Hepatology.2015; 27(9): 1074.     CrossRef
  • Transient elastography for diagnosis of stages of hepatic fibrosis and cirrhosis in people with alcoholic liver disease
    Chavdar S Pavlov, Giovanni Casazza, Dimitrinka Nikolova, Emmanuel Tsochatzis, Andrew K Burroughs, Vladimir T Ivashkin, Christian Gluud
    Cochrane Database of Systematic Reviews.2015;[Epub]     CrossRef
  • Noninvasive assessment of alcoholic liver disease using unidimensional transient elastography (Fibroscan®)
    Monica Lupsor-Platon
    World Journal of Gastroenterology.2015; 21(42): 11914.     CrossRef
  • Alcohol Dependence and Alcoholic Liver Disease
    Caroline Charles
    EMJ Hepatology.2015; : 20.     CrossRef
  • Utilisation de l’élastométrie hépatique comme outil de dépistage de la fibrose hépatique dans un service d’addictologie
    Pierre Lahmek, Nadine Meunier, Laurent Michel, Henri-Jean Aubin, Sylvain Balester-Mouret
    La Presse Médicale.2014; 43(3): e17.     CrossRef
  • Non-invasive diagnosis of alcoholic liver disease
    Sebastian Mueller
    World Journal of Gastroenterology.2014; 20(40): 14626.     CrossRef
  • Correlation between Ultrasound Reflection Intensity and Tumor Ablation Ratio of Late‐Stage Pancreatic Carcinoma in HIFU Therapy: Dynamic Observation on Ultrasound Reflection Intensity
    Hui-Yu Ge, Li-Ying Miao, Jin-Rui Wang, Liu-Lin Xiong, Fang Yan, Cui-Shan Zheng, Jian-Wen Jia, Li-Gang Cui, Wen Chen, C. Kappas, C. S. Morris
    The Scientific World Journal.2013;[Epub]     CrossRef
  • Clinical applications of transient elastography
    Kyu Sik Jung, Seung Up Kim
    Clinical and Molecular Hepatology.2012; 18(2): 163.     CrossRef
  • Histological subclassification of cirrhosis using the Laennec fibrosis scoring system correlates with clinical stage and grade of portal hypertension
    Moon Young Kim, Mee Yon Cho, Soon Koo Baik, Hong Jun Park, Hyo Keun Jeon, Chong Kun Im, Chan Sik Won, Jae Woo Kim, Hyun Soo Kim, Sang Ok Kwon, Min Seob Eom, Seung Hwan Cha, Young Ju Kim, Sei Jin Chang, Samuel S. Lee
    Journal of Hepatology.2011; 55(5): 1004.     CrossRef
  • Comparison of transient elastography, serum markers and clinical signs for the diagnosis of compensated cirrhosis
    Raza Malik, Michelle Lai, Amama Sadiq, Rory Farnan, Shruti Mehta, Imad Nasser, Tracy Challies, Detlef Schuppan, Nezam Afdhal
    Journal of Gastroenterology and Hepatology.2010; 25(9): 1562.     CrossRef
  • Characterization of one time‐sequential stereoscopic 3d display ‐ Part I: Temporal analysis ‐
    Pierre Boher, Thierry Leroux, Véronique Collomb‐Patton
    Journal of Information Display.2010; 11(2): 57.     CrossRef
  • 8,158 View
  • 135 Download
  • Crossref
Clinical Significance of the Correlation of Serum ProcollagenⅠand Ⅲ Propeptide Concentrations in Chronic Liver Diseases
Dong Il Park , Soong Hwan Lee , In Kyu Paik , Yong Hyeon Cho , Yun hu Cho , Byoung Hun kim , Dong Hoo lee
Korean J Hepatol 1996;2(1):13-20.
Background/Aims
Most liver diseases lead to a pathobiochemical reaction termed liver fibrosis. Hepatic fibrosis is not a uniform phenomenon and it comprises increased deposition of the liver connective tissue components(collagen, noncollagenous glycoprotein, proteoglycan) in the intercellular space, leading to disturbances of intrahepatic blood flow and hindrance of exchange processes between blood and cells, Fibrosis can be determined by morphological examination o f the liver, but this approach cannot be used to assess accurately the activity of collagen synthesis at any given point in time, Thus, the development of biochemical markers of hepatic fihrosis might allow a promising diagnostic approach for the identification and quantitation of this process, Aminoterminal procollagen III pn)peptide(PIIINP) and carboxytermina1 procollagen I propeptide(PICP) are known as the most widely used parameter for evaluating liver fibrosis, but it is diAicult to find previous report discribing the correlation ot each other. To elucidate the clinical significance of the corretation of PICP(x) and PIIINP(y) concentrations in patients with chronic liver diseases, radioimmunoassay was employed in this investigation. Methods:Sera tested were obtained from pathologically proven 43 patients;4 cases of fatly liver, 11 cases of chronic persistent hepatitis, 13 cases of chronic active hepatitis, l5 cases of liver cirrhosis. All the patients except 4 cases ot fatty liver were shown positivity of HBsAg. PICP and PIIlNP radioimmunoassay kits(Farrnos Diagnostica, Oulunsalo, Finland) wcre purchased for this study. Results:In the patients among the three groups of chronic active hepatitis, liver cirrhosis, chmnic persistent hepatitis, the correlations were significant in orders(y= - 10.27 +0.l3938x, r=0.92286, p=0.000007;y=-1.185+0.06611x, r=0.73656, p=0.001737;y=1.1174+0.03273x, r=0.56879, p=0.067849). Four cases of fatty liver reveal no signiticant correlation(y=4,8671- 0,0079x, r= 0.1959, p=0.804054). Conclusion:0n the basis of these data, we s st that the correlation of each showed a significant increase with heightening degree of inflammation, activity of diseases and fibrosis.
  • 2,980 View
  • 12 Download
Evaluation of Angiogenin Concentrations using ELISA in Sera from the Patients with Chronic Liver Diseases.
Kee Woon Kweon, Soong Hwan Lee, Seong Hee Lee, Hong Ju Kim, Chang Hwa Lee, Byoung Hun Kim, In Kyu Paik, Dong Il Park, Sung Soo Park, Dong Hoo Lee
Korean J Hepatol 1996;2(1):29-36.
Backgroud:Liver fibrosis by the progression of the chronic processes of the liver diseases induces deforrned microcirculations of the hepatic lobules. And this eventually resolted in portal hypertension. On the other hands, angiogenic stimu4nt factors are physiologically activated in order to repair the tissue damage. Overexpression of angiogenic factors, however, can stimulate neovascularization as in a fonnation of the tumor that liberates uncontrolled overgrowing of the tumor cells. Methods: To elucidate the dynamic changes of the serum concentration of angiogenin in chronic liver diseases, this study is intended to employ an ELISA in 44 pathologically proven patients. Quantikiae human angiogenin kit (R & D,systems Inc. Mmneapolis, MN) was used for this investigation. Results:Mean value and standard error of angiogenin concentration (ng/ml) of the sera was 238.92+ 50.95 in 5 cases of chronic persistent hepatitis, 184.47+ 12.75 in 6 cases of chronic active hepatitis, 131.36+ 10.99 in 19 cases of liver cirrhosis, and 211.03+ 19.08 in 14 cases of hepatocellular carcinoma, respectively. Serum angiogenin level in the liver cirrhosis was significantly lower than in chronic persistent hepatitis(p=0.00336), and than in chronic active hepatitis(p=0.018673). Angiogenin concentration in hepatocellular carcinomas was significantly higher than the level of the liver cirrhosis investigated(p=0.00569). Conclusions:These data support that persistent inflammatory insults in the chronic hepatitis were compensated by the elevation of angiogenin but complete fibrosis as in liver cirrhosis showed the depressed level. And emerging of the hepatocellular carcinoma is accompanied by the elevated stimuli of angiogenin for the neovascularization.
  • 58,658 View
  • 17 Download
A Study on the Efficacy and Safety of Dipheny - dimethyl - dicarboxylate in Patients with Chronic Liver disease
Hyoung Sik kim , Soo Taek Lee , Dae Gon kim , Deuk Soo Ahn
Korean J Hepatol 1996;2(1):54-60.
Background/Aims
The spectrum of clinical features of chronic liver disease bas wide range from asymptomatic cases to hepatic failure, The natural course and long-term prognosis of chronic liver disease also varies greately, and this diversity makes it diflicult to predict the clinical course of individual patient. The two majar approaches to the treatment of chronic liver disease are 1) directed toward the eradication of the virus and 2)designed to modulate cellular and humeral immunity. Progress has been made in the development of antiviral chernotherapeutic agents for hepatitis. But as yet no safe and reliably effective treatment or combination of treatrnents is available. In tkis study, we performed trial of diphenyl-dimethyl-dicarboxylate to evaluate the therapeutic effect and safety of it. Methods: The ciinical trials of DDB(complex capsule of diphenyl dimethyl dicarboxylate 7.5mg and polysorbate 80 1,5mg and polyethylene glycol 6000 66mg) were carried out in 30 patients with chronic liver disease for 6 months. All patients had abnormal liver function test ouer a period of 6 months. Results:In selected groups mean serum aspartate aminotransferase and alanine aminotrans- ferase dropped from pretreatment level of' 115.9+ 74.1 IU/L and 201.6+ 173.0 1U/L to posttreatment level of46.6+ 21.6 UU/L and 28.7- 15.4IU/L, respectively(p<0.01). There was no significant hernatological and biochemical change after administration of DDB. Untoward side effects were easily controlled by discontinuing the drugs, Conclusions:Administration of DDB(for 6 months) appears to be effective for decrement of transaminase level and safe for the treatment of patients with chronic liver disease.
  • 4,230 View
  • 103 Download
The Detection of Hepatitis G Virus RNA by RT - PCR in Various Liver Diseases
Kwang Hyub Han , Won Choi , Young Nyun Park , Young Woong Hwang , Wang Sik Ryu , Eun Sin Park , Kwan Sik Lee , Chae Yoon Chon , Young Myoung Moon , Chan Il Park
Korean J Hepatol 1997;3(2):123-132.
Background/Aims
Recently, nucleotide sequences from a novel virus, termed hepatitis G virus (HGV), were identified in serum from a patient with cryptogenic hepatitis and suggested as agent of non A-E hepatitis. HGV has been isolated from patients with various liver diseases but clinical implications of this new agent remain largely unresolved. In Korea, the etiology of substantial fraction of hepatitis has remained undefined and there has been no report concerning HGV. Methods: To determine the infection rate of HGV, RT-PCR of 5 UTR of HGV was performed, and to understand the clinical implication of HGV, medical records of 115 patients with various liver diseases were reviewed. Of 115 patients, 63 were male and 52 were female. Their mean age was 44 years (19-74) and their mean AST and ALT were 121.3+278.7 IU/L and 172.2+253.3 IU/L, respectively. Of 115 patients, 58 (50.4%) had no specific cause of liver diseases, 37 (32.2%) were infected with hepatitis B and/or C virus and 20 (17.4%) had non-viral identifiable liver diseases. Results: 1. HGV RNA was detected in 15 (13.0%) patients of 115 patients. 2, Among the 15 HGV RNA positive cases, 7 were male and 8 were female. Their mean age was 48 years (19-72) and their mean AST and ALT were 71.9+45.2 IU/L, 97.4+66.8 IU/I respectively. 3. HGV RNA was detected in 8(13.8%) of 58 patients without obvious causes of their liver diseases and in 7 (18.9%) of 37 patients infected with HBV and/or HCV. However, HGV RNA was not detected fram 20 patients with non-viral liver diseases such as alcoholic liver diseases, autoimmune hepatitis, PBC, or fatty liver. 4. HGV RNA was detected in 5 (19.2%) of 26 patients with acute hep- atitis, in 6 (9.4%) of 64 patients with chronic hepatitis, in 1 (14.3%) of 7 patients with liver cirrhasis, and iB 3 (27.3%) Of 11 pafients with hepatocellular caIcinoma. 5. These was no slatistically significant difference in sex, age, history of transfusion, serum ALT level, etiologies and status of liver diseases between HGV RNA positve and negative group. Conclusions: the prevalence of HGV infection is quite high among the patients who have no specific cause of acute or chronic liver diseases and HGV can be coinfected with HBV and/ar HCV infection in Korea.
  • 3,323 View
  • 22 Download
Distinct Expressions of TGF - α among Chronic Hepatitis , Liver Cirrhosis , and Hepatocellular Carcinoma
Byeong Moo Yoo , Sung Soo Park , Dong Hoo Lee , Jung Dal Lee
Korean J Hepatol 1997;3(4):316-328.
Background
/Aim: Transforming growth factor-a(TGF-a) is a polypeptide cytokine related to cell proliferation and transformation. TGF- a binds to EGF receptor and stimulating DNA synthesis in liver cell. The hepatitis B virus (HBV) by itself is also believed to play a role in the hepatic carcinogenesis. Recently, it was reported that TGF- a and HBV were synergistic in action with rapid appearance of hepatocelluar carcinoma in bitransgenic mice. Although TGF- a is thought to play an important role in hepatocarcinogenesis, its expression during the natural history of HBV hepatitis was poorly understood. This investigation was performed to elucidate the dynamic changes and distinct immunohistochemical staining patterns in the course of chronic HBV hepatitis with specific reference to hepatocelluar carcinoma and to explain the role of TGF- a in the pathogenesis of hepatocelluar carcinoma. Materials/Methods: Employing TGF- a monoclonal antibody, signal detection was carried out by peroxidase-conjugated streptavidin in deparaffinized liver tissue sections taken from HBsAg positive patients. All of the liver tissue sections were proven HBV DNA positive by in situ hybridization. Immunohistochemical staining was performed in the tissue sections obtained from four normal controls, six from patients with chronic persistent hepatitis, five with chronic active hepatitis, eight with liver cirrhosis and eleven with hepatocellular carcinoma. Results: The patterns of TGF- a immunoreactivity were cytoplasmic-grain types in normal controls and chronic persistent hepatitis, honeycomb types in chronic active hepatitis, occasional cytoplasmic-flooding types in liver cirrhosis, and cytoplasmic-grape types in hepatocellular carcinoma. A Shapiro-Wilk W test for frequency table analysis for the expression of TGF- a in these different disease groups was statistically significant. Conclusion: These data suggest that step-wise distinct expression of TGF-a enhancement in HBV associated chranic liver diseases which eventually resulted in the development of hepatocellular carcinoma were conceivably due to dysregulation of liver cell cycles by both HBV and TGF- a during the persistent repetition of cell cycles. (Korean J Hepatol 1997;7:316 328)
  • 2,900 View
  • 13 Download
Validation of the Korean Version of Liver Disease Quality of Life (LDQOL 1.0) Instrument
Sehyun Kim, Ph.D.1, Ki Hyun Choi, M.D.2, Seong Gyu Hwang, M.D.2, Ji Hyun Lee, M.D.2, Sun Young Kwak, M.D.2, Pil Won Park, M.D.2, Yukyung Kim, M.D.2, Hye Ja Park, Ph.D.3, Soon Joo Kim, M.A.4, Kyu Sung Rim2, M.D.
Korean J Hepatol 2007;13(1):44-50.
Background/Aims
Assessment of Health-related quality of life (HRQOL) outcomes in treatment of chronic disease is increasingly important. The
objective
of this study was to validate a Korean translation of the Liver Disease Quality of Life instrument (LDQOL version 1.0) for use in patients with chronic liver disease. Methods: Two native Korean speakers with fluent English translated LDQOL including instructions, items, and response choices. This Korean translation of the LDQOL was administered to 121 patients with chronic liver disease. Cronbach's alpha coefficients were applied to test an internal consistency reliability of disease-specific scales of the LDQOL. MELD and modified CTP scores were calculated for all patients. Associations of MELD and modified CTP scores with severity of liver disease were analyzed with LDQOL. Results: Internal consistency reliability was good (Cronbach's Alpha=0.69-0.94) in liver disease specific scales, except for the quality of social interaction scale (Cronbach's Alpha= 0.56). Mean modified CTP score and MELD score were 6.2±1.9 and 9.3±5.3, respectively. Both MELD score and modified CTP score showed correlations with most of the scores of liver disease specific scales of LDQOL 1.0, except for the quality of social interaction and sleep scale.
Conclusions
The Korean version of the liver disease specific scales of the LDQOL 1.0 is validated and useful for measuring HRQOL in Korean patients with chronic liver disease. (Korean J Hepatol 2007;13: 44-50)
  • 3,835 View
  • 72 Download
First First Prev Prev
Page of 1
Next Next Last Last
CMH : Clinical and Molecular Hepatology
Twitter